Functional studies of serine/threonine protein kinase signalling in Mycobacterium tuberculosis. by Patel, D.P.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  Year  °   ^   Name of Au Name of Au
COPYRIGHT
This  is  a  thesis  accepted  for  a  Higher  Degree  of the  University  of  London.  It  is  an 
unpublished typescript and the copyright is held by the author.  All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I   recognise that the copyright of the above-described  thesis  rests with  the author and 
that no quotation  from  it or information  derived  from  it  may be  published  without the 
prior written consent of the author.
Theses may  not be  lent to  individuals,  but the  University  Library  may  lend  a  copy to 
approved  libraries within the  United  Kingdom, for consultation solely on the  premises 
of those  libraries.  Application  should  be  made to:  The Theses  Section,  University of 
London Library,  Senate House,  Malet Street,  London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from the  University of London  Library.  Enquiries should  be addressed  to 
the  Theses  Section  of  the  Library.  Regulations  concerning  reproduction  vary 
according to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before  1962.  Permission  granted  only  upon  the  prior written  consent  of the
author.  (The University Library will provide addresses where possible).
B.  1962-1974.  In  many cases the author has agreed to permit copying  upon
completion of a Copyright Declaration.
C.  1975 - 1988.  Most theses  may  be  copied  upon  completion  of a  Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
This  copy  has  been  deposited  in  the  University  of  London  Library,  Senate
LOAN
This copy has been deposited in the Library of
House, Malet Street,  London WC1E 7HU.National Institute for Medical Research
Division of Molecular Structure
Functional Studies of Serine/Threonine Protein Kinase Signalling
in Mycobacterium tuberculosis
A thesis submitted by 
Dony P. Patel
in partial fulfilment of the requirements of the 
University of London
for the degree of Doctor of Philosophy.
January 2006
lUMI Number:  U592B80
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI  U592B80
Published by ProQuest LLC 2013.  Copyright in the Dissertation held by the Author.
Microform  Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying under Title  17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml  48106-1346Abstract
Fork-head associated (FHA) domains function in the assembly of signalling complexes 
through specific interactions with phospho-threonine motifs. FHA domains are found in 
eukaryotes,  and  intriguingly  in  a  subset  of bacterial  species  including Mycobacteria 
tuberculosis.  In  addition,  the  M.  tuberculosis  genome  encodes  11  eukaryotic-like 
serine/threonine protein kinases (STPKs). In M. tuberculosis, the co-expression of FHA 
domain-containing  proteins  and  STPKs  strongly  suggest  that  these  bacterial  FHA 
domain-containing  proteins  engage  in  phospho-dependent  protein-protein  interaction, 
and  FHA  dependent  processes  in  bacteria  are  controlled  by  STPK-dependent 
phosphorylation.  This  study  describes  a  body  of  biophysical  and  biochemical 
experiments which characterises the interactions between two STPKs, PknA and PknB, 
and three FHA domain-containing proteins, Rv0019, Rv0020 and Rvl827.  Isothermal 
titration  calorimetry  and  surface  plasmon  resonance  combined  with  site-directed 
mutagenesis are used to investigate interactions of kinase domains with FHA domains. 
These  experiments  reveal  that  the  FHA  domains  interact  with  specific  phospho- 
threonine residues  located within the kinase domain activation  loop.  Additionally,  in 
vitro kinase assays demonstrated that the interactions also involve phosphorylation of 
the  FHA  domains  and/or  adjacent  segments  of the  protein.  These  data  suggest  that 
STPK-mediated signalling in M.  tuberculosis involves a complex series of interactions 
and  suggests  a  ‘molecular docking’  model  for the  phosphorylation of FHA  domain- 
containing proteins. Finally, high-throughput assays have been used to identify several 
inhibitors of PknB which will serve as the basis for development of novel antimicrobial 
therapies.
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111   Introduction
1.1  The Origins of Signal Transduction
The term ‘signal transduction’  encompasses a multitude of mechanisms by which the 
transfer of biological  information  occurs.  These mechanisms regulate  cellular events 
such  as  signal  output  of  cell  surface  receptors,  DNA  repair,  cell  cycle  control, 
cytoskeletal changes and protein degradation.  Protein-protein interactions provide the 
principal  framework  through  which  the  many  signals  for  these  cellular  events  are 
initiated.  Such protein  recognition  and  interaction  events  must be  tightly  controlled, 
specific  and  reversible,  as  they  control  the  route  of  a  signalling  pathway.  Post- 
translational modifications are commonly utilised for the regulation of these molecular 
interactions as well as conformational changes. Post-translational modifications include 
acetylation,  methylation,  hydroxylation  and  ubiquitination,  but  by  far  the  most 
commonly employed post-translational modification is phosphorylation.  Over 30% of 
human  proteins  contain  a  covalently  bound  phosphate  at  some  time  during  their 
existence.  In  addition,  enzymes  that  catalyse  protein  phosphorylation,  kinases,  have 
been determined to be one of the largest gene families in eukaryotes, with 518 putative 
protein genes (Manning et al., 2002).
The study of protein phosphorylation began with work carried out in the late  1930s by 
Carl and Gerty Cori. Their work on the interconversion of phosphorylase a and b won 
them the Nobel Prize in Physiology and Medicine in 1947 for “discovering the course 
of the catalytic conversion of glycogen”.  While the Coris were unaware of the exact 
manner of the  interconversion  of phosphorylase,  they  demonstrated  that  an  enzyme 
termed  ‘prosthetic-group-removing’  (or  PR)  enzyme  acted  on  phosphorylase  a  to 
convert it to the b form. This was the first example of what is now known as allosteric 
activation.
It was twenty years later that the exact chemical nature of the interconversion reaction 
of phosphorylase  a  and  b  was  revealed.  Working  at  the  same  department  of the 
University  of Washington as the  Coris,  Edwin  Krebs and  Ed Fischer tried  to purify 
phosphorylase a from muscle using the same methods as their predecessors. To clarify
12the muscle extract they initially used centrifugation, and were only able to purify the b 
form.  If this was replaced by a filtration  step, they obtained the a  form.  It was also 
found that the conversion did not occur if the muscle extract was aged. It was eventually 
established that ATP was the essential constituent and that this was lost over time. This 
led  to  the  identification  of  phosphorylase  kinase;  an  enzyme  that  catalysed  a 
phosphotransferase  reaction  in  which  the  terminal  phosphoryl  group  of  ATP  was 
transferred to phosphorylase b. Further study identified the critical difference between 
the centrifugation and filtration methodologies. The filter paper contained a source of 
calcium.  Calcium  was  required  for  the  activity  of phosphorylase  kinase  and  other 
activators of this enzyme.
Despite the ubiquity of phosphorylated proteins in nearly every aspect of cellular life, 
the  identification  of phosphorylated  amino  acids  was  only  discovered  in  the  1970s. 
Pioneering work on the v-Src protein from Rous sarcoma virus (RSV). v-Src was the 
first  oncogene  to  be  discovered  (Martin, 1970)  and  shown  to  encode  an  abnormally 
regulated tyrosine kinase (Collett & Erikson, 1978). During their study of polyomavirus 
middle T antigen (PyMT), Hunter and Eckhart found that PyMT was phosphorylated 
(Eckhart et al.,  1979). Further analysis showed the phosphorylated amino acid to be a 
tyrosine.  Aberrantly  regulated  kinase  activity  is  now  recognised  as  a  cause  or 
consequence of many human diseases.
1.2  The Transmission of Signals by Protein Phosphorylation
Phosphorylation is the most common regulatory mechanism adopted by eukaryotic cells 
and  to  a  lesser  extent,  prokaryotic  cells.  The  coupled  reactions  of  protein 
phosphorylation  and  dephosphorylation  are  catalysed by  protein  kinases  and  protein 
phosphatases, respectively.  Working in tandem, these enzymes are able to modify the 
function of proteins  in numerous  ways;  they can  disrupt protein-protein  interactions, 
modulate  biological  activity,  signal  subcellular  compartmentalisation,  translocation, 
involve signal destruction or alter protein stability.
13Protein kinases catalyse the specific  transfer of the terminal  (y) phosphoryl  group of 
ATP to either serine or threonine residues in the case of serine/threonine kinases, and to 
tyrosine in the case of tyrosine kinases. Human genome sequence analysis by Manning 
et al (2002)  suggests that humans may possess  388  serine/threonine kinases  and  90 
tyrosine kinases.  A further class of protein kinases are the histidine/aspartate kinases 
that catalyse the phosphorylation of specific histidine residues (N7 1  or NT  residues on the 
histidine  ring).  These  enzymes  are  most  prevalent  in  prokaryotic  cells  and  will  be 
discussed later.  Eukaryotes also posses two additional  classes of protein kinases,  the 
myosin heavy chain kinase/EF-2 kinase and the mitochondrial protein kinases which 
including pyruvate dehydrogenase kinase (Krupta and Srinvasan, 2005).
The reversibility, specificity and flexibility of phosphorylation make it ubiquitous as a 
control  mechanism.  However,  there  are  many  physical  consequences  of 
phosphorylation; the addition of a phosphoryl group adds two negative charges to the 
modified  protein.  This  can  lead  to  profound  alterations  to  electrostatic  interactions 
within the protein that can in turn lead to structural changes. The phosphoryl group is 
also  able  to  form  a  maximum  of  three  hydrogen  bonds.  The  free  energy  of 
phosphorylation  is  -12kcal/mol,  such  a  large  free  energy  change  ensures  that  the 
conformation  change  of the  modified  protein  is  very  stable.  The  cycling  between 
phosphorylation  and  dephosphorylation  can  occur very quickly.  This means  that the 
effects of phosphorylation can be quickly amplified. The activation of one kinase can 
lead to it phosphorylating many target proteins in a short space of time, especially other 
kinases leading to a signalling cascade.
141.3  Protein Phosphorylation in Prokaryotes
Until  recently,  the  prevailing  model  of  prokaryotic  signalling  largely  involved 
phosphorylation of histidine and aspartic acid residues via two-component regulatory 
systems. Serine/threonine and tyrosine kinases were thought to be unique to eukaryotes. 
However, the accumulation of genomic sequence data has revealed that some bacteria 
contain phosphoester kinases (both Ser/Thr and Tyr kinases) and phosphatases as well 
as associated adaptor molecules that have eukaryotic homologs.
Extracellular  signals  such  as  osmotic  stress  or  sugar  concentration  are  generally 
transduced  into  cellular  responses  by  two-component  systems  (aka.  the  His-Asp 
phospho-relay system) in bacteria (Figure  1.1).  The sensor component of this system 
contains  an  extracelluar  ligand-binding  domain  that,  once  bound,  leads  to  the 
autophosphorylation of its intracellular segment on a conserved histidine residue carried 
in  the  H-box  domain  of the  histidine  kinase.  The  sensor  protein  then  transfers  the 
phosphoryl group to a conserved aspartate on its associated response regulator protein.
It was not until  1991  that a  serine/threonine protein kinase, pknl,  from Myxococcus 
xanthus was purified and characterised (Munoz-Dorado et al., 1991).  It has now been 
established that bacterial signalling through serine/threonine and tyrosine protein kinase 
is the rule rather than the exception. This is evident from the presence of these proteins 
in more than 20 of the 50+ bacterial genomes sequenced to date (Pallen et al., 2004). 
Analysis of GC content and codon usage suggests that bacterial serine/threonine protein 
kinases (STPKs) are genuine prokaryotic enzymes rather than genes acquired through 
horizontal  gene  transfer  from  eukaryotes  to  prokaryotes  (Han  &  Zhang, 2001).  If 
horizontal gene transfer of STPKs had occurred  from eukaryotes to prokaryotes then 
this would have occurred early in the evolution of the bacteria that possess the genes 
(Han and Zhang, 2001). Genome analysis has shown that eukaryotes also utilise two- 
component systems containing histidine kinases (Wolanin et al.,2002).
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Figure 1.1. Prokaryotic signal transduction systems involving  histidykaspartyl 
phosphorelay. Histidine kinase domains are represented as rectangles, receiver domains as 
ovals and transmembrane domains by black bars. Histidine-containing phospho-transfer 
protein (HPt) is indicated by rounded rectangles. Sites of phosphorylation upon histidine 
(H) and aspartic acid (D) residues are indicated. (A) A basic two-component regulatory 
system which employs a histidine kinase that contains an extracellular sensor domain and 
a response regulator. (B) A phospho-relay system that empbys a HPt protein intermediate 
between the sensor hybrid kinase and the response regulator. TM, transmembrane 
domain.
16In prokaryotes, STPKs are generally involved in either growth or pathogenicity. There 
are a large number of STPKs encoded in the genomes of bacteria that have the ability to 
differentiate into a new developmental state, including Anabaena spp. (Zhang and Libs., 
1998),  Streptomyces  (Urabe  and  Ogawara  et  al.,  1999),  and  Myxococcus  xanthus 
(Inouye et al., 2000). In these species, STPKs are essential for controlling the late stages 
of development,  sporulation  and  secondary  metabolite  production.  STPKs  are  also 
involved in pathogenicity. Examples include Yersinia pseudotuberculosis STPK, yopO 
(Barz et al., 2000), and the complement of Pseudomonas aeruginosa STPKs (Wang et 
al.,  1998). These STPKs are implicated in survival of the pathogen in the human host 
and are essential for full virulence in mouse models.
1.4  Protein Interaction domains
The use of modular protein binding domains in cell signalling has emerged as one of the 
major themes of signal transduction in the past decade.  These domains,  often called 
interaction  domains,  recognise  post-translational  modifications  and  direct  protein- 
protein interactions. They can also recognise lipids, proteins and nucleic acids as shown 
in  Figure  1.2  (Pawson  &  Nash, 2003).  Eukaryotic  regulatory  proteins  have  a 
multidomain  architecture  made  up  of  a  combination  of  sensor,  enzymatic  and 
interaction domains.  The  enzymatic  domains  of regulatory proteins  often  generate  a 
modified amino acid on a substrate protein, this can then be recognised by an interaction 
domain.  In  this  way,  multi-component  signalling  complexes  may  be  built  up  and 
cytosolic  signal  transduction  cascades  generated.  Interaction  domains  control  the 
specificity of signal transduction as well as the kinetics of interactions. They therefore 
regulate the formation of signalling complexes at appropriate cellular locations, and are 
essential  for  the  generation  of complex  cellular  behaviour.  In  contrast,  prokaryotic 
signalling predominantly involves separate genes for enzyme and interaction domains 
encoded in the same operon.
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Figure 1.2. Modular interaction domains used in signal transduction. Interaction domains 
have been identified which associate with proteins, nucleic acids and phospho-lipids. A 
selection of domains and their binding partners are shown. The full names of domains are 
given in the SMART (Simple Modular Architecture Research Tool) database 
(www.smart.embl-heidelberg.de). Adapted from Pawson and Nash, 2003.
18A modular system has allowed the tailoring of proteins during evolution. This in turn 
has  facilitated  diverse  combinations  of protein interactions  and activities.  However, 
there  are  only  a  limited  number  of protein  interaction  domain  classes  that  can  be 
inserted into genes and operons.  This results in many signalling systems utilising the 
same interaction domains, as is the case with Src homology domains (SH2 and SH3). 
The human genome encodes approximately  115  SH2 domains and 253  SH3  domains 
(Pawson,2004).  Specificity can be achieved despite similar domains targeting related 
motifs. Firstly, the affinity of the interaction domain for a particular peptide motif may 
be enough to distinguish between related targets. Signalling systems may achieve higher 
selectivity by the use of not one, but several, interaction domains as well as a number of 
scaffold or adaptor proteins. In addition, local concentration conditions brought about 
by subcellular localisation and temporal expression may influence in vivo selectivity.
The use of different classes of protein interaction domains shown in Figure  1.2 allows 
for the generation of many systems of regulation. This discussion will now concentrate 
on  the  subset  of regulatory  processes  based  on  the  actions  of protein  kinases  and 
phosphopeptide-binding domains, and in particular, serine/threonine kinases and FHA 
domains.
191.5  Phosphopeptide-binding domains
A number of phosphopeptide-binding domains have been studied in detail and several 
reviews  exist  on  phosphoserine/threonine  (pSer/pThr)  -binding  domains  (Yaffe  & 
Smerdon.2004)  and  phosphotyrosine  (pTyr)-binding  domains  (Pawson,  2004).  In 
general, isolated phosphodependent interaction domains fold in a manner that leaves a 
ligand-binding  surface  able  to  recognise  exposed  short  phosphorylated  motifs.  For 
example, growth factor-receptor tyrosine kinases autophosphorylate at specific tyrosine 
residues  on  their  extended  tails  in  response  to  an  extracellular  signal.  These 
phosphotyrosine  sites  are  able  to  bind  effectively  with  a  number  of pTyr-binding 
domains such as SH2 domains and phosphotyrosine binding domains (PTB) (Wybenga- 
Groot et al, 2001).
The  versatility  of  interaction  domains  is  exemplified  by  the  signalling  between 
transforming growth factor-p (TGF-p) receptor kinases and R-SMAD signal transducer 
proteins.  Upon  TGF-p  binding,  the  transmembrane  Ser/Thr  kinase  TGF-p  receptors 
autophosphorylates a specific glycine- and serine-rich sequence in the juxtamembrane 
region at exposed serine residues. The R-SMAD protein contains an N-terminal DNA 
binding domain (MH1) and a C-terminal protein interaction domain (MH2). This MH2 
domain binds to the phosphopeptide motif of the phosphorylated TGF-p kinase.  The 
MH2 domain also associates with the scaffold protein SARA, and once phosphorylated 
by TGF-P kinase, MH2 can then recognise other phosphorylated MH2 domains. The R- 
SMAD domains/proteins trimerise through the phosphorylated MH2 C-terminal region, 
which binds  to  the  same  phospho-binding  region  of the  adjacent monomer.  In  turn, 
trimers  then  dissociate  from  the  receptor  kinase  and  translocate  to  the  nucleus 
(Miyazono et al.,2004). In the nucleus the MH1 domain binds to DNA whilst the MH2 
domain forms new interactions with various transcriptional components, altering gene 
expression (Wu et al,2001). Surprisingly, the structures of FHA domains are related to 
the SMAD MH2 domain described previously despite the lack of sequence homology 
(Durocher et al, 2000). The FHA domains play a major role in this thesis and will be 
the topic of the following Section.
201.6  FHA domains
1.6.1  Overview
Forkhead-associated domains, or FHA domains, were originally identified by Hoffman 
and  Bucher  (1995).  This  domain  was  initially  discovered  in  a  subset  of Forkhead 
transcription factor family members, from which their name derives. FHA domains are 
now  known  to  be  present  in  over  450  proteins,  in  many  organisms  ranging  from 
prokaryotes to higher eukaryotes. They are a class of small protein interaction domain 
found  to  recognise  phosphothreonine  peptide  motifs  (Durocher  et  al.,  2000).  The 
majority of FHA domains studied to date have been shown to selectively bind peptide 
motifs defined by amino acids from the -4 to the +3 positions relative to a pThr using in 
vitro peptide library screens (Yaffe and Smerdon, 2004). The domains can be  130-140 
residues  in  length  with a  core homology region  of around  50-75  residues.  The  core 
homology region  can be  separated  into  three  conserved regions  with  five  absolutely 
conserved amino acids (Figure 1.3).
1.6.2  Functional versatility of the FHA domain
One  of the  best  characterised  FHA  domain-containing  proteins  with  respect  to  its 
physiological  role  and  FHA  domain  structure  is  Rad53.  This  is  a  protein  from 
Saccharomyces cerevisae and is involved in the DNA damage cell cycle checkpoint. It 
has two FHA domains flanking a central serine-threonine protein kinase domain. The 
FHA  domains  of Rad53  are  involved  in  the  association  with  phosphorylated  Rad9 
following DNA damage (Sun et al, 1998) where the Rad53/Rad9 interaction leads to a 
high  local  concentration of Rad53.  Consequently,  Rad53  autophosphorylates  in  trans 
and  becomes  active,  resulting  in  activation  of the  Rad53  branch  of the  checkpoint 
pathway for DNA damage repair (van den Bosch et al, 2004).
An  FHA  domain  was  also  found  to  be  important  in  the  CLV1  signal  transduction 
pathway that controls cell proliferation and differentiation in Arabidopsis thaliana (Li et 
al, 1999).  The  interaction between the kinase-associated protein phosphatase  (KAPP)
21and CLV1  from A.  thaliana was shown to be dependent on both a kinase interaction 
(KI)  domain  present  in  KAPP,  and  phosphorylation  of  CLV1.  CLV1  is  a 
serine/threonine  protein  kinase.  A  52  amino-acid  stretch  of  the  KI  domain  is 
homologous to the conserved region of FHA domains. Mutations in key residues of this 
FHA homology region abolished binding of KAPP to CLV1.
1.6.3  Structure of FHA domains
Rad53  FHA2  was  the  first  FHA  domain  structure  to  be  determined  using  nuclear 
magnetic resonance (NMR) (Liao et al., 1999). This was followed by crystallographic 
structures of both FHA1  of Rad53,  human Chk2 FHA domain and the FHA domain 
from  ring  finger  containing  checkpoint protein,  Chff  (Liao  et  al.,2000,  Durocher  et 
al.,2000, Stavridi et al.,2002, ,Li et al., 2002). Comparisons of these structures show that 
the core structure of the FHA domain is an 11 or 12 /2-stranded sandwich of around 50- 
75  amino acids in size (Figure  1.3).  Variability in FHA domains arises as a result of 
insertions in the loops between (3-strands and these are often helical. The mechanism of 
phospho-peptide binding will be discussed based on the structures of Rad53 FHA1  and 
Chk2 FHA. Later, these examples will be compared to the structure of the first bacterial 
FHA domain to be solved, that of Rv0020 of Mycobacterium tuberculosis.
The  mechanism  of binding  and  selectivity  is  explained  by  the  structures  of FHA 
domains  solved  in  complex  with  an  optimal  binding  peptide  derived  from  peptide 
library screening. The FHA domain binds phosphopeptides through direct contact to the 
phosphopeptide backbone and via hydrogen-bonding to the phosphothreonine residue. 
These  interactions  involve  a  large  number  of residues,  probably  forming  a  binding 
surface rather than  a few localised amino acids (Durocher and Jackson.,  2002).  This 
surface is generated by the loops that connect the /2-strands /23-/24, >04-/25, /T6-/27, and 
/210-/211  (Figure  1.4).  The  residues  involved  in  contacting  the  phospho-peptide 
backbone or the phosphothreonine itself are best conserved. The specificity-determining 
residues are less well conserved, allowing FHA domains to impart selectivity which is 
most  prominent  for  the  residue  +3  relative  to  the  phosphothreonine  (Durocher  et 
al., 2000).
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Figure 1.3. Multiple sequence alignment of selected FHA domains. The amino acid sequence and secondary structure elements 
of human Chk2 FHA domains are shown above the alignment as p-sheets (green arrows). The FHA residues critical for phospho- 
threonine recognition are indicated by stars. Rvl827, Rv0019 and Rv0020 are from M. tuberculosis, Rad53 FHA domains from 
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65The  structure  of  the  Rad53  FHA1 :phospho-peptide  complex  clearly  shows  the 
importance of the five most conserved residues of FHA domains (Gly69, Arg70,  Ser85,
•  107  •
His  and Asn  ) (Figure 1.4). These residues are all found around the peptide-binding 
site.  Arg70, Ser85 and Asn107 are involved in the binding to the peptide backbone whilst 
in addition, Arg70 forms a salt bridging interaction with pThr and Ser85 forms a direct 
contact with the phosphate. In fact, the hydroxyl moiety of Ser85 (Ser140 in Chk2) forms 
a hydrogen bond with the phosphate oxygen as well as stabilising the binding pocket by 
hydrogen bonding to a main chain amide nitrogen on the 06-01 loop. Gly69 and His88 is 
in  stabilising  the  architecture  of the  domain  by  tethering  the  loops  that  bind  the 
phospho-peptide motif.
As  mentioned  above,  Arg70,  Ser85  and  Asn107  (Arg117,  Ser140  and  Asn166  in  Chk2) 
interact with the peptide main chain atoms that flank the pThr via a number of hydrogen 
bonds. The conserved asparagine makes contact with the main chain carbonyl oxygen of 
the pThr + 1   residue and the main chain nitrogen of the pThr + 3 residue. In addition, 
this residue secures the 06-/31 loop to the/B-/?4 loop. This asparagine residue can also 
make contact with the pThr y-methyl group in Chk2 (Li et al, 2002). The interaction to 
secure  the  06-01  loop  to  the  04-/35  loop  involves  the  asparagine  side  chain  amino 
moiety and the carboxyl moiety of Arg85 (Thr138 of Chk2). Finally, the Arg70 contacts 
the phosphate group and hydrogen bonds to the main chain carbonyl oxygen of the pThr 
+ 2 residue.
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Figure 1.4. The protein fold of the  Rad  5 3 FHA1 domain from Saccharomyces cerevisiae in 
complex with its optimal binding peptide. (A) The domain architecture is formed from a 
total of 11  (3-strands that associate to forma compact, P~ sandwich fold. Phospho-peptide 
binding occurs through interaction with residues from the p3-p4, p4-p5, p6-p7, and plO- 
pi 1  loops. (B)Key protein-phospho-threonine contacts made by conserved residues of the 
FHA domain of Rad53 FHA1. The phosp ho-threonine and key FHA domain residues are 
shown in stick representation and hydrogen bonds shown as dashed lines.
251.6.4  The specificity of FHA domains
A  closer  inspection  of  the  peptide  binding  region  gives  an  indication  as  to  the 
mechanism by which FHA domains not only bind phospho-peptides but target particular 
peptide motifs. Oriented peptide library selection is routinely used to identify a peptide 
that forms the tightest affinity to a particular domain (Yaffe and Smerdon., 2004). This 
selection is conducted by applying a degenerate library of phosphorylated peptides to 
resin-bound interaction domain proteins, after incubation of peptides with the protein 
for 10 minutes, unbound peptides were removed by rapidly washing the resin with PBS. 
Bound peptides are eluted and sequenced using Edman degradation. This enables raw 
selection ratios to be determined by comparing the relative molar percentage of each 
amino-acid at each amino-acid  sequencing cycle in the recovered peptides to that of 
each  amino-acid  in  the  original  peptide  libraiy  mixture  at  the  same  position.  If the 
original  peptide  library  contains  a  central  phosphorylated  residue  flanked  by  a 
degenerate series of residues at positions -3, -2, -1, +1, +2 and +3 relative to the fixed 
phosphorylated  amino  acid,  the  binding  preferences  of  phospho-peptide  binding 
domains can be investigated.
The Rad53 FHA1  and Chk2 FHA show highest selection at the pThr +3 residue. This 
implies  that  the  pThr  +3  residue  is  a  major  contributor  to  specificity.  Indeed,  the 
structure  of Rad53  FHA1  shows that the  selection  for an asparagine  at this position 
forms a salt-bridge interaction with the guanodine side chain of arginine (Durocher et 
aly   2000).  Chk2  FHA  selects  for  either  an  isoleucine  or  leucine  at pThr  +3.  These 
amino-acids posses non-polar side chains that are able to fit into a pocket on the domain 
surface  leading  to  contact  with  residues  of  neighbouring  /2-strand  loops  namely 
Ser192/Leu193 (/210-/211  loop) and Thr148 (/21-/25 loop) (Li et al.y  2001). This interaction 
is brought about by the fact that Chk2 has a helical insertion in the /24-/25 loop, leading 
to a larger /210-/211  loop than in Rad53, which creates a second binding cleft (Li et al, 
2001).
There appears to be little structural variation in the FHA domains studied to date. This 
can be attributed to the restrained nature of the binding of the phospho-peptide in an
26extended conformation along the domain surface. This results in a forced selection at 
the regions of greatest structural variability, namely the surface around the pThr + 3 
residue (Li et ah 2001).
1.6.5  The similarity between prokaryotic and eukaryotic FHA domains
The  structure  of  a  FHA  domain  from  the  protein  Rv0020  of  Mycobacterium 
tuberculosis has recently been solved in complex with its optimal peptide (Westcott S, 
unpublished  data).  The  structure  of Rv0020  FHA  is  strikingly  similar to  eukaryotic 
domains  with  10/11  /2-strands  but  has  no  additional  a-helical  insertions  in  the 
connecting loops (Figure  1.5). Again, the domain shows an absolute requirement for a 
pThr residue. Its optimal peptide also binds in an extended conformation as described 
above for Rad53. The FHA binding surface interacts with the phospho-peptide via five 
hydrogen bonds mediated by side-chain and main-chain atoms of Arg459, Ser473, Asn495, 
Arg474 and Thr494. The only novel interactions of Rv0020 are Arg474 and Thr494; all other 
interactions  exist  in  FHA  domains  previously  discussed.  The  Arg474  was  found 
hydrogen bonded to the phosphate group of the phospho-peptide.
The  specificity  of Rv0020  for its  phospho-peptide  is mediated by  a number  of key 
contacts; an isoleucine is highly selected for in the pThr +3 position of the peptide in a 
manner analogous to that of Chk2.  Again a specificity ‘pocket’  is created for a large 
hydrophobic  side  chain  by  the  residues  Asn495  (Jib-pi)  and  His519  (J3\0-J3\ 1). 
Asparagine  contributes to the  selection of isoleucine by forming one hydrogen bond 
between main-chain atoms. Taking the structural and specificity data collectively one 
can class FHA domains into two categories based on their specificity at the pThr + 3 
position  of their  optimal  phospho-peptide.  The  FHA  domains  of Rv0020  and  Chk2 
prefer large hydrophobic residues while Rad53 FHA1 and another FHA domain, Cdslp, 
show preference for an acidic residue (Durocher et al., 2000, Westcott S., unpublished 
data).
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Figure 1.5. (A) The protein fold of the Rv0020 FHA domain fromM tuberculosis in complex with its 
optimal binding peptide showing a characteristic b-stranded sandwich topology. Highly conserved 
residues (N495, R459, G458, S473 and H476) critical for phosp ho-threonine recognition are shown as 
spheres. (B) Surface representation of  the FHA domain of  Mycobacterium tuberculosis protein Rv0020 
cocrystallised with its optimal binding peptide. FHA domain surface is coloured blue. Highly conserved 
residue surfaces cotoured yellow and also shown in stick representation (yellow). The pTXXI optimal 
binding peptide is shown and co toured green. The phosphate group of the phosp ho-threonine residue is 
cotoured red.
281.7  Structural Features of Protein Kinase Domains
1.7.1  Overview
Currently there are 46 unique protein kinase structures available, which include active 
and  inactive  conformations  as  well  as  complexes  with  inhibitors  and  regulatory 
subunits. The basic architecture observed in all these structures involves a bilobal fold 
that is highly conserved in both serine/threonine and tyrosine kinases. The N-terminal 
lobe (~ 85aa) consists of anti-parallel p-sheets made of five [3-strands and a single a- 
helix, known as the aC-helix and the C-terminal lobe (~ 170aa) is predominately helical 
(Lew, 2003) (Figure 1.6).
The  volume  of structural  data  on  protein  kinase  domains  has  greatly  increased  our 
understanding  of how  kinases  phosphorylate  their  targets  and  how  this  activity  is 
regulated. This Section will attempt to define the structural features of the catalytically 
active conformation, with reference to the first solved kinase structure, that of PKA, and 
will outline some key regulatory mechanisms.
1.7.2  The active conformation
ATP  is  bound  within  a  cleft  between  the  two  lobes  and  is  positioned  in  a  precise 
orientation  for phospho-transfer by  interactions  with  ~10  conserved  residues.  A  key 
interaction coordinates the phosphates of ATP with the backbone of a glycine-rich loop 
composed  of a  ‘GXGXy/G’  motif (X  represents  any  amino  acid  and  y/ is  usually  a 
tyrosine or phenylalanine).  The glycines give flexibility to the loop allowing it to get 
close to the ATP and the side chain of the aromatic residue caps the site of phosphate 
transfer.
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Figure 1.6. Key protein-pep tide contacts made by conserved residues of the FHA domain 
of Rv0020. The peptide and key FHA domain residues are shown in ball-and-stick 
representation and hydrogen bonds shown as green lines. (A) The phosphate group of the 
threonine is bound through contacts from S473 and R459, along with contacts from the 
non-conserved residues T494 and R474. (B) N495 and R459 form hydrogen bonds with 
the main chain atoms of the peptide.Further interactions  occur to position the phosphates  of ATP  for catalysis  when the 
conserved Lysine/Glutamate ion pair (Lys72/Glu9 1  in PKA) form contacts with the a- 
and (3-phosphates (Figure 1.7). The conserved Glutamate (Glu9 1  in PKA) of the Glu-Lys 
ion pair is located in the Ca-helix, this is a conserved helix of the N-terminal lobe that 
makes  direct  contacts  with  the  N-terminal  anchor  point  of the  activation  loop.  A 
divalent metal ion (Mg2+ or Mn2+) binds to the (3- and y-phosphates as well as conserved 
Asparagine (Asp184 in PKA) from an important DFG tripeptide motif at the N-terminal 
anchor of the important active site segment termed the activation loop. When a protein 
substrate binds in an extended conformation across the nucleotide binding pocket, an 
Asp (Asp166 in PKA) residing in the catalytic loop from the C-terminal lobe acts as a 
base to remove the proton from the substrate residue hydroxyl group leaving it free to 
attack the nearby y-phosphate group. The final conserved feature of the active site is the 
APE tripeptide motif at C-terminal anchor of the activation loop which is critical for 
substrate binding, particularly the residue preceding the phospho-acceptor residue (P+l 
residue).
1.7.3  Controlling Activity through Activation Loop Conformation
Undoubtedly, the most common mechanism for regulation of kinase activity involves 
conformational  changes  of the  activation  loop  (Nolen  et  al,  2004),  a  multipurpose 
structural element that has clearly evolved to control activity of the kinase domain. It 
has  been  found  to  sterically  block  substrate-  or  co-factor binding  in  the  active  site 
(Hubbard et al.,  1994).  It can also impede correct positioning of the aC Helix (Engh 
and Bossemyer, 2001) and act as a docking site for activating or inactivating cofactors 
or regulatory domains (Sahara et al.,  1996). In addition, it provides the P+l  residue- 
binding pocket to accommodate the peptide substrate (Engh and Bossemyer, 2002).
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Figure 1.7. The catalytically active conformation of serine/threonine protein kinase domains of 
Protein kinase A (PKA) and PknB shown in ribbon representation. Key structural elements 
within the kinase domain including the bound nucleotide are indicated. Panel (A) shows the 
phosphorylated residue critical to activation of PKA, pT197. (B) The activation bop is absent 
from the structure of active PknB due to disorder arising fromphosphorylatbnof four residues 
within this regbaA number of kinases require the activation loop to be phosphorylated for full activity, 
Johnson  and  colleagues  noted  that  all  these  kinases  possess  a  conserved  arginine 
immediately preceding the conserved aspartate  in the  catalytic  loop  (Asp166 in PKA) 
(Johnson  et  al.,  1996).  Therefore,  this  group  of kinases,  to  which  PKA  and  PknB 
belong,  were  termed  RD  kinases.  The  structure  of  active  PKA  reveals  a 
phosphothreonine in the activation loop which allows the formation of a network of key 
interactions for catalytic activity (Figure  1.8).  The importance of phospho-residues in 
the activation loop is also well illustrated in the active and inactive structures of insulin 
receptor  kinase  (IRK).  In  the  inactive  unphosphorylated  form,  the  activation  loop 
collapses into the active site and impedes binding of nucleotide and peptide substrate 
(Hubbard,  1997). Upon phosphorylation of three tyrosine residues, the activation loop 
moves  out  of  the  active  site  and  is  involved  in  both  phospho-tyrosine  and  non- 
phosphotyrosine interactions resulting in the activation loop being positioned to allow 
correct orientation of the APE motif for substrate binding (Hubbard et al, 1998).
In addition to the activation loop regulatory mechanisms described above, the loop can 
also  be  an  important  site  of protein-protein  interaction.  A  recent  crystal  structure 
presented evidence of activation loop phosphorylation playing a role in recruitment of 
downstream signalling proteins. Hubbard and colleagues solved the structure of the Src 
homology domain (SH2) of Adaptor protein,  APS  (adaptor molecules containing PH 
and SH2 domains), bound to IRK via two phospho-tyrosines in the activation loop (Hu 
et al., 2003). Another study (Wolf et al.t 2001) demonstrated mutations of activation 
loop residues within Erk2 kinase that affect its transport to the nucleus by eliminating 
activation  loop  interaction  with  cytosolic  anchoring proteins.  This  newly  discovered 
mechanism  for substrate recruitment has implications on the conclusions drawn from 
data presented here and will be the subject of later discussion.
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Figure 1.8.Sc hematic representation of the interactions in the active site of protein kinases and 
the possfole mechanism for the phosphorylation of the serine substrate with the y-phosphate of 
ATP. It also illustrates the involvement of the phosphorylated threonine (pThr 197in PKA) in 
the correct positioning of the key residues for catalysis.
Adapted from Nolen et al., 2004.
341.7.4  Coupling Activity to Ca-Helix conformation
Another common regulatory strategy of kinases involves conformational changes in the 
aC  helix.  A  number  of Src  kinase  domains  are  inhibited  when  an N-terminal  SH3 
domain  binds  to  the  surface  of the  N-terminal  lobe,  stabilising  the  aC  helix  in  an 
inactive conformation.  Only when a ligand binds to the SH3  domain does the kinase 
assume an active conformation (Huse and Kuriyan, 2002).  The switch between active 
and  inactive  conformation  of the  aC  helix  can  concurrently  cause  a  switch  in  the 
activation loop. This is exemplified in the case of Cyclin-dependent kinase (CDK). The 
inactive conformation consists of a conserved glutamate out of position for catalysis as 
a  consequence  of aC  helix  rotation  (DeBont  et  al.,  1993).  The  binding  of cyclin 
reorientates the aC helix to place the glutamate in the active site. This also necessitates 
movement of the activation loop from the inactive position to an active position where it 
can be phosphorylated by CDK-activating kinases.
35Name ORF
M.lepma
homolog
Tma Unique features
Associated FHA 
domains
Other adjacent/nearby 
genes
Proposed regulatory 
function
pknA rv0015c + + - R\0O19and
Rv0020
pknB, pbpA, rodA  and 
POP
cell
elongation/septation
pknB r\0O14c + + Extracellular PASTA 
domains
R\0O19and
Rv0020
pknA, pbpA, rodA  and 
PPP
cell
elongation/septation
pknD n0931c - +
PQQ domain, 
extracellular P-propeller
-
phosphate uptake 
operon
phosphate uptake
PknE rv1746 - + - - ABC-trans porter membrane transport
pknF rv1743 - + - Rvl 747 ABC-transporter membrane transport
pknG r>O410c + - TPR motif - GlnH
Glutamine uptake, 
pathogenesis 
metabolism
pknH rv1266c - + AfsK- like EmbR ABC-transporter
Arabinan
metabolism
pknl n£914c - + Asn in active site - ffh, ftsY cell division
pknJ n/2088 - + - - transposon ?
pknK rv3080c - - PDZ and AAA domains - luxA  like ?
pknL rv2176 + + - - transcriptional regulator ?
Table 1.1. Features of serine/threonine protein kinases of Mycobacterium tuberculosis. A brief survey 
of the 10 serine/threonine protein kinases and associated functions. Abbreviations: ORF, open 
reading frame (M. tuberculosis H37Rv ORF designation); TM, transmembrane-spanning region; 
PASTA, penicillin binding domain and ser/thr protein kinase associated domain; PQQ, 
pyrroloquinoline quinone; TPR, tetratricopeptide. Table adapted from Av-Gay and Everett, 2000.1.8  FHA  and  Serine/Threonine  Protein  Kinase  Domains  of 
Mycobacterium tuberculosis
1.8.1  Overview
There  are  11  STPKs  (PknA  to  L,  except  C)  and  4  protein  phosphatases  in  the  M. 
tuberculosis genome and investigation to date implicates many of these STPK in either 
regulation  of developmental  processes  or pathogenicity  (Table  1.1).  Also  in  the  M. 
tuberculosis  genome,  four  of the  six  FHA  domain-containing  proteins  are  encoded 
within gene clusters that also contain STPKs or Ser/Thr protein phosphatases (STPPs) 
(Figure  1.9)  (Pallen  et  al.,  2002).  Interestingly,  there  is  a  near  perfect  correlation 
between  the  presence  of  FHA-domain  containing  proteins  with  the  presence  of 
eukaryotic-like STPK and STPPs in bacterial genomes suggesting synergistic activity of 
the  two  protein  classes  (Ponting  et  al,  1999).  Presently,  little  is  known  about  the 
physiological role of many FHA domain-containing proteins and even less is known 
about  the  function  of FHA  and  STPK proteins  in bacteria.  The  occurrence  of FHA 
domain-containing  proteins  in  other bacterial  genomes  has  been  noted,  generally  in 
bacteria  with  more  complex  life  cycles  (Pallen  et  al.,2002),  perhaps  reflecting  the 
requirement for more advanced signalling pathways.
Although the role of these kinases is not fully understood, they are likely to regulate 
growth,  development,  metabolic processes and  interactions with the host cell  (in the 
case of intracellular parasites). It is hoped that greater understanding of how prokaryotic 
STPK activities are regulated may identify drug targets to disrupt essential activities in 
M.  tuberculosis and other important pathogens.  It is important to note that sequence 
analysis of the  11  STPKs from M.  tuberculosis shows they are significantly divergent 
from  mammalian  kinase  domains  and  should  therefore  represent  tenable  targets  for 
therapeutic  intervention  (Figure  1.10).  To  date,  little  is  known  about  the  effects  of 
kinase inhibitors on M.  tuberculosis. Kinase inhibitors erbstatin and staurosporine were 
shown by
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Figure 1.10. Phybgenetic tree depicting the relatbnship between members of the super family of human protein kinase and selected bacterial 
protein kinases. The seven major groups of human kinases are labelled and coloured distinctly, bacterial kinases are cofoured in grey. Group 
names: AGC containing PKA, PKG, PKC femilies; CAMK Cabium/calmodulin-dependent protein kinase; CK1 Casein kinase 1; CMGC 
Containing CDK, MAPK, GSK3, CLK femilies; STE homo logs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK Tyrosine kinase; TKL 
Tyrosine kinase-like. A selection of human and bacterial kinase domain amino-acid sequences were aligned using ClustalW and a neighbor- 
joining tree was produced using Phylip software. (S.g, Streptomyces griseus; S.c, Streptomyces coelicolor.;  L.m, Listeria monocytogenes; E.£ 
Enterococcus faecalis; B.c, Bacillus cereus; B.s, Bacillus subtilis', S.e, Staphylococcus epidermidis; S.a, Staphylococcus aureus', C.t, 
Clostridium tetani).(Prabhakaran et al., 2000) to prevent phagocytosis of Mycobacterium leprae by mouse 
macrophages.  In  addition,  die  protein  kinase  inhibitor  H7  was  found  to  inhibit  the 
growth  of two  mycobacterial  strains  Mycobacterium  bovis  Bacille  Calmette  Guerin 
(BCG) and Mycobacterium smegmatis me2 (Drews et al, 2001). The following Section 
will review recent investigations on M.  tuberculosis STPKs and their associated FHA 
domain-containing proteins.
1.8.2  PknA and PknB
The  operon  containing  two  FHA  domain-containing  proteins  (Rv0019  and  Rv0020) 
along with two STPKs (PknA and PknB) also contains the cell cycle protein rodA, a 
penicillin-binding  protein  pbpA,  and  a  protein  phosphatase  ppp  (Table  1.1).  PknB 
transcription is stable from early to late log phase with a 10-fold decrease upon entry to 
stationary phase in M. tuberculosis cultures. Presumably this is the same for all proteins 
in the PknB  operon (Kang et al.,  2005).  Av-Gay and co-workers also detected pknB 
expression in alveolar macrophages taken from a patient with tuberculosis (Av-Gay et 
al.,  1999).  Recently,  Kang  et  al,  2005,  showed  over-expression  of PknA  and  PknB 
separately  in M.  tuberculosis  cells  results  in  a broad,  bulgy  cell  morphology,  while 
partial  depletion  of  PknA  and  PknB  using  RNAi  caused  a  narrow  elongated 
morphology.  Using  a  proteomic  approach,  this  study  also  demonstrated  Wag31,  an 
ortholog of the cell division protein DivIVA of gram-positive bacteria, was an in vivo 
substrate of these kinases. These STPKs are therefore likely to regulate cell shape and 
division,  especially  in  light of their genetic proximity to pbpA and rodA.  Penicillin- 
binding  proteins  (PBPs)  are  known  to  control  cell  shape  by  the  regulation  of 
peptidoglycan polymerisation and genetic studies in Esherichia coli have demonstrated 
that the protein PBP2 directs cell elongation, while PBP3, encoded by ftsl, is involved 
in  cell  division.  The  homolog  of PBP2  in M.  tuberculosis  is  PbpA  (29%  identity), 
encoded by pbpA. In E. coli, PBP2 and RodA is also directs cell elongation and RodA 
mutants grow in a spherical shape because only septal synthesis is increased relative to 
cell elongation (Popham & Young, 2003) (Nanninga, 1998).
There is structural information available for two proteins from this important operon, 
Rv0020  and  PknB.  The  structure  of Rv0020  FHA  domain  has  been  solved  by  Dr.
40Smerdon’s  lab  at the National  Institute  of Medical  Research,  Department of Protein 
Structure  (unpublished data)  and  is  discussed in  Section  1.6.  The  structure  of PknB 
kinase domain in complex with a nucleotide analog was published at the start of 2003 
by two groups, (Young et al., 2003) (3A resolution) and (Ortiz-Lambardia et al., 2003) 
(2.2A  resolution)  and was  the  first known  structure  of a bacterial  STPK.  Critically, 
PknB was found to be autophosphorylated at four residues in its activation loop upon 
activation and this region was disordered in the crystal structure (Young et al., 2003).
The  extracellular  domain  of  PknB  contains  four  penicillin-binding  protein  and 
serine/threonine  kinase  associated  (PASTA)  domain  repeats  of  approximately  70 
residues in length (Yeats et al., 2002).  The domain binds to  /Mactam antibiotics and 
their peptidoglycan analogues, and PASTA domains are purported to direct proteins to 
the  site  of cell  growth.  Genetic  evidence  suggests  that the  PASTA  domain  and the 
transmembrane of a PknB homolog in Bacillus subtilis are capable of forming dimers in 
vivo  (Madec  et al.,  2005).  Therefore,  this enzyme may be  localised to  areas  of cell 
growth by means of extracellular PASTA domains, leading to oligomerisation and auto­
activation.  Another  regulatory  mechanism  involves,  PPP,  the  only  mycobacterial 
protein phosphatase which was found to dephosphorylate PknB (Boitel et al., 2003) and 
PknA  (Chopra  et  al.,  2003).  It  can  be  hypothesised  that  a  third  mechanism  of 
intracellular regulation of these STPK is via the FHA domain containing proteins in this 
operon.
It is important to note that this operon is conserved throughout the mycobacterial genus 
(100%  identity  in  M.  bovis  BCG)  and  in  many  other  Gram-positive  actinobacteria, 
including  Streptomyces  coelicolor  and  Corynebacterium  glutamicum  (Boitel  et  al,
2003).  The  fact  that  this  operon  is  located  near  the  origin  of  replication  and  is 
continuously  transcribed  in  animal  models  indicates  that  it  is  essential  for  normal 
growth of M. tuberculosis. Together these data indicate PknA and PknB are involved in 
a mechanism for the regulation of cell shape, one that may be conserved among gram- 
positive actinobacteria.
411.8.3  PknD
Currently, little is known about the function of PknD but genomic and expression data 
suggest that it plays a role  in sensing levels  of extracellular phosphate (Av-Gay and 
Everett., 2000). An important insight into the function of extracellular sensor domains 
of M. tuberculosis STPKs was provided by Alber and colleagues with the X-ray crystal 
structure  of the  PknD  extracellular sensor domain  (Good  et al.,  2004).  This  domain 
forms a six-bladed (3-sheet fold with a flexible tether to the transmembrane domain. It is 
similar  many  other  (3-propeller  motifs  with  diverse  functions  and  remains  the  only 
structure of (3-propeller domain linked to a kinase solved to date. The structure contains 
a  ‘cup’  motif that  is  the  site  for  ligand/protein-binding  surface  for  many  other  (3- 
propeller  structures  (Good  et  al.,  2004).  Although  the  domain  seems  able  to  bind 
extracellular ligands, it is difficult to see how a signal is transmitted to the intracellular 
kinase domain. Close inspection of the structure suggests there is little conformational 
change upon ligand binding and the flexibility of the transmembrane linker limits the 
propagation of any conformational change.
Further work by Grunder and co-workers showed, through the use of in  vitro kinase 
assay, PknD was able to phosphorylate one of the Rvl747 FHA domains (Grunder et 
a/., 2005).
1.8.4  PknE and PknF
Initial  characterisation  of  PknE  has  determined  that  the  protein  is  located  in  the 
membrane  fraction  (Molle  et  al.,2003).  Further  work  by  Grunder  and  co-workers 
showed,  through  the  use  of  in  vitro  kinase  assay,  PknE  and  PknF  were  able  to 
phosphorylate  Rvl747  FHA  domains  and  PknF  could  also  phosphorylated  Rv0020 
(Grunder et al.,  2005).  Koul  et al (2001)  also determined that PknF was  capable of 
autophosphorylation.  More  recently,  Deol  et  al  (2005)  carried  out  PknF  expression 
studies in M. tuberculosis using an anti-sense strategy. A reduction in PknF expression 
caused  faster growth,  aberrant septum  formation  and  increased uptake  of D-glucose. 
Over-expression led to a reduced growth rate and swelling of cells.  Rvl747 is encoded 
by a gene that is present in the same operon as PknF and close to PknE (Figure  1.9).
42Rvl747 is an ATP-binding cassette transporter protein (ATP) with two N-terminal FHA 
domains.
Molle et al.,2003, have shown that the recruitment and phosphorylation of Rvl747 by 
PknF is dependent on the two FHA domains of Rvl747.  Buxton and colleagues later 
presented evidence to demonstrate that the growth of an Rvl747 knockout strain of M. 
tuberculosis was reduced in vivo but normal in vitro (Curry et al., 2005).
1.8.5  PknG
Koul and co-workers found PknG localised to the cytosol of cells (Nugyen et al., 2005). 
This is consistent with the fact that PknG along with PknK are the only STPK in M. 
tuberculosis that lack a membrane spanning domain. The same group also demonstrated 
that  PknG  was  secreted  within  macrophage  phagosomes  and  inhibited  phagosome- 
lysosome fusion thereby mediating intracellular survival of mycobacteria (Walburger et 
al., 2004). PknG is expressed in M. bovis Bacille Calmette-Guerin (BCG) as well as M. 
tuberculosis, but interestingly not in the non-pathogenic mycobacterium, M. smegmatis. 
Macrophages  infected  with  PknG-expressing  M.  smegmatis  prevented  lysosomal 
transfer  whereas  the  vast  majority  of  wild-type  bacteria  were  found  within  the 
lysosome.  Significantly, an inhibitor specific  to PknG, tetrahydrobenzothiophene, has 
been  identified  and  is  able  to  cause  a  dose-dependent  inhibition  of M.  tuberculosis 
intracellular growth with additional effects on viability outside host cells (Walburger et 
al., 2004).
Cowley et al,  2004, demonstrated that PknG can autophosphorylate within the kinase 
domain and its C-terminal tetratricopeptide (TPR) domain.  They also demonstrated a 
direct  correlation  between  PknG  expression  and  glutamate/glutamine  levels  in  M. 
tuberculosis. This concurs with the fact that the PknG gene is encoded in an operon that 
includes  glnH,  a  glutamine  binding  lipoprotein.  However,  Koul  and  colleagues 
concluded  that  in  M.  bovis  BCG,  PknG  does  not  regulate  glutamine  metabolism 
(Nugyen et al., 2005). This may suggest differing role for PknG among M. tuberculosis 
and M. bovis BCG.
431.8.6  PknH
Molle  et  al  (2003)  presented  evidence  for  an  interaction  between the  STPK,  PknH 
(Rvl266), and EmbR (Rvl267), an FHA domain containing protein in M. tuberculosis. 
This has further strengthened the case for functional linkage between the STPKs and 
FHA domain-containing proteins. They also determined that the FHA domain of EmbR 
is essential  for the PknH-EmbR interaction and that abrogation of this interaction by 
mutation  of  conserved  S85  to  alanine  in  the  FHA  domain  of  EmbR  prevents 
phosphorylation by PknH.  Furthermore, a study by (Sharma et al.,2004), determined 
that  under  stress  conditions  such  as  low  pH  and  heat  shock,  PknH  was  able  to 
autophosphorylate and was downregulated, suggesting a role in adaptation to the host 
environment.  Indeed,  PknH  knockout  M.  tuberculosis  had  increased  resistance  to 
acidified  nitrite  stress.  The  knockout  strain  was  also  found  to  replicate  to  a  higher 
bacillary load in mouse organs than a wild type strain of M. tuberculosis.
EmbR is a transcription factor that is able to modulate the level of arabinosyltransferase 
activity  in  Mycobacterium  avium.  This  enzyme  is  involved  in  the  biosynthesis  of 
arabinan.  Arabinan is a component of the mycobacterial cell wall as a constituent of 
arabinogalactan and lipoarabinomannan (LAM). The anti-tuberculosis drug ethambutol 
(EMB) has been shown to target arabinosyltransferases encoded by the adjacent genes 
embC, embA and embB.  Mutations in EmbR have been linked to EMB resistance in 
human isolates of M. tuberculosis (Sreevatsan et al., 1997).
1.8.7  Other STPKs in M. tuberculosis
No information has been gathered as to the function or properties of any other STPKs in 
the M. tuberculosis except limited characterisation of Pknl. Here, standard cloning, 
expression and characterisation of Pknl confirm that it is a functionally active kinase 
able to autophosphorylate on serine and threonine residues in a manganese-dependent 
manner (Gopalaswamy et al., 2004).
441.8.8  GarA
Rvl827  is  also referred to  as GarA  (glycogen-accumulation regulator A).  This FHA 
domain-containing protein  is  almost  entirely  taken  up by  its  FHA  domain.  GarA  is 
found in the M.  tuberculosis cell as both a full-length protein and in a truncated form 
(residues 31-162) and both were found to induce protective immunity in animal models 
(Weldingh and Andersen.,  1999). The storage of glycogen is necessary for the growth 
of  Mycobacterium  smegmatis  and  GarA  was  determined  to  be  essential  for  the 
regulation of this process. Further functional information was provided by a GST pull­
down experiment that identified candidate binding partners for GarA, NAD-dependent 
glutamate  dehydrogenase  (Rv2476)  and  ferrodoxin-dependent  glutamate  synthase 
(Rv3859)(Westcott S., unpublished data).
The  optimal  phospho-peptide  motif selected  for  by  the  GarA  FHA  domain  has  a 
pThrXXY motif (Durocher et al,  2000).  The pThrXXY phospho-peptide  ligand was 
determined  to  bind  to  GarA  FHA  with  a  Kd  of  0.23pM  by  isothermal  titration 
calorimetry  (ITC).  The  GarA  FHA  demonstrates  a  preference  for  bulkier 
hydrophobic/polar residues at the pThr + 3 position of its phospho-peptide ligand in a 
manner analogous to Rv0020 FHA.
Although there  is  no obvious associated  STPK for GarA,  PknG  is linked to cellular 
glutamate/glutamine levels in M. tuberculosis and hence may be functionally associated 
with GarA (Cowley et al.,2004). Villarino et al, 2005, demonstrate that GarA is an in 
vitro substrate for PknB, D, E and F (Grundner et al, 2005).
451.9  Mycobacterium and Tuberculosis
The genus Mycobacterium consists of rod-shaped Gram-positive bacteria. Most of the 
60+ species are harmless  although a  subset of this genus is able to cause  disease in 
humans  and animals.  The  most severe  of these human diseases are tuberculosis  and 
leprosy caused by M. tuberculosis and M. leprae, respectively. Robert Koch, discovered 
that M. tuberculosis was the causative agent of tuberculosis (TB) in 1882.
Despite  extensive  investigation  into  tuberculosis,  which  has  led  to  a  detailed 
understanding of the disease mechanism,  it remains a global epidemic.  Mycobacteria 
are  facultative  intracellular  pathogens  that  preferentially  infect  macrophages  and 
multiply within their phagosomes. Infection occurs predominantly in the lungs, but can 
progress  to  infection  of other anatomical  sites.  Most people  who  carry  the  bacteria 
suffer no  obvious  symptoms  and cannot pass the disease  to  others  during this  acute 
phase of the infection. Both M.  tuberculosis and M.  leprae are essentially non-toxic to 
the host cells and much of the tissue damage comes about from the persistent activation 
of macrophages. The chronic nature of the infection leads to sever immunopathology 
with the formation of granulomas (‘tubercles’  in TB). Granulomas are small necrotic 
structures in which bacteria are sequestered in sheaths of phagocytes and lymphocytes. 
In most cases,  acute  infection does not occur and the bacteria may remain dormant, 
localised to the lungs. One-third of the global population are reported to be carriers of 
TB. A small subset of individuals become symptomatic leading to a mortality rate of 
50% if untreated.  The mechanism by which the bacteria remain dormant is unknown 
and the precise reason for reactivation is unclear.  Factors predisposing individuals to 
reactivation may be stress, overcrowding, malnutrition or hormone imbalance.
Throughout history, TB has accounted for more deaths than any other single infectious 
disease, with the exception of malaria. The World Health Organisation (www.who.intl 
estimate that of the 6 billion people in the world, approximately 2 billion are infected 
with M.  tuberculosis  and that each year about 8 million new cases of TB develop. The 
bacterium causes active disease in between 5 and  10% of those infected.  The highest 
prevalence  of  TB  is  in  developing  countries,  which  account  for  95%  of  cases
46worldwide. In 2002, the disease killed nearly 2 million people, the vast majority of them 
in low- and middle-income countries (latest WHO data reveals one death from TB every 
15 seconds worldwide and in India tuberculosis kills one person every minute).  More 
than half of cases occur between the ages of 15 and 49, leading to significant socio­
economic  impact.  Infections  with  HIV  increase  the  likelihood  that  latent  TB  will 
develop into active disease, amplifying the effects of TB worldwide.  In fact TB kills 
more AIDS patients than any other infection, and costs the global economy $16 billion 
each year.  Although 95% of the burden falls on developing countries globalisation is 
fuelling its spread internationally and no country is immune.  This has been recognised 
by the G8 countries, which issued a resolution to halve the morbidity from tuberculosis 
within 10 years. Recently the WHO sounded a warning over the growing prevalence of 
drug  resistant  TB  and  noted  that  the  worst  affected  areas  were  Eastern  Europe  and 
Central Asia with as many as 14% of cases in these areas involving multi-drug resistant 
(MDR) strains of the bacterium.  The former Soviet Union has the largest MDR rate of 
the world and there is a worrying spread of MDR in China
The vaccine for tuberculosis is not very effective.  Treating tuberculosis is hampered by 
diagnostic tests that fail to identify at least half of cases, and by drug treatments that 
must continue for at least six months to be effective.  The difficulty many patients have 
in completing such long treatment has contributed to new strains of TB that are resistant 
to many drugs.  Since research and development for new TB drugs came to a virtual 
standstill after the 1960s, TB treatment relies on drugs that are 40-50 years old.  This is 
because the TB market lacks sufficient incentives to support a pipeline of continually 
improving drugs.  Even with the market potentially reaching $700 million by 2010, it is 
concentrated in poor countries and no single pharmaceutical company has pursued the 
full  development  of an  anti-TB  drug.  Standard therapy  for pulmonary TB  includes 
isoniazid and rifampicin for 6 months, along with pyrazinamide and ethambutol for the 
first two months (isoniazid and rifampicin without pyrazinamide and ethambutol may 
be used for 9 months if necessary).  Occasionally used are streptomycin, thiacetazone, 
rifabutin and rifapentin.  The costs of curing MDR-TB are up to 1400 times the cost of 
regular treatment.  Since MDR-TB cannot be adequately treated through the standard 
short course of therapy, treatment entails up to 2 years of treatment with “second line” 
drugs including cycloserine, para-aminosalicyclic acid (PAS), ethionamide,  amikacin, 
kanamycin  and  capreomycin,  which  is  much  too  long  to  ensure  compliance  and 
currently cure rates are limited to 60%.  It is hoped that with a new drug and a shortened
47treatment regimen of less than two months, then cure rates of 90% could potentially be 
achieved (WHO).
481.10  The biological perspective
M. tuberculosis is reported to have a large number of eukaryotic-like proteins (Krupta et 
al., 2005) and therefore has developed one of the most complex signalling systems of 
all bacteria. This intricate signalling system facilitates the bacterium’s ability to lead a 
complex  life  cycle  and  exact  such  a  devastating  disease.  The  primary  focus  of this 
project is a putative operon that contains two FHA domain-containing proteins (Rv0019 
and Rv0020) along with two STPKs (PknA and PknB) plus a differentially expressed 
FHA  domain-containing protein Rvl827  (GarA)  (Figure  1.11).  The co-expression of 
FHA domain-containing proteins and STPKs strongly suggests that these bacterial FHA 
domain-containing proteins engage in phospho-dependent protein-protein interactions, 
and  FHA  dependent  processes  in  bacteria  are  controlled  by  STPK-dependent 
phosphorylation.  In  addition,  the  fact  that  STPK  domains  and  FHA  domains  are 
covalently linked in some eukaryotic proteins (i.e. Rad53, see above) implies functional 
linkage.
Initial yeast two-hybrid screens carried out by the Division of Mycobacterial Research, 
NIMR, demonstrated an interaction existed between PknA and Rv0020, and PknB and 
Rv0019.  These data provided the opportunity to study the relationship between FHA 
domains and STPKs in the context of mycobacterial signalling. These interactions may 
form the basis of a mechanism of phosphorylation dependent control that is a precursor 
to systems utilised by eukaryotes.
The aim of this  study was to further characterise the  interactions between PknA and 
Rv0020,  and  PknB  and  Rv0019  along  with  interaction  with  Rvl827  through  the 
application  of a number of biophysical  and biochemical  methods.  This  investigation 
concentrated  on  the  interrelationship  between  these  two  important  STPKs  and FHA 
domains.  It is hoped that a greater understanding of how prokaryotic  STPK activities 
are regulated may identify drug targets.
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Figure 1.11. Schematic representation of  proteins used in this sidy. Mycobacterium 
tuberculosispknA,  pknB andRv0020 encode predicted transmembrane proteins with a single 
transmembrane helix (TM) connecting a periplasmic domain to a cytosolic domain. pknA and 
pknB encode typical kinases of the STPK femily with conserved motifs (shown above). All 
domains were predicted using the SMART (Simple Modular Architecture Research Tool) 
database (www.smart.embl-heidelberg.de).___________________________________________
502  Quantitative techniques in protein-complex interactions
2.1  Surface Plasmon Resonance
2.1.1  Overview
Surface  plasmon  resonance  (SPR)  is  a  powerful  technique  that  allows  the  user  to 
observe biomolecular complex formation and dissociation in real time.  SPR is able to 
measure the interaction properties of multi-molecular complexes across a wide range of 
affinities,  sizes  and  purities.  SPR  provides  a  rapid  and  robust  method  for  the 
measurement  of  kinetic  and  equilibrium  interaction  data.  However,  this  technique 
cannot  conveniently  measure  stoichiometry.  The  basic  concepts  of  SRP  will  be 
discussed but for further detail refer to BIAcore textbooks (BIAtechnology handbooks,
2004)  and  reviews  by  (Morton  &  Myszka, 1998),  (Winzor,2003)  and  (Nedelkov  & 
Nelson, 2003).
SPR is essentially based on the total internal reflection of polarised light. Total internal 
reflection occurs when light transverses a medium of high refractive index (glass prism) 
and  encounters  an  interface  with  a  medium  of lower  refractive  index  (an  aqueous 
interface).  The  BIAcore  instrument is arranged with a prism-metal-solution interface 
such that the  total  internal reflection of incoming light  generates  an electromagnetic 
field of reflected photons that penetrate beyond the reflecting surface (Figure 2.1a). This 
electromagnetic component is called the evanescent wave.  This evanescent wave can 
penetrate the interface by a distance of one quarter of its wavelength.
The BIAcore instrumentation is set up to generate an evanescent wave that is parallel to 
the plane of incident.  To achieve this, polarised light enters  the  system at a specific 
angle  of incidence  and  causes  the  intensity  of reflected  light  to  be  reduced.  This 
phenomenon is due to the energy transfer from incoming photons
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Figure 2.1. Generation and detection of surface plasmon resonance signal. (A) Total internal 
reflection at the metal coated interface generates an evanescent wave that propagates into the 
medium of tower refractive index (B)  Changes in the refractive index of the surface layer of 
a solution in contact with the  sensor chip are detected by SPR. 1. There is a decrease in 
reflected intensity at an angle dependant on the refractive index of the medium  on the non­
illuminated surfece. 2. There is a shift in the SPR angle as biomolecules bind to the surfece 
changing the refractive index. 3. A sensorgram is a plot of the SPR angle against time. 
Adapted from the BIAtechnology handbook.
52to surface plasmons (free electrons in the metal film). Thus, this technique is known as 
surface plasmon resonance.
The BIAcore instrument measures the energy reflectance as a function of the SPR or 
incident angle to generate an SPR spectrum (Figure 2.1b). The SPR angle is dependent 
on  three  factors:  the  properties  of  the  metal  film  (i.e.  thickness),  wavelength  of 
incidence light and the refractive index of the environment into which the evanescent 
wave  propagates.  The  BIAcore  instrument  can therefore  measure  the  SPR  angle  in 
relation to the refractive index of the aqueous solution on the non-illuminated side. The 
refractive index of this medium is altered by the chemical composition of the solution 
close to the surface. In this way SPR is utilised to transduce the accumulation of mass at 
a surface into an optical signal.
2.2.2  General methodology
The  BIAcore  instrument is  able to  use  SPR  for real-time  analysis  of changes  in the 
concentration of molecules which contact the sensor surface. To adapt this principle to 
measure  protein/protein  or protein/nucleic  interactions  the  BIAcore has  a number of 
essential features. The sensor surface has a non-illuminated surface allow biomolecular 
complexes to form on it.  This is achieved by the use of interchangeable sensor chips 
onto which bio-molecules can be immobilised. The sensor chip is a glass slide coated on 
one side with a thin gold film, and covalently bound with a flexible matrix on the other 
side. Bio-molecules are first attracted to the flexible surface by electrostatic interactions 
at low ionic strength. This is followed by covalent immobilisation of the bio-molecules 
onto  the  non-illuminated  surface  of the  sensor chip.  In  the  case  of this  study CM5 
sensor chips were used which contains a flexible surface of carboxymethylated dextran 
and proteins were immobilised on this surface by an amine-coupling reaction.  Amine 
coupling involves modification of the dextran carboxymethyl groups with a chemical 
reaction  involving  N-hydroxysuccinimide  (NHS)  and  N-ethyl-N’-(dimethyl- 
aminopropyl)-carbodimide  (EDC).  This  introduces  N-hydroxysuccinate  esters  to  the 
dextran that then react spontaneously with the nucleophilic groups on the ligand, such 
as amines, to form covalent links.
53Once a bio-molecule is immobilised onto the sensor chip the liquid handling system of 
the BIAcore instrument allows the controlled transport of analytes over the sensor chip. 
The BIAcore instrument detects the changes in SPR angle, which can be related to any 
mass increase or decrease on the surface, including specific and non-specifically bound 
analyte.  These changes in resonance signal as a function of time are represented in a 
sensorgram plot (Figure 2.2).
2.2.3  Real-time biomolecular interaction detection
The association and dissociation of an analyte to the immobilised ligand is monitored to 
give accurate kinetic information on the interaction (Figure 2.2).  In a typical binding 
study,  the  association  phase  consists  of an  analyte  sample  being  injected  over  the 
immobilised ligand at a constant flow rate. As analytes bind to the immobilised ligand 
there is a concurrent increase in signal, this gives information on the association-rate of 
the interaction. At the point where there is no further increase in signal, all binding sites 
have been saturated and an equilibrium phase is obtained. This is a steady-state point 
defined by the  concentration of the analyte  in the  sample.  The  signal at equilibrium 
phase  is  used  to  determine  the  association  constants  for  this  interaction.  After 
equilibrium is achieved, the injection of sample is stopped and buffer is passed over the 
surface,  this  begins  the  dissociation  phase.  All  non-covalently  bound  material  is 
detached  from  the  chip  surface  giving  information  on  the  dissociation-rate  of the 
interaction.
All  binding  experiments  should  be  accompanied  by  the  use  of a  reference  surface 
containing no immobilised protein as a control to ensure reliability of BIA data. The 
contribution of the injected analyte to the total refractive index can be determined from 
a  sensorgram  of a  reference  cell  without  immobilised  ligand.  The  first  step  of data 
analysis should always be to subtract the response of the
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Figure 2.2. Schematic sensorgram from a typical surface plasmon resonance experiment. A 
sensorgram displays the progress of the interaction at the sensor surface. Adapted from the 
BIAtechnology handbook._____________________________________________________
55reference surface from the reaction surface. To obtain the most accurate possible kinetic 
data for the interaction there are a number of experimental parameters that should be 
optimised. The experiment should be conducted over a range of analyte concentrations. 
The concentration of analyte sample should be chosen with the signal to noise limitation 
in mind. The flow rate should be selected to minimise the effect of the mass-transport 
limitation  (see  Section  2.2.6).  Faster  flow  rates  can  reduce  the  amount  of analyte 
rebinding during dissociation phase. During dissociation phase, the amount of available 
binding sites increases leading to rebinding of the analyte. Consequently, the apparent 
dissociation-rate is lower than the actual rate.
2.2.4  Application areas
SPR techniques have been applied to different areas, such as the studies of interactions 
involving  proteimprotein  complexes,  proteinrnucleic  acid  complexes  and 
proteinxompound complexes.  Generally the BIAcore instrument is a versatile tool to 
address a variety of questions:
■   The  instrument provides  a way  of screening  binding  activities  from  samples 
without the need for labelling
■   The  kon  and  kQ ff rate  constants  can  be  determined  from  the  association  and 
dissociation phases of a sensorgram and are often more informative in biological 
settings than equilibrium constants
■   Binding  of  an  analyte  to  a  ligand  can  be  monitored  in  the  presence  of  a 
preexisting analyte complex and an immobilised ligand.
■   The relative binding affinities and rate constants of a series of analytes can be 
evaluated
562.2.5  Data analysis
2.2.5.1  Kinetic measurements
Kinetic rate constants are determined with respect to the chosen interaction model for 
the system. This interaction model should be selected based on background biological 
knowledge and/or previous biophysical experiments. In general, complex models should 
only be  applied  when  simple  models  do  not provide  a  suitable  fit to  data.  The  1:1 
binding  model,  was  utilised  for  this  study,  and  will  be  discussed  here.  The  model 
assumes rapid mixing of the analyte with the sensor surface layer in the bulk phase and 
a single binding step.
A  homogenous  interaction  with  a  stoichiometry  of  1:1  between  analyte  A  and  an 
immobilised ligand B is described below:
A + B= -AB
Kff a)
Where, kon is the association rate constant and & off is the dissociation rate constant. In the 
association phase, the rate of complex formation is described below:
As the concentration of the complex [AB] is measured by the BIAcore instruments as 
the response, R, at time, t, to express equation (2) in terms of SPR signal:
57dR
-^=kU\r^ - r)-kr (3)
Where, dRJdt is the rate of change of the SPR signal and Rmax is the maximum analyte 
binding capacity.  If the expression (&on[A]+&0ff) is termed  then in accordance with 
this model the slope of the plot of dRJdt against R will be ks. A series of experiments are 
carried out at a range of analyte concentrations will give a range of ks values. When 
these ks values are plotted against the analyte concentrations a straight line should be 
generated. The slope of the plot is the A :on and the intercept of the Y-axis defines the & 0ff 
value.
During the dissociation phase there is no analyte addition and equation (2) is modified 
to:
—   =   -k offR 
dt  o f f (4)
the integrated logarithmic form of equation (4) is:
R (5)
where, Rq  is the response at an arbitrary starting time , to. If \n(Ro/Rt) is plotted against 
(t-to), a straight line will be generated with the slope being & 0ff-
582.2.5.2  Equilibrium measurements
If the  interaction  is  able  to  reach  a  steady  state,  or  equilibrium,  then  equilibrium 
constants may be determined from BIAcore data using the following scheme.
The equilibrium constants are defined by the following two formulae:
where Ka is the association constant and Kd is the dissociation constant.  Equations (6) 
and (7) can be applied to BIAcore data. The concentration of free analyte is equal to the 
concentration of analyte sample injected. If the surface binding capacity is known, the 
concentration of free ligand can be derived from the concentration of the complex. The 
concentration of the complex is the response of equilibrium.
K  - \M
(6)
K ‘ '  M *  J
(7)where, C is the concentration of analyte, Rm ax is the total surface binding capacity and is 
the steady state binding level. Rm ax and Req are both expressed in terms of response units 
(RU).
2.2.6  Complexities and artifacts
Sensorgrams that do not fit a homogeneous interaction with a  1:1  stoichiometry may 
indicate  a  more  complex  mode  of  interaction  or  maybe  due  to  artefacts  of  the 
measurements.  Several  frequently  observed causes  of deviation  are  discussed in this 
Section.
The kinetic model in equation (1) assumes that the observed rate of binding reflects the 
interaction kinetics between the analyte and ligand.  In practice, the mass transport of 
analyte to the sensor chip surface can be a limiting factor and to take account of this 
factor, the reaction should be described as:
A  —  A  -i- /?z=i A R
bulk  T ~   surface  +  D  7 ----  (9)
K off
where km  is the rate constant for mass transport to and from the surface assuming that 
the rate constant for mass transport is the same in both directions.
During the dissociation phase, if the mass transport is much faster than association of 
analyte with ligand, the observed binding will be governed by the kinetics between the 
analyte and the ligand. On the other hand, if mass transport is slower than association, 
the mass transport process will limit the binding and the apparent on rate will be slower 
than the true value. During the dissociation phase, analyte molecules removed from the 
surface by dissociation can either be transported to the bulk solution or rebind to free 
ligand sites on the surface. The observed dissociation rate is the result of competition 
between these two processes, and will reflect the dissociation rate constants only when 
mass transport is fast compared to dissociation.
60When mass transport is limiting, the plots of dR/dt versus R curve downwards instead of 
being linear.  It is important to be  aware  that this downwards curvature may also be 
caused by heterogeneity in either the ligand or analyte. If ligands with more than one 
binding constant are present on the same surface, the observed sensorgram would be the 
sum  of two  or more  independent  sensorgrams,  one  for each  ligand  species.  At low 
concentrations,  the  high  affinity  sites  will  dominate  the  binding,  whereas  at  high 
concentrations, the low affinity process will become more evident. Ligand heterogeneity 
may be caused by either the heterogeneity of the starting material or may be created 
during the immobilisation process.
612.2  Isothermal Titration Calorimetry
2.2.1  Overview
To fully understand the nature of a protein recognition event and the forces that stabilise 
the  interaction,  the  thermodynamics  of  association  should  be  characterised.  The 
thermodynamics of association are define by the stoichiometry of the interaction (n), the 
binding  constant  (K),  the  Gibbs  free  energy  of binding  (A G b ),  enthalpy  of binding 
(A H b ), entropy of binding (A S b ) and heat capacity of binding (A C P). Isothermal titration 
calorimetry (ITC) is a now a well established technique that allows the calculation of all 
but one of these parameters in a single experiment. A typical ITC experiment consists of 
stepwise injections of one reactant into a reaction cell containing the other reactant. The 
heat  evolved  or  absorbed  in  a  liquid  sample  as  a  result  of injecting  a  reactant  is 
measured.
This system provides equilibrium binding constant, the stoichiometry and enthalpy of 
binding using the Wiseman isotherm theory (Wiseman et al., 1989). Gibbs free energy 
of binding  and  the  entropy  of  binding  can  subsequently  be  determined  once  the 
association constant is established. The most commonly used instrument for conducting 
ITC  is the VP-ITC  MicroCalorimeter from MicroCal Inc.  (Northampton MA, USA). 
The VP-ITC MicroCalorimeter is able to directly measure the heat evolved from the 
association of a ligand to its binding partner.  This technique has been widely used to 
determine the thermodynamic parameters for a range of biomolecular binding events 
(Leavitt & Freire,  2001). When used in tandem with structural information, important 
residues within the binding interface can be identified and their energetic contribution to 
binding can be established. This review of the basic concepts of ITC is based on the VP- 
ITC  user  guide,  although  more  detailed  guides  to  using  ITC  exist  (Ladbury  & 
Chowdhry, 1996).
622.2.2  Wiseman isotherm theory
In this study, the Wiseman isotherm theory will be applied to a binding event with a 1:1 
stoichiometry involving single-step binding. The independent variables for a single step 
binding events are the association constant, Ka, the enthalpy, AH®, and the number of 
binding sites. As mentioned above these parameters are directly measured by the VP- 
ITC  MicroCalorimeter,  and  details  of  this  process  will  be  discussed  later.  The 
dependent variables  for binding are  Gibbs  free energy of binding {AGb)  and entropy 
(ASb). AGb and ASb can be calculated from the following equation:
A Gb  =-RT\nKA=AHb- TASb  (io)
A  binding  model  to  characterise  the  change  in  uncomplexed  protein  after  each 
successive injection is explained below. A binding event with the stoichiometry of 1:1 
is described by the binding equilibrium M + X =MX then:
[ m x]  
- [M\X] (11)
and
X„ =[X]  + [M X] (12)
and
M,ol =  [M]+ [MX] =  + [MX] (13)
63where KA   is the equilibrium association constant, Xtot is the total ligand concentration 
and Mt0, is the total macromolecule concentration in the system. Equation (12) can be 
expressed in terms of the ligand concentration, [X], and substituted into equation (13) to 
give the following quadratic equation:
0 = [MX]1  +  -  Xm   -  -J-) + M „x „   (14)
If
b = -M lo l - X In l — — lot  tot  y
k a
c=MtJCtot  (15)
then the only real root of equation (14) is:
[ m x]=
- b-y!b2-Ac
(16)
substitution of (15) into (16):
d[MX]  1
=   —   +  ■
M ,"  2  J x 2 r -  2Xr (1 -  r) + (1 —  r):
(17)
where  r  is  equal  to  \l{KA Mtot)  and  Xr  is  equal  to  Xlot/Mlot.  The  change  in  the 
concentration of MX can be related to the heat change by:
64dQ = d[MX]»AHb   • V 0 (18)
where AHb is the enthalpy of binding,  Vo is the reaction cell volume and Q is the heat 
evolved from the reaction. Then, substitution of equation (17) into (18) yields the final 
equation:
------------------= A//,
V0(dQ/dXtot)
Equation (19) describes a curve, used originally by Wiseman,  1989, which represents 
binding  isotherms  for  a  single-site  interaction  (Figure  2.3).  The  microcalorimeter 
measures the finite differential heat dQ/dXtot. It should be noted that the differential heat 
measured is dependent on the value of Mtot in relation to the values of KA  and to Xtot.
A precise values for the equilibrium association constant, KAi and enthalpy of binding, 
AHb, can only be established if Mtot is in the appropriate range to yield an informative 
binding isotherm.  The shape of a binding isotherm is very sensitive to changes in the 
KA Mtot value, designated c, as seen in Figure 2.3. In
1   l-(l + r)/2-X /2 
-+  ,
2  J X 2  -2J„n-rH n + rV
(19)
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Figure 2.3. Theoretical binding isotherms for a single-site binding interaction. Isotherms for 
a range of  c values (equal to KAMtot) are shown. The plot shows that for c values between 1  
and 1000 (experimental K window), small changes in c cause large changes in the shape of 
the isotherm. For accurate binding constant determination a value of c between 10 and 100 is 
most desirable. Adapted from BIAtechno logy handbook.
66other  words,  reactions  with  tight  Ka  must  be  studied  at  low  macromolecular 
concentrations  and  reactions  with  weak Ka  must be  studied  at high  concentrations. 
Therefore, it is mandatory that the values of c be in the range of 1  to 1000, although c 
value  between  10  and  100  is  most  desirable.  This  range  is  referred  to  as  the 
‘experimental  K window’.  A  titration  with  a  c  value  beyond  this  range  causes  the 
isotherm to decrease in curvature and therefore lose information.
2.2.3  General methodology
A  schematic  of the  VP-ITC  MicroCalorimeter is  shown  in  Figure  2.4.  Samples  are 
introduced  to  the  reaction  cell  through  a  narrow  access  tube  using  a  long-needled 
syringe.  Filtered,  degassed water is loaded into the reference cell.  The cells must be 
loaded carefully to avoid introduction of air bubbles and samples should be degassed 
prior to  loading.  The  second  sample  is  added  to  the  syringe,  again  in  a manner  to 
prevent the acquisition of air bubbles. The injection of sample from the syringe to the 
reaction cell will follow a pre-set schedule. Specific requirements for schedules in each 
experiment  will  be  discussed  later.  All  injection  schedules  have  an  initial  smaller 
injection to remove any air bubbles and bring the sample in the syringe to the correct 
volume.  In  addition,  all  schedules  have  a  pre-equilibration  before  the  titration 
commences that lasts 30 minutes and brings both samples to the same temperature.
Both cells have two heaters, and between the cell surfaces, a thermoelectric device is 
placed to measure the temperature difference AT\. The temperature difference between 
the inner shield and the outer cell surfaces, AT2, is measured and fed to a heater on the 
jacket to maintain its temperature close to the temperature of the cells. There is also an 
outer shield that is maintained at the same temperature in order to minimise fluctuations 
due to room temperature changes.
The  ITC  measurement  works  on  a  heat  compensation  principle  (Leavitt  and  Freire, 
2001). Throughout a titration, less than a milliwatt of power is dissipated by the heater 
of the reference cell. This activates the cell feedback circuit to
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Figure 2.4. Schematic of the VP-ITC instrument. This illustration includes the VP-ITC cells 
that are kept at a constant temperature by the inner and outer shields (blue). The 
injector/stirrer assembly (green and brown) allows accurate addition of the ligand through 
the injection needle, while the stirrer blade ensures complete mixing in the cell throughout 
the injection period. The reaction cell temperature is maintained at the same temperature as 
the reference cell by feedback. The change in temperature of  the reaction cell during 
addition of the ligand forms the basis of the ITC measurement.
68maintain AT\  at zero.  In the absence of an interaction, the feedback power will be a 
constant that is resting at the baseline value. In the case of an exothermic interaction, 
there will be a temporary decrease in feedback power causing the reaction cell to return 
to the baseline value of the reference cell. Conversely, an endothermic reaction will lead 
to an increase in power to bring the reaction cell to the temperature of the reference cell. 
The  heat  change  in  the  reaction  cell  upon  each  injection  can  be  determined  by 
integrating the area under each peak.
A number of considerations  should be made when designing an ITC  experiment.  As 
mentioned  above  the  concentration  of  sample  in  the  reaction  cell  of the  VP-ITC 
MicroCalorimeter  should  be  carefully  selected  to  obtain  a  c  value  within  the 
experimental K window. Essentially, the macromolecular concentration should be close 
to the dissociation constant. It is preferable to have complete saturation of the binding 
sites in the final few injections.  The baseline should be stable between each injection 
and a there should be an adequate interval between successive injections allowing return 
to baseline temperature.
The number of and volume of injection should be considered.  This can be estimated 
from  the  total  heat,  Q,  required  in  the  reaction.  An  estimated  value  for  Q  can  be 
determined from prior knowledge of the enthalpy of binding, using a rearranged form of 
equation (18):
e = AH, x M,o, x V (20)
where V is the reaction volume (around 1.3mL for the VP-ITC MicroCalorimeter).
Control titrations can be run to determine the contribution of the heat of dilution of the 
protein  sample  to the  total  heat of the  reaction.  This  is conducted by titrating the  a 
ligand solution into a cell filled with buffer. Conversely, buffer may be titrated into a 
reaction cell containing the protein sample.
692.2.4  Data analysis
Raw ITC data should initially be corrected by subtracting the heat of dilution. Accurate 
initial concentrations of samples in the syringe and cell are used to determine the free 
and  bound  concentrations  of both  macromolecules  in  the  reaction  cell  after  each 
injection.  These  values  are  related  to  the  integrated  heat  signal.  This  analysis  is 
performed by the VP-ITC data analysis software.
As already described the values for Xtot and Mtot can be determined using equations (12) 
and (13). When taking equations (11-13) into consideration, the complex concentration 
can be expressed in terms of Mtot and KA:
ka [A (21)
As the heat,  Q, evolved from the reaction is proportional to the concentration of the 
complex in an ITC experiment:
Q = V AH b[Mjx
1  + K A[X]
(22)
Using floating values of KA and AHt, the raw ITC data can be fitted to Q as a function 
of [X\  using equation  (22).  Using the  approximations  of KA   and AHt generated,  the 
ligand  concentration  is  calculated  at  each  point  and  equation  (22)  is  refitted  as  a 
function of [X\. The fitted curve represents the generation of heat with respect to the 
ligand concentration.  This allows the values of KA   and AHt to be redefined.  Further 
iterations are conducted until constant values for KA  and AHt are achieved.
702.3  Circular Dichroism
2.3.1  Overview
Circular  Dichroism  (CD)  is  a  widely  used  technique  for  the  elucidation  of protein 
conformational information. CD is itself an expression of optical activity and all optical 
activity originates in the absorption bands of dissymmetric compounds. Dissymmetric 
compounds cannot be superimposed on their mirror image. Proteins are dissymmetric in 
two ways: Configuration and Conformation.
All  amino  acids  residues  with  the  exception  of  glycine  have  a  dissymmetric 
configuration  due  to  the  L  configuration  about  their  a-carbon  atom.  In  addition, 
threonines and isoleucine residues contain additional dissymmetric centres that increase 
their optical  activity.  Conformational  dissymmetry is  a  consequence  of the  fact that 
electronic interactions between different residues in a protein also contribute to optical 
activity  and  therefore,  the  secondary  structure  of a  proteins  also  affects  its  optical 
activity. Thus, CD spectroscopy has been widely used to study proteins because it is 
remarkably  sensitive  to  molecular  conformation.  This  Section  reviews  the  basic 
methodology  of CD  spectroscopy  and  some  of its  applications,  and  is  based  on  a 
number of excellent reviews on the subject (Yang et al., 1986)(Woody, 1996)(Johnson, 
1990).
2.3.2  General methodology
In a conventional protein absorption spectrum, several amino acid side chains (notably 
Tyr, Trp, Phe, His and Met) absorb light strongly in the far-UV region (below 250nm) 
mainly through the contribution of the peptide bond (amide chromophore). As CD is an 
absorption phenomenon,  the chromophores that contribute  to a  CD  spectrum  are the 
same  for a conventional absorption spectrum.  However, the parameter measured in a 
CD experiment is the difference in absorbance from left and right circularly polarised 
light:
71DA —  A  i —  Ar (23)
Where A l  is the measured absorbance for left circularly polarised light and A r  is the 
absorbance for right circularly polarised light. Electrons participating in the transition to 
an  excited  state  sense  a  dissymmetric  environment,  giving  rise  to  a  difference  in 
absorption of light in each direction. These differences in absorption cause the resultant 
beam  (a  recombination  of both  left  and  right-handed  emergent  beams)  to  form  an 
ellipse. CD spectropolarimeters are capable of measuring this difference in absorption 
and hence the ellipticity.
As CD is an absorbance measurement, it uses a version of the Beer-Lambert Law:
Ae«n.=-^  (24) c,l
where sm rw  is the mean residue molar extinction coefficient (M^cnT1 ), cr is the mean 
residue  molar  concentration  and  /  is  the  path  length.  The  mean  residue  molar 
concentration  can be  determined by  multiplying  the  concentration  of protein by the 
number of amino acids or peptide bonds.
The  far-UV CD bands are principally derived from peptide bond absorption and are 
sensitive  to  the  secondary  structure  of  the  protein  (a-helix,  p-sheet,  p-tum  and 
random/unordered  main  chain  conformations).  Far-UV  spectra  are  particular 
informative  in the  170nm to 240nm region,  where the  characteristic contributions of 
secondary  structure  are  well  known  (Figure  2.5).  In  the  context  of this  study,  it  is 
important to note that whilst the  content of proteins can also be  estimated from CD 
spectra, there is some degree of uncertainty because P structures are less regular than a 
helices and contribute less to the CD spectrum.
72160  180  200  MO  240  2«0
Wavelength (am)
Figure 2.5.  Far UV spectra associated with various types of secondary structure. Solid line, 
a-helix; long dashed line, anti-parallel (3-sheet; dotted line, type I (3-turn; cross dashed line, 
extended 3,-helix or poly (Pro) II helix; short dashed line, irregular structure.
Adapted from Kelly et al., 2005.2.3.3  CD Applications
Although CD only provides low-resolution structural information, it does have two 
great strengths: First, it is extremely sensitive to changes in molecular conformation and 
second, it is applicable in a wide range of solvent conditions and utilises a small amount 
of protein. In the study of proteins CD spectroscopy is mainly utilised for:
•  Determination of protein secondary structure
•  Determination of optical purity
•  Analysis of the tertiary structure of proteins and conformational changes
•  Comparison of the  secondary and tertiary structures  of wild-type  and mutant 
proteins
•  Binding studies involving conformational changes
•  Nucleic acid structure and changes upon binding or melting
•  Thermodynamic parameters from temperature dependencies of CD signals
•  Kinetics of conformational changes on millisecond time scales
Data collection and analysis of CD spectra are outlined in the following Chapter 
(Section 3.2.5)
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3.1  Materials
3.1.1  Chemicals
Chemicals used in this study were produced from the following companies: Amersham- 
Pharmacia,  Fluka,  Novagen,  Merck,  Pierce,  Qiagen,  Sigma-Aldrich,  and  Invitrogen. 
Contributions from individuals are mentioned specifically.
3.1.2  Enzymes
Benzonase nuclease 
KOD DNA polymerase 
Restriction enzymes 
T4 DNA ligase 
T4 DNA polymerase 
PreScission protease
Novagen
Novagen
New England Biolabs 
New England Biolabs 
New England Biolabs 
Amersham-Pharmacia
3.1.3  Kits
Qiagen Plasmid Mini Kit  Qiagen
Qiagen Plasmid Midi Kit  Qiagen
Qiagen Gel Extraction  Qiagen
QuikChange Site directed mutagenesis  Stratagene
3.1.4  Chromatography media
DEAE-Sepharose Fast Flow  Amersham-Pharmacia
Glutathione Sepharose 4B  Amersham-Pharmacia
NTA-agarose Superflow  Amersham-Pharmacia
Superdex 75 and 200  Amersham-Pharmacia
Immobilised Metal Affinity Column (IMAC)  Pierce
753.1.5  Microorganisms
E. coli Top 10  F- mcrA A(mrr-hsdRMS-mcrBC) cp80/acZAM15 AlacXIA recAl  araD\2>9
A(araleu) 7697 gal\J galK rpsL (StrR) endAl nupG (Invitrogen)
E. coli BL21 (DE3)  B, F, hsdSB (rB~, mB~), gal, dcm, ompT, X(DE3 (Novagen)
E. coli Rosetta  pRARE containing the tRNA genes argU, argW, ileX,
leuW, glyT,proL, metT, thrT, tyrU, and thrU(Novagen)
3.1.6  Media, special reagents and antibiotics
Luria-Bertani (LB)  10 g/1 Bactotryptone, 10 g/1 NaCl, 5 mM NaOH, 5 g/1 
media  yeast extract
TAE  40 mM Tris.HCl, pH 8.0; 40 mM Acetic acid; 1  mM EDTA
10X SDS buffer  0.25 M Tris.HCl, 1.92 M Glycine, 1  % SDS 
Electroblotting buffer lOx buffer, 22.13g CAPS in 900mL dHzO, titrate to pH  11  with 
NaOH and add (IH2O  to final volume of 1L.
HBS-EP buffer  1  OmM HEPES, pH 7.4, 150mM NaCl, 3mM EDTA,
0.005% surfactant P20 
Yeast Protein Extraction Reagent (YPER)  Pierce
Antibiotics  from  Sigma  were  used  at  the  following  concentration:  100  pg/mL; 
Ampicillin and 34 pg/mL; Chloroamphenicol.
Electroblotting buffer lOmM CAPS, pH 11, 10% analytical grade methanol.
763.2  Methods
3.2.1  Recombinant DNA
3.2.1.1  Agarose gel electrophoresis
Agarose  gels  were  prepared  and  run  according  to  standard  procedures  (Sambrook, 
1989).
3.2.1.2  Isolation of plasmid DNA
DNA isolation was carried out using either QLAprep Spin Miniprep or Midiprep Kits 
from Qiagen, according to the manufacturer’s instructions.
3.2.1.3  Polymerase chain reaction (PCR)
Amplification  of  DNA  fragments  was  carried  out  using  KOD  DNA  polymerase 
(Novagen)  according  to  standard  procedures  (Sambrook,  1989).  Fragments  were 
digested  according  to  enzyme  specification  (NEB  Handbook)  and  purified  by  1% 
agarose gel electrophoresis was followed by extraction using QLAquick Gel Extraction 
Kit according to manufacturer’s protocol.
3.2.1.4  Ligation
Vector and insert DNA were quantified in agarose gels using digested ^.-marker (New 
England Biolabs) as a reference.  100 ng of vector was ligated with a four fold molar 
excess of insert overnight at 8 °C using T4 ligase (New England Biolabs) according to 
the manufacturer’s protocol.
773.2.1.5  Sequencing of recombinant plasmid constructs
The nucleotide sequence of all synthesised and mutated genes was verified to ensure 
error-free  amplification.  Capillary  dye  terminator  sequencing  was  performed  by 
Cytomyx sequencing services of Cambridge.  Sequence analysis was performed using 
Chromas and DNAstar software.
3.2.1.6  Ligation-Independent Cloning (LIC)
3.2.1.6.1  Overview
The  Ligation-Independent  Cloning  (LIC)  method  uses  a  version  of the  pGEX  6P1 
vector (Amersham Biosciences) modified to include a variation of the TEV/LIC linker 
(Stols  et  al.,  2002)  cloned between the  BamHl  and  EcoRl  restriction endonuclease 
sites.  Using  the  3’  to  5’  exonuclease  activity  of the  phage  T4  DNA  polymerase, 
overhanging  single-stranded  DNA,  15-17  nucleotides  in  length,  is  generated  in  the 
vector  and  insert  The  exonuclease  activity  of the  DNA polymerase  continues  until 
either a cytosine or guanoside nucleotide is reached, provided a complementary dNTP 
(dC or dG) is present in the reaction mix. Once the base complementary to the unique 
nucleotide is reached the exonuclease activity ceases as polymerase activity competes 
with it. LIC-compatible primer and vector sequences are designed to anneal following 
T4  DNA  polymerase  digestion.  Mixing  of the  T4  DNA  polymerase  digested  PCR 
product and vector therefore generates a stable nicked-circular plasmid that can be used 
directly for transformation without the need for ligation of DNA fragments (Figure 3.1).
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Figure 3.1.  Overview of Ligation independent cloning (LIC). 3'-5' exonuclease activity of phage T4 DNA polymerase 
generates a 15-17 nucleotide single-stranded overhang on both vector and insert. The length of overhang is determined 
by presence of a single dNTP (dC or dG) in the reaction mixture. This dNTP is added by T4 DNA polymerase to a site 
opposite the ’unique’ G or C nucleotides in the template strand. At this point further exonuclease activity ceases as a 
'competition'  is set up between the exonuclease and polymerase activities. The sequence of the linker and the 5' and 3' 
extensions on the PCR product are complementary. Annealing is sufficient to generate a stable nicked-circular plasmid 
that can be used directly to transform suitable E. coli strains with high efficiency.3.2.1.6.2  Oligonucleotide design
The  LIC  method  requires  the  following  leader  sequences  to  be  present  in  the 
oligonucleotide primer designs:
Forward primer  5’ -  TACTTCCAATCCCACGCA  -  3’
Backward primer  5’ -  TTATCCACTTCCCACGTTA  -  3’
18  bases  of the  target  sequence  were  added  to  the  end  of these  leader 
sequences. The PCR was carried out as described previously.
3.2.1.6.3  Vector preparation
Digestion of the vector was carried out in a reaction volume of 50pL containing:
1  pL pGEX 6P1-LIC (lpg)
5pL 10 x Pmll buffer (New England Biolabs)
1 pL Pmll (20 units)
0.5pLBSAx 100 
42.5pL distilled water
The linerised vector was gel purified from a  1% agarose gel using the QIAGEN Gel 
Purification Kit according to manufacturers instructions. The linerised vector was then 
ethanol precipitated and re-dissolved at 300ng/pL.
803.2.1.6.4  T4 DNA polymerase digestion
The linearised vector and the PCR product were digested using T4 DNA polymerase in 
order to generate the complementary overhangs:
Vector
0.7pmol Pmll cut vector 
1  pL T4 DNA polymerase (3 units)
4pL lOx T4 buffer 
lpL lOOmMdGTP 
Add distilled water to 40pL
The reaction was carried out for one hour at room 
at 70°C to heat inactivate the enzyme.
3.2.1.6.5  Annealing 
The annealing reaction was carried out in a 9pL volume containing:
1  pL vector digest reaction 
4pL PCR product digest reaction 
5pL distilled water
The annealing reaction was carried out for five minutes at 4°C.  lpL of this reaction was 
used to transform E. coli.
3.2.1.7  Transformation
The heat shock method was used according to the standard protocol (Sambrook,  1989). 
This  involves 30  minute  ice  incubation of 1   pg DNA and  100-200  pi  of chemically 
competent cells followed by a 45 second heat shock at 42°C and again placed on ice for 
15 minutes.  1   ml of LB medium without antibiotic is added to this and incubated at
PCR product
0.5pmol PCR product 
0.5pL T4 polymerase 
4pL lOx T4 buffer 
lpL lOOmM dCTP 
Add distilled water to 40pL
temperature, followed by 30 minutes
8137°C for 40 minutes with shaking, centrifuged carefully and 100/xl cell suspension was 
plated. Ligated DNA was transformed in E.  coli Top 10 strain, amplified and isolated. 
The isolated DNA was transformed in BL21 (DE3) expression bacteria.
3.2.1.8  Site specific mutagenesis
Site-specific  mutagenesis  was  carried  out  using  the  QuickChange  kit  (Stratagene) 
according to the manufacturer’s protocol.
3.2.1.9  Constructs
Table 3.1. Constructs generated
Construct* Description Source
pGBD R.V18271 '1 6 2
pGBD with a 486bp fragment encoding the entire Rvl827 
protein (162 residues)
Provided by 
J. Currie
pGEX 6P1 
Rv1827M 62
pGEX with a 486bp BamHI/Hindlll fragment encoding the 
entire Rvl827 protein (162 residues) de novo
pGEX 6P1 
Rvl82725'1 6 2
pGEX with a 41 lbp BamHI/Hindlll fragment encoding the 
entire Rvl827 protein (137 residues)
Provided by 
S. Westcott
pGEX 6P1 
Rv00191156
pGEX with a 468bp BamHI/EcoRI fragment encoding the 
entire Rv019 protein (156 residues)
Provided by 
J. Currie
pGEX 6P1 LIC 
Rv001929156
pGEX  with  a  38 lbp  LIC  fragment  encoding  the 
intracellular segment of Rv0019 protein (127 residues) de novo
pGEX 6P1 LIC 
Rv00195 7'1 5 6
pGEX  with  a  297bp  LIC  fragment  encoding  the  FHA 
domain of Rv0019 protein (99 residues) de novo
pGEX 6P1 
Rv00201 -5 2 7
pGEX with a 2,046bp EcoRI/XhoI fragment encoding the 
entire Rv0020 protein plus 155 residues prior to the protein 
start site (682 residues)
Provided by 
J. Currie
pGEX 6P1 
Rv00201 5 5 '5 2 7
pGEX  with a  l,581bp EcoRI/XhoI fragment encoding the 
entire Rv0020 protein (372 residues) de novo
pGEX 6P1 LIC 
Rv0020423'5 2 7
pGEX  with  a  312bp BamHI/XhoI  fragment  encoding the 
FHA domain of Rv0020 protein (372 residues)
Provided by 
S. Westcott
pGEX 6P2 PknB1 -6 2 6
pGEX with a  1,878bp BamHI/XhoI fragment encoding the 
entire PknB protein (626 residues)
Provided by 
J. Currie
pGEX 6P1 LIC 
PknB1 '3 3 2
pGEX with a 996bp LIC  fragment encoding the intracellular 
segment of PknB protein (332 residues) de novo
82pGEX 6P1 LIC pGEX  with  a  837bp  LIC  fragment  encoding  the  kinase de novo
PknB1 '2 7 9
domain of PknB protein (279 residues)
pGEX 6P1 PknA1 -4 3 1
pGEX with a  1,293bp BamHI/XhoI fragment encoding the 
entire PknA protein (431 residues)
Provided by 
J. Currie
pET TOPO 151 pET TOPO  151  fragment encoding the entire PknA protein de novo
PknA1 -2 9 0
inserted via the TOPO system (290 residues)
*all pGEX vectors encode GST tagged proteins and pET vectors encode six histidine 
tagged proteins.
3.2.1.10  Point mutants
Table 3.2. Point mutations generated
Construct Point Mutants
r r s r pGEX 6P1 LIC Rvl827 
pGEX 6P1 Rvl8272 5'1 6 2
pGEX 6P1 Rv00201 5 5 '5 2 7
pGEX 6P1 Rv0020432'5 2 7  
pGEX 6P1 LIC PknB1 '2 7 9
pET TOPO 151 PknA
1-290
S95A (de novo)
S95A (Provided by S. Westcott)
S473A  (de  novo,  sense  and  antisense  primers 
provided by S. Westcott)
S473A (denovo)
K40A, T171A, T173A, T171A/T173A (de novo) 
K40A (de novo)
3.2.2  Protein expression and purification
3.2.2.1  SDS-PAGE
Separation  of proteins  of  different  molecular  weight  was  performed  according  to 
(Laemmli,  1970)  using  denaturing,  discontinuous  SDS-polyacrylamide  gel 
electrophoresis (SDS-PAGE).
833.2.2.2  Determination of protein concentration
Protein concentration was determined by measuring absorbance of the protein sample at 
280nm  and dividing the A280 by the  calculated molar extinction coefficient for each 
protein and the path length.
3.2.2.3  Electrospray ionisation mass spectrometry (ESI-MS)
Protein  molecular weight was  determined  using a  stand-alone  syringe pump  (Perkin 
Elmer,  Foster  City  CA)  coupled  to  a  Platform  electrospray  mass  spectrometer 
(Micromass, Manchester, UK).  Samples were desalted on-line using a 2mm x  10mm 
guard column (Upchurch Scientific,Oak Harbor WA) packed with 50 micron Poros RII 
resin (Perseptive Biosystems, Framingham) inserted in place of the sample loop on a 
rheodyne  7125  valve.  Proteins  were  injected onto  the  column  in  10%  acetonitrile,
0.10% formic  acid,  washed with the same solvent  and then  step eluted into the mass
spectrometer in 70% acetonitrile,  0.1%  formic acid at a flow rate of lOpl/min.  The 
mass spectrometer was calibrated using myoglobin.  Experiments were carried out by 
Dr.  Steve  Howell,  National  Institute  for  Medical  Research,  Division  of  Protein 
Structure.
ESI MS results in proteins gaining multiple positive charges upon ionisation. As each 
protein  molecule  differs  in  the  number  of added  protons,  the  function  of the  mass 
spectrometer is to resolve the mass/charge {ml2) and measure the intensities for each set 
of differently charged protein molecules.  The data is plotted in the  form of intensity 
versus mlz from which the molecular mass can then be determined using the following 
equation:
.  (M + nH+)
m /z = ±----------- 1   (26)
n
where n  is the integer number of charges on the ions and H is the mass of a proton 
(1.008Da). As n is usually known, simultaneous equations can be used to determine the 
number of charges by assuming the peaks {mlz of differently charged protein molecules) 
are separated by a single charge, n can thus be defined by the equation:
84m!z{n + \)-H *  (2?)
m / z{n) —  ml z(n +1)
A  number  average  can  thus  be  determined  for  n  by  solving  for  all  peaks  and  the 
molecular mass of the protein then calculated by substitution of n back into equation 
(27).
3.2.2.4  Test expression of proteins
To test expression and  solubility  of proteins  expressed  from pGEX  or pET vectors, 
plasmids containing the desired insert were transformed into expression bacteria (BL21- 
DE3 and BL21-DE3 Rosetta). A 50 ml bacteria culture in LB medium was induced at of 
OD600 of -0.4-0.6 with 500 /xM IPTG and grown at 37 °C overnight. This was repeated 
in  triplicate  with  inductions  using  50  /zM  and  200  /xM  IPTG  and  grown  at  18  °C 
overnight.
To test expression, 1  ml of the overnight culture was pelleted, resuspended in water and 
analysed using SDS-PAGE. To test the solubility,  1   ml bacteria culture was pelleted, 
resuspended  in  100/xl  Y-PER reagent  (Pierce),  5U/mL benzonase,  2mM  MgCL  and 
lysed for 3 min at room temperature. The solution was centrifuged at 25000 X g for 10 
min at 4 °C. Fractions of 5 and 10 /xl of the supernatant were analysed by SDS-PAGE.
853.2.2.5  Protein overexpression and preparation of soluble bacteria extract
Proteins were overexpressed using the parameters described in Table 3.3.
Table 3.3. Expression conditions
Plasmid
E. coli 
strain
Antibiotics
Induction 
at OD60o
T/°C
Expression 
time / h
pGEX 6P1 Rvl827 
(all constructs)
BL21DE3 Amp 0.6 25 16
pGEX 6P1 LIC 
Rv001929'1 5 6
BL21DE3 Amp 0.8 18 16
pGEX6Pl LIC
Rv00195 7'1 5 6 B121DE3 Amp 0.6 25 16
pGEX6Pl
Rv0020432'5 2 7 BL21DE3 Amp 0.6 25 16
pGEX6Pl
Rv00201 5 5 * 5 2 7
Rosetta Amp, Cam 0.8 18 16
pGEX 6P1 LIC
PknB Rosetta Amp, Cam 0.8 18 16
(all constructs)
pET TOPO 151 
PknA1 '2 9 0
Rosetta Amp, Cam 0.9 18 16
In all the cases, bacteria were grown at 37 °C until the desired optical density (O.D.) 
was reached. Upon IPTG induction, temperature was reduced to increase solubility of 
protein.  After  expression,  bacteria  were  pelleted  at  4000 x g,  resuspended  in  their 
respective buffer (see individual protein purification methodology) plus one EDTA-ffee 
protease inhibitor tablet (Roche), 5U/mL units Benzonase, 2mM MgCh and 5% YPER. 
Cells  were  broken  by  30-second  bursts  of sonification  on  ice  using  a  Sonifier 450 
(Branson  Ultrasonics,  Danburry,  USA)  at  40%  duty  cycle.  Insoluble  material  was
86removed by centrifuging at 20,000 x g for 45 min, and the supernatant used for further 
purification.
3.2.2.6  Purification of Rvl827
Limited proteolysis experiments were carried out to define the FHA domain boundaries 
in Rvl827  and a stable  fragment of 138  residues was identified.  For this study both 
wild-type and truncated form of Rvl 827 were purified. All constructs of Rvl 827 and 
Rvl 827 S95A were purified according to (Durocher et al, 2000). Bacteria were broken 
in Rvl 827  buffer  (300mM NaCl  and  50mM Tris.HCl pH  8.0)  with addition of one 
EDTA-ffee protease inhibitor tablet (Roche), 5U/mL Benzonase, 2mM MgCb and 5% 
YPER.  The  cell  supernatant  was  applied  to  a  GST-column  (25  ml,  Amersham) 
equilibrated with Rvl 827 optimal buffer. The column was washed extensively with at 
least  500mL  1M NaCl,  50mM Tris.HCl  pH  8.0 to  remove  bound contaminants  and 
DNA, followed by buffer exchange to Rvl 827 optimal buffer plus ImM DTT. The GST 
was cleaved by addition of 200 units PreScission protease (Amersham) and overnight 
incubation  at  4°C.  Rvl 827  was  eluted  with  optimal  buffer  and  the  protein  was 
concentrated (5-10mg/mL) using a Vivaspin centrifugal concentrator (5 kDa cutoff) and 
further purified on a Sephadex 75 gel filtration column using Rvl 827 optimal buffer as 
running buffer. Rvl 827 eluted in one peak from gel filtration at an apparent molecular 
weight of 20kDa. Protein from this peak was collected and concentrated to lOmg/mL, 
then finally flash frozen in liquid nitrogen for storage at -80°C.
3.2.2.1  Purification of Rv0019
Constructs of Rv0019 were purified in different buffers depending on their predicted 
isoelectric point (Rv001929* 156 pi =  10.38  and Rv001957'156 pi =  8.35).  Bacteria were 
broken in Rv001929156 buffer (300mM NaCl and 50mM Tris.HCl pH 8.0) or  Rv001959' 
156 buffer (300mM NaCl and 50mM Tris.HCl pH 7.0) with addition of one EDTA-ffee 
protease inhibitor tablet (Roche), 5U/mL Benzonase, 2mM MgCh and 5% YPER. The 
cell  supernatant was applied to a GST-column (25  ml, Amersham) equilibrated with 
optimal buffer.  The column was washed extensively with at least 500mL  1M NaCl, 
50mM Tris.HCl  pH  8.0, to remove bound contaminants and DNA;  this  is especially 
important as the Rv0019 protein is basic and could be associated with an increase in
87bound DNA. The buffer was exchanged for optimal buffer plus  ImM DTT. The GST 
was cleaved by addition of 200 units PreScission protease  (Amersham) and overnight 
incubation  at  4°C.  Alternatively,  a  GST  fusion protein  was  obtained  by  incubating 
protein-bound resin with 20mM reduced glutathione and overnight incubation at 4°C. 
Rv0019 was eluted with optimal buffer and the protein was concentrated (5-10mg/mL) 
using a Vivaspin centrifugal concentrator (5 kDa cutoff). For anion-exchange, the NaCl 
concentration of the buffer was adjusted to 50mM by dilution of the protein sample. To 
remove  all remaining bound DNA the protein sample was applied to a Q-Sepharose 
column  equilibrated  with  50mM  NaCl,  50mM  Tris.HCl  pH8.0  and  flow-through 
containing protein stripped of DNA was collected. The protein was further purified on a 
Sephadex 75 gel filtration column using respective protein buffers as running buffers. 
Both  Rv0019  protein  fragments  eluted  with  a  single  peak  from  gel  filtration  at  an 
apparent molecular weight of 20kDa. GST-Rv001929'156 was applied to a S200 column 
and eluted in one peak from gel filtration at an apparent molecular weight of 50kDa. 
Protein peaks were collected and concentrated to lOmg/mL, then finally flash frozen in 
liquid nitrogen for storage at -80°C.
3.2.2.8  Purification of Rv0020
Constructs of Rv0020 were purified differently according to the construct properties. 
Bacteria were broken in Rv0020 buffer (300mM NaCl and  50mM Tris.HCl pH  8.0) 
with addition of one EDTA-ffee protease inhibitor tablet (Roche), 5U/mL Benzonase, 
2mM MgCb and 5% YPER. The cell supernatant was applied to a GST-column (25 ml, 
Amersham) equilibrated with optimal buffer. The column was washed extensively with 
at least 500mL 1M NaCl, 50mM Tris.HCl pH 8.0, to remove bound contaminants and 
DNA, followed by buffer exchange to the Rv0020 buffer plus ImM DTT. The GST was 
cleaved  by  addition  of 200  units  PreScission  protease  (Amersham)  and  overnight 
incubation at 4°C.  Rv0020423-527 was eluted with optimal buffer and the protein was 
concentrated (5-10mg/mL)  using an Vivaspin centrifugal concentrator (5  kDa cutoff) 
and further purified on a Sephadex 75 gel filtration column using the respective protein 
buffer as running buffer. Rv0020 eluted in one peak from gel filtration at an apparent 
molecular  weight  of 20kDa.  Protein  from  this  peak  was  collected,  concentrated  to 
lOmg/mL  and  then  finally  flash  frozen  in  liquid  nitrogen  for  storage  at  -80°C. 
Rv0020155-527 was eluted off the GST-column with Rv0020 buffer and the protein was
8 8concentrated to lmg/mL using a Centricon centrifugal concentrator (10 kDa cutoff). It 
was previously found that concentration to higher than ~lmg/mL would result in protein 
aggregation.  The protein sample was applied to a Sephadex 200 gel filtration column 
using respective buffer as running buffer.  Rv0020423'527 eluted in one peak from  gel 
filtration  at  an  apparent  molecular  weight  of 20kDa,  protein  from  this  peak  were 
collected and concentrated to ~lmg/mL, then finally flash frozen in liquid nitrogen for 
storage at -80°C.
3.2.2.9  Purification of PknB
All constructs of PknB and mutants were purified using the same procedure. Bacteria 
were broken in PknB buffer (300mM NaCl and 50mM Tris.HCl pH 8.0) with addition 
of one EDTA-ffee protease inhibitor tablet (Roche),  5U/mL Benzonase, 2mM MgCh 
and 5% YPER. The cell supernatant was applied to a GST-column (25 ml, Amersham) 
equilibrated  with  optimal  buffer.  The  column  was  washed  extensively  with  at  least 
500mL  1M NaCl, 50mM Tris.HCl pH 8.0, to remove bound contaminants and DNA. 
The buffer was exchanged for PknB buffer plus ImM DTT. The GST was cleaved by 
addition of 200 units precision protease (Amersham) and overnight incubation at 4°C. 
PknB  was  eluted with optimal  buffer and  the NaCl concentration of the buffer was 
adjusted to 50mM by dilution of the protein sample in preparation for ion-exchange. 
The  protein  sample  was  applied  to  a  Q-sepharose  column  equilibrated  with  50mM 
NaCl,  Tris.HCl  pH8.0  and bound proteins  were  eluted  using  a NaCl  gradient of 0- 
300mM, 50mM Tris.HCl pH 8.0. Fractions containing PknB were identified using SDS- 
PAGE,  pooled  and  the  protein  was  concentrated  (2-5mg/mL)  using  a  Vivaspin 
centrifugal  concentrator  (10  kDa  cutoff).  The  protein  was  further  purified  on  a 
Sephadex 200 gel filtration column using optimal buffer as running buffer. PknB eluted 
in one peak from gel filtration at an apparent molecular weight of 45kDa. Protein from 
this  peak  was  collected  and  concentrated  to  5mg/mL,  then  finally  flash  frozen  for 
storage at -80°C in liquid nitrogen.
893.2.2.10 Purification of PknA
PknA1'290  was purified using the  following procedure.  Bacteria expressing PknA1'290 
were broken in PknA buffer (300mM NaCl, 50mM Tris.HCl pH 8.0) with addition of 
one  EDTA-ffee  protease  inhibitor  tablet  (Roche),  5U/mL  Benzonase,  2mM  MgCh, 
5mM imidazole and 5% YPER.  The cell supernatant was applied to an NTA-column 
(25 ml, Amersham) equilibrated with optimal buffer plus 5mM imidazole. The column 
was washed extensively with at least 500mL  1M NaCl,  50mM Tris.HCl pH  8.0 and 
30mM imidazole, to remove bound contaminants and DNA. Bound protein was eluted 
off the  column  using  an  imidazole  gradient  from  50-250mM  (buffer also  contained 
50mM NaCl,  50mM Tris.HCl pH 8.0). Fractions containing PknA were identified by 
SDS-PAGE  and  pooled.  The  eluted  protein  sample  was  applied  to  a  Q-sepharose 
column equilibrated with 50mM NaCl, Tris.HCl pH 8.0 and bound proteins were eluted 
using a NaCl gradient of 0-300mM, 50mM Tris.HCl pH 8.0. Fractions containing PknA 
were identified using SDS-PAGE, pooled and the protein was concentrated (2-5mg/mL) 
using  a  vivaspin  centrifugal  concentrator  (10  kDa  cut-off).  The  protein  was  further 
purified on a Sephadex 200 gel filtration column using optimal buffer as running buffer. 
PknA eluted in one peak from gel filtration at an apparent molecular weight of 45kDa. 
Protein from this peak was collected and concentrated to  lOmg/mL, then finally flash 
frozen for storage at -80°C in liquid nitrogen.
3.2.3  Limited Proteolysis
3.2.3.1  Limited tryptic digestion
Purified fragment of Rv0019 consisting of residues 29-156 were subjected to limited 
proteolysis using the protease trypsin and Asp-N (Roche, sequencing grade). Reactions 
were  carried out in  a  lOOpL  volume  containing protein  and  trypsin in the  digestion 
buffer  (150mM  NaCl,  50mM  Tris.HCl  pH  8.0).  The  trypsimprotein  ratio  for  this 
digestion  was  1:250  and  1:500.  Products  of  the  time  course  of  digestion  were 
‘quenched’ by adding lOpL of SDS gel loading buffer and heating the sample to 100°C 
for five minutes. Samples were resolved using SDS-PAGE on a 12% gel.
903.2.3.2  Protein blotting
Proteins resolved on an SDS-PAGE gel after limited trypsin digestion experiments were 
transferred to a ProBlott membrane (Applied Biosystems).  This was achieved cutting 
the ProBlott membrane to the size of the gel and wetting in analytical grade methanol. 
The membrane was then placed in the electroblotting buffer (see Sections 3.1.6). The 
gel  was  allowed  to  equilibrate  in  electroblotting  buffer  for  five  minutes  before  the 
blotting ‘sandwich’ was assembled:  pad > filter paper > gel >  membrane  >  filter 
paper > pad.
The transfer was carried out in an electroblotting tank at a constant voltage of 50V for 
45 minutes with cooling using an ice block in the gel tank. After blotting was complete, 
the  membrane  was removed  and  rinsed  in  distilled  water before being immersed  in 
methanol.  The membrane  was  stained  using 0.1%  Coomassie®  Blue  R-250  in 40% 
methanol and 1% acetic acid, and destained using 50% methanol. The bands of interest 
were then excised for protein sequencing.
3.2.3.3  Protein sequencing
Protein from the western blot was sent to Dr. Mike Bacon of the Babraham Institute, 
Cambridge,  to  determine  the  six  N-terminal  residues  using  the  Edman  degradation 
technique.  The N-terminus  of the  amino-acid was modified by phenylisothiocyanate 
(PITC) which was subsequently removed by acid hydrolysis resulting in the release of 
2-anilino-5-thiazolinone amino acid derivative.  This derivative is then converted to a 
phenylthiohydantoin  amino  acid  and  HPLC  analysis  is  used  for  amino  acid 
identification. Six amino acid residues were identified in a cyclical sequencing reaction 
as described above.
913.2.4  Phosphorylation Mapping
2.1.2.2  In-gel digestion of proteins and sample preparation
Phosphorylation mapping was performed by first digesting  lOpg of the target protein 
with  1:10  (w/w)  sequencing grade modified trypsin (Promega)  in  lOmM  ammonium 
bicarbonante.  Phosphopeptides  were  isolated  from  peptide  mixtures  using an IMAC 
Spheres gel with chelated Ga3+ (Pierce).  The tryptic digest was diluted  1:1  with 20% 
acetic acid and incubated on the gallium resin for 30 minutes at room temperature. The 
resin  was  washed  with  1 0%  acetic  acid,  followed  by  10%  acetic  acid  plus  2 0% 
acetonitrile.  The resin was then equilibrated with MilliQ H2O followed by elution in 
lOOmM ammonium bicarbonate (pH 9.0) plus 10% acetonitrile.
3.2.4.1  Matrix  assisted  laser  desorption  ionization/Time  of  Flight 
(MALDI/TOF)
Phosphorylation mapping was performed using a Reflex III MALDI time-of-flight mass 
spectrometer (Bruker Daltonik, GmbH) by Dr. Steve Howell (NIMR), equipped with a 
nitrogen laser and a Scout-384 probe, to obtain positive ion mass spectra of digested 
protein with pulsed ion extraction in reflectron mode. An accelerating voltage of 26kV 
was used with detector bias gating set to 2kV and a mass cut-off of m/z 650. Thin layer 
matrix  surfaces  were prepared  using  recrystallised  a-cyano-4-hydroxycinammic  acid 
and  nitrocellulose  using  the  fast  evaporation method  (Vorm  et al,  1994).  0.4 pL  of 
acidified digestion supernatant was deposited on the matrix surface and allowed to dry 
prior to desalting with water.
Specific  phosphorylation  sites  shown  to  be  ambiguous  by  MALDI-TOF  were 
determined by loading the remaining sample onto a 2mm x 0.8mm Cl8 microcolumn 
(LC Packings), washed and step eluted with 60% methanol, 0.1% formic acid directly 
into an Econo 12 nanospray needle (New Objective Inc.). Nanospray mass spectra were
92acquired  on  an LCQ  ‘classic’  quadrupole  ion trap mass  spectrometer  (ThermoQuest 
Corp.) equipped with a nanospray source (Promega) operated at a spray voltage of 800V 
and a capillary temperature of 150°C.  Tandem (MS2) mass  spectra were acquired at 
collision energy of 30% and a parent ion isolation width of 3 Da. The resulting spectra 
were analysed for phosphate containing fragments using the MS-Product program in the 
Protein Prospector Suite (http://prospector.ucsf.edu/). In addition, phospho-peptide mass 
fingerprints  thus  obtained were  searched  against the  non-redundant protein  database 
placed  in  the  public  domain  by  the  National  Centre  for  Biotechnology  Information 
(NCBI) using the program MASCOT (Perkins et al 1999).
3.2.5  Circular Dichroism
Far-UV spectra were recorded on a Jasco J-715 spectropolarimeter (Jasco) using 1mm 
fused silica cuvettes. All experiments were carried out by Dr.  Steve Martin (NIMR). 
Protein samples were at ~0.15mg/mL in 50mM Tris.HCl pH 8.0,  150mM NaCl buffer. 
Multiple scans were averaged and the appropriate buffer blanks were subtracted. In the 
case of thermal denaturation, the temperature dependence of enthalpy (AH) is described 
by the following equation:
AH = AH0+ACp(T-T0)  (26)
where  T  is  the  temperature  (°K)  and  AHq   is  the  values  of  AH  at  any  reference 
temperature To, and ACp is the change in heat capacity at constant pressure (Schellman, 
1987).  In this model ACp is assumed to be independent of temperature (Privalov and 
Khechinashvilli,  1947).  The  experimental  data  were  fitted  to  equation  (26)  using  a 
standard non-linear least squares fitted procedure written by Dr. S. Martin.
3.2.6  Synthesis of peptides
Peptides were synthesised by solid phase technique with an addition tyrosine residue 
and  two  C-terminal  lysines  to  enhance  solubility  and  facilitate  concentration 
determination by optical  absorbance.  Peptides were purified by reverse phase HPLC 
following deprotection, and sequence confirmation by MALDI-TOF mass spectroscopy. 
All peptide synthesis was carried out by Dr. Pete Fletcher (NIMR) or Dr. Will Mawby 
(University of Bristol).
933.2.7  Characterisation of binding
3.2.7.1  Isothermal titration calorimetry
The enthalpy of binding was determined by titrating  1.3mL of protein solution, at an 
appropriate  concentration,  with a solution of either FHA or peptide using a VP-ITC 
MicroCalorimeter instrument from MicroCal. Both proteins were dialysed overnight in 
the  same  buffer  containing  50mM  Tris.HCl  buffer,  pH  8.0  and  300mM  NaCl  and 
degassed prior to use. The sample cell was maintained at 18°C. The enthalpy of binding 
was determined from heats of multiple injections of lOpL each. An equilibration time of 
300  seconds  was  set between  injections.  The heat of dilution  of each injection was 
established as a control by measuring the injection of ligand into buffer. The mean of 
the enthalpies measured was subtracted from the raw titration data prior to curve fitting.
Data analysis was carried out using the Origin data-analysis software supplied with the 
VP-ITC. This software uses principles based on Wiseman isotherm theory as discussed 
in Chapter 2 (Section 2.2).
3.2.7.2  Surface plasmon resonance
All surface plasmon resonance (SPR) experiments were conducted using a Biacore 2000 
(Pharmacia)  machine.  A research  grade  CM5  sensorchip  which  contained  a  dextran 
sensor  surface  with  four  flow  cells  for  protein  immobilization.  Proteins  were 
immobilised  to  the  dextran  using  the  amine  coupling method  outlined in  Chapter 2 
(Section 2.2). For immobilisation, flow cells were activated with a mixture of EDC (0.2 
M) and NHS (0.05 M). The PknA and PknB proteins were passed over the surface in a 
lOmM sodium acetate buffer, pH 4.5-6, at 40-120pg/mL concentrations. The low ionic 
strength  and  buffer  pH  value  below  the  isoelectric  point  of the  protein  led  to  the 
concentration  of  protein  at  the  matrix  surface  by  electrostatic  attraction  allowing 
spontaneous  reaction of lysine residues  with the  active esters.  The remaining  active
94esters of the chip surface are converted into amides via reaction with ethanolamine. This 
sequence was performed automatically using a program scripted for the BIAcore 2000 
control software and typically lasted 45 minutes. An immobilization level between 500 
and 5000 response units and typically achieved by varying parameters such as protein 
concentration,  protein  ionic  strength,  buffer  pH  and  reaction  time.  Protein  was 
immobilized to the first 3 flow cells and the 4th flow cell was left as a reference ‘mock’ 
immobilization surface.
The reference surface makes it possible to subtract the response changes related to non­
specific  binding,  changes  in  the  matrix  conformation  or  instrument  derived  errors. 
Kinetic  analysis was performed by injecting FHA domain protein in HBS-EP buffer 
over immobilised protein kinase at a flow-rate of 50pL/min at 24°C. During equilibrium 
analysis the sensor-gram (RU vs time) was recorded at a flow-rate of 5pL/min at 24°C.
Data analysis was performed using a global fitting method on the BIAevaluation 3.0 
program. Further details on the models used to fit data are found in Chapter 2. Further 
analysis  of primary  data  was  performed  for  accurate  determination  of equilibrium 
binding  constants.  After  subtracting  the  sensorgram  generated  on  from  the  protein 
surface from the curve generated from the control or ‘reference’  surface, steady-state 
response  values  (RU) were  obtained  at each FHA  concentration.  These  values were 
fitted, using non-linear regressional analysis, to a single site saturation curve, where the 
amount of ligand bound is plotted as a function of the initial FHA concentration.
= Capacity±FHA\ 
K.+IFHA]
Competition experiments were conducted using the same immobilised proteins and a 
solution with fixed concentration of FHA domain were passed over them spiked with 
varying concentrations of synthetic peptide. The steady-state response values (RU) were 
obtained at each peptide concentration after subtracting the control value. This response 
value  would  equate  to  the  maximal  binding  of the  FHA  the  ligand  at  a  specific 
concentration  of competing  peptide.  Readings  were  taken  for  at  least  12  different 
peptide  concentrations  and  IC50  values  were  calculated  by  fitting,  using  non-linear 
regressional  analysis,  the  response  versus  peptide  inhibitor  concentration  to  dose 
response curve:
95RU  = ------——g      + Background
1 + f [p g p ^ g ]Y
(29)
where range is the maximum y range, and s is the slope factor.
Assuming that the interactions investigated are simple 1:1 reversible interactions where 
the two ligand species are competing for binding to the same site, the IC50 calculated for 
the  titration  of each  peptide  in  SPR  competition  experiments  can be  related  to  the 
equilibrium dissociation constant of the complex between the peptide and FHA domain 
using the following formula:
where  K ! Dis  the  peptide  equilibrium  dissociation  constant  as  determined  by  SPR
FHA  domain  to  the  surface  immobilised  kinase  by  50%,  KD   is  the  equilibrium 
dissociation constant for the complex between the FHA and surface immobilised  kinase 
and [S] is the concentration of FHA domain.
(30)
competition assay, IC50 is the concentration of the peptide that inhibits binding of the
963.2.8  Characterisation of phosphorylation activity
3.2.8.1  In vitro radiolabelling kinase assay
The  ability  of PknA  and  PknB  to  autophosphorylate  and  phosphorylate  exogenous 
substrates  was  determined  by  radiolabelling  experiments.  2pM  PknA  or  PknB  was 
incubated with 20mM of FHA containing protein or myelin basic protein (Invitrogen). 
Each assay was conducted in 10pL of buffer containing 150mM NaCl, 50mM Tris.HCl 
pH  8.0,  5mM MgCh  and  ImM MnCb plus 0.2pCi of [y-32P]ATP (Amersham).  The 
reaction proceeded for 60 minutes at room temperature and stopped with the addition of 
SDS-PAGE  sample  buffer  plus  EDTA  (25mM  final  concentration).  10pL  were 
subjected to SDS-PAGE on a 4-12% polyacrylamide gel. Gels were fixed and stained in
0.1%  Coomassie®  Blue  R-250,  10%  methanol,  10%  glacial  acetic  acid.  Gels  were 
destained in 40% methanol,  10% glacial acetic acid and 5% glycerol, then wrapped in 
Saran wrap for gel drying. Dried gels were exposed to phosphoimage screens (Kodak) 
overnight.  The  radiolabelled  protein  was  visualised  using  the  Molecular  Dynamics 
Storm 860 phosphorimaging scanner and quantification analysis was performed using 
Image Quant software (Molecular Dynamics).
3.2.8.2  In vitro coupled kinase assay
Kinetic data for enzymatic activity was determined using the classical coupled pyruvate 
kinase:  lactate dehydrogenase assay followed spectrophotometrically at 340nm  (A340) 
according to the method of (Roskoski,  1983) (Figure 3.2). ATP, phosphoenolpyruvate, 
NADH,  pyruvate  kinase  and  lactate  dehydrogenase  were  purchased  from  Sigma. 
Standard  reactions  were  carried  out  in  a  buffer  containing:  150mM  NaCl,  50mM 
Tris.HCl pH 8.0, 5mM MgCh,  ImM MnCh, 20 units/mL pyruvate kinase, 30 units/mL 
lactate  dehydrogenase,  ImM  phosphoenolpyruvate  and  0.25mM  NADH.  Optimal 
concentrations of lactate
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Figure 3.2. In vitro coupled kinase activity assay. (A) Enzymatic steps for linking the turnover 
of ATP to the oxidation of reduced NAD (NADH) by Lactate dehydrogensase (LDH). (B) A 
typical graph generated by the phosphorylation of Rvl8271-162 byPknB. The turnover of ATP 
is linked to the oxidation ofNADH and is followed spectrophotometrically at 340nm. 
Contaminant ADP is converted into ATP instantaneously; therefore, after recording the 
reduction in A 340 , the reaction was initiated by the addition of kinase. The reduction in A 340 
recorded for ~4 minutes.
O Qdehydrogenase  and  pyruvate  kinase  were  determined  in accordance  with  (Roskoski, 
1983). All reactions were carried out in lOOpL volume containing 2pM PknA or PknB 
using Rv1827M62 substrate at concentrations in the range of 1.3pM-500pM and an ATP 
concentration  of  ImM.  ATP  dose  response  experiments  were  also  carried  out  in  a 
lOOpL volume containing 2pM PknA or PknB using Rvl827M62 substrate at 40pM and 
ATP at concentrations in the range of 0.63pM-5mM. As a control the above controls 
were carried out in the absence of substrate, this would provide a measurement for the 
auto-phosphorylation activity of PknA and PknB.
Initial NADH input was in the 0.6-1.3 O.D range. Contaminant ADP is converted into 
ATP  instantaneously;  therefore,  after  recording  the  minor  ATPase  activity  of  the 
components,  the  reaction was  initiated by the  addition  of kinase  and mixing of the 
solution by gentle pipetting. The reduction in A340 recorded for 4 minutes. All enzyme 
assays were conducted at 25°C, and all experiments were done in triplicate. Absorbance 
data  was  collected  on  a Cary  50  UV-vis  spectrophotometer using  Enzyme  Kinetics 
mode and readings were made at 0.5 second intervals.
The ATP turnover rate was determined by using the equation (23):
dA
Rate{fjmolA TP. min  ] = -----— [OD / min] x e’^NADH  (28)
dt
where e^NADH  is the molar absorption coefficient of NADH at 340nm
(6220 A/^cnT1 ).  Rates were  calculated per  10  second time  frame  overlapping in 0.5 
second increments and plotted as a function of time. Maximal rate was determined as 
dA
the minimal slope ( -J - ) during which the absorbance decline was linear.
Data was fitted to equation (24) for normal Michelis-Menten kinetics:
r  r_ [s]  « «
Km + [S]
99where [S] is the substrate,  Vm^ is the maximal enzyme velocity and Km  is the Michelis 
constant.  The  data  was  analysed by non-linear regression  using  GraFit  5.0  Enzyme 
Kinetics module.
3.2.9  Inhibitor Screening
Inhibitor  studies  were performed  using the  Kinase-Glo™  Luminescent Kinase  Assay 
(Promega) according to manufacturers guidelines. All experimented was carried out at 
Medical Research Council Technology in collaboration with D. Whalley and B. Saxty. 
Initial  optimization  of reaction conditions  was performed.  To  determine  the  optimal 
concentration of ATP,  different concentrations  of ATP  (0.4-15 pM)  were made with 
lpM  PknB  and  ImM MnCl2,  150mM NaCl,  50mM Tris.HCl-HCl pH  8.0  in a total 
reaction volume of 20pL. As a control, a repeat titration was performed in the absence 
of kinase. The incubation was performed at room temperature for a total of 10 minutes. 
After  10  minutes  the  reactions was  stopped by the  addition  of 20pL  of Kinase-Glo 
reagent.  Luminescence  was  read  after  10  minutes  using  a  BMG  Polarsar  reader 
(luminescence mode,  1 second integration time) and the change in relative luminescence 
signal  (RLU)  compared  to  the  zero  enzyme  control.  RLU  was  plotted  against  Log 
[ATP] and the optimal kinase substrate concentration was around the EC50.
To determine the optimal concentration of substrate, Rvl8271162, several concentrations 
of Rv1827 were made with lpM kinase and 1.5pM ATP,  ImM MnCh,  150mM NaCl, 
50mM Tris.HCl-HCl pH 8.0 in a total reaction volume of lOOpL. As a control, a repeat 
titration was performed in the absence of kinase. The incubation was performed at room 
temperature, and at the time points indicated 20pL aliquots were removed and mixed 
with an equal volume of Kinase-Glo reagent. Luminescence was read after 10 minute 
incubation  using a  BMG  Polarstar reader (luminescence  mode,  1  second  integration 
time) and the change in relative luminescence signal (RLU) compared to the no enzyme 
control.  RLU was plotted against time  for each different Rvl827  concentration.  The 
optimal  substrate  concentration  would  give  a  linear decrease  in  RLU  over the  time 
period.
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Active Compounds (LOPAC) (1,240 compounds, Sigma-Aldrich). All stock compounds 
are  purchased  dissolved  in  DMSO.  Each  compound  was  tested  at  a  final  assay 
concentration  of  lOpM  in  a  total  reaction  volume  of  22 pL  with  a  final  DMSO 
concentration of 1%  and a final ATP concentration of 1.5pM.  Aliquots  (15pL) of a 
1.46x  master  mix  containing  1.46x  the  final  concentration  of PknB  (0.15pM  final 
concentration),  Rvl827  substrate  (5pM),  NaCl  (150mM),  Tris.HCl pH  8.0  (50mM), 
MnCU  (ImM),  Triton X-100  (1%)  and DTT (ImM)  were added to Matrix 384-well 
polypropylene  plates  using  the  Biomek  FX  Laboratory  automated  workstation 
(Beckman-Coulter).  Stock solutions of the inhibitor compounds were made at  108pM 
and 2pL was added to the master mix using the automated pipettor. The mastermix was 
then incubated for 30 minutes. The kinase reaction was initiated by the addition of ATP 
to the reaction buffer using the Wellmate automated pipettor (Matrix). After a reaction 
time  of 20 minutes 22 pL of Kinase-Glo reagent was added to each well to  stop the 
reaction and the plate was incubated for a further 10 minutes prior to reading. The plate 
was  read  using the  BMG  Polarstar reader (‘Hithunter  1*  luminescence  mode).  As  a 
positive control, compounds were replaced with DMSO in all wells of the last column 
of the plate.  As a negative control no enzyme was added to the wells of the first column 
of the plate and compound solutions were replaced with DMSO only.
To assess the compounds as inhibitors the percentage inhibition of each compound was 
calculated as follows:
RLU =  1  -  [LU (data well) -  LU(negative control)]  (30)
LU (positive control) -  LU (negative control)
where  negative  and  positive  control  reactions  were  carried  out  in  the  absence  and 
presence of ATP respectively, and data well reactions were carried out in the presence
101of test  compounds  and ATP.  Hits  were  defined  as  any compound producing  >20% 
inhibition of PknB activity.
Quality of the assay was evaluated with the Z’ factor. This is a statistical value which is 
the ratio of the separation band to the dynamic range of the assay, based on the positive 
and negative control data and is defined as:
Z'= 1- (3<x,.+3<7  )  (3l)
\Mc+ ~Mc-1
where C T c +  and ac. are the standard deviation of the positive and negative control signals, 
respectively,  and  pc+  and  pc-  are  the  averages  of die  positive  and  negative  control 
signals, respectively. Z ’ factor values above 0.5 indicate good assay quality and a value 
of 1 is a perfect assay.
The screening window coefficient (Z-factor) is similar to the previous equation:
z = 1 _(3o1 ± 3£f)  (32)
Mc\
where  /4 and //c  are  the  means  of the population and control  (usually background) 
signals, respectively, and the signal standard deviations are crs and < jc, respectively. As 
before,  Z factor values above 0.5  indicate  good assay quality and a value  of 1   is  a 
perfect  assay.  This  assay  informs  the  user  about  data  variation  associated  with  the 
sample measurements and reference controls as well as informing about assay signal 
dynamic range (Zhang et al., 2000).
As a validation and for additional characterisation of ‘Hit’ compounds IC50 values were 
determined. To each well of a 96-well plate 25 pL of a reaction mixture containing 2x 
the reaction buffer (PknB (0.2p.M), Rvl827 substrate (5pM), NaCl (150mM), Tris.HCl- 
HCl pH 8.0 (50mM), MnCb (ImM) and DTT (ImM)) was added except for column 1. 
In the first column 50pL of inhibitor diluted in the  reaction mixture was added. A two­
fold  serial  dilution was made  across  the plate by transfer pipetting.  25pL of 2x the
102concentration of ATP (1.5pM) was added to all the wells to initiate the reaction.  The 
reaction was allowed to continue for 2 0 minutes at room temperature and readings were 
taken as previously described. The IC50 values were obtained by fitting the data using 
non-linear regressional analysis to the following equation:4  Protein purification and characterisation
4.1  Overview
A  total  of  18  constructs  were  designed  and  Table  4.1  lists  the  properties  for  each 
purified protein.  Protein expression was carried out in E.  coli because of the ease in 
which  plasmids  can  be  transferred  into  the  bacterium,  the  ease  of  culture,  fast 
replication rate and immediate induction of the expression system.
10 recombinant proteins were made representing three FHA domain-containing proteins 
Rv0019, Rv0020 and Rvl827 in three forms:  1) as full-length wild type protein (in the 
case of membrane bound protein Rv0019, a protein representing the full intracellular 
region was produced) 2) proteins representing the isolated FHA domain were generated 
(using limited proteolysis to  define domain boundaries)  3) mutants proteins where a 
conserved  serine  in  the  FHA  domain  essential  to  the  phospho-binding  function  is 
mutated  to  an  alanine.  All  proteins  were  characterised  by  electrospray  mass 
spectroscopy after purification to confirm expected molecular weight.
Eight recombinant fragments of two STPKs PknA and PknB were also expressed and 
purified. The full intracellular region of PknB was produced in addition to the isolated 
kinase domains of PknA and PknB. PknA and PknB were also generated with mutation 
of  conserved  kinase  domain  activation  loop  threonine  residues  to  alanines  and 
separately with mutation of a conserved catalytic lysine to an alanine. All proteins were 
characterised by electrospray mass  spectroscopy which indicates differing degrees of 
phosphorylation of kinase  constructs displayed as an increase  in observed molecular 
weight due to added phosphate groups. PknA and PknB K40A were also subjected to 
matrix-assisted  laser  desorption/ionisation  (MALDI)/Time-of-flight  (TOF)  mass 
spectrometry in an effort to identify the sites of phosphorylation.
104Table 4.1. Recombinant proteins expressed for this study
A. FHA Domain-Containing Proteins__________________________________________
Expected  Electrospray
Protein fragment  Residues  Molecular Weight  Molecular Weight  Purification method*1  
_________________________________________________ (Da)a_______________(Da)_____________________________
Rv1827M 62 162 17630.3 17632.1±1.2 GST, GF75
Rv1827M 62 S95A 162 17614.3 17612.3±2.4 GST, GF75
Rvl82725-162 137 14691.1 14689.8+1.3 GST, GF75
Rvl82725* 162 S95A 137 14675.1 14674.8±1.5 GST, GF75
Rv001928*156 156 15282.4 15284.3±1 GST, GF75
R vO O ^156 127 11391.9 11392.8+0.5 GST, GF75
Rv0020155'527 527 40615 40609±4.1 GST, GF75
Rv0020155'527 S473A 527 40599 40600±2.0 GST, GF75
Rv0020432527
______ 411.S17 _____
95 12093.3 12105.5±1.5 GST, GF200
Rv0020432'527 S473A  95  12077.3  12088.4±2.2  GST, GF200
B. Serine/Threonine Protein Kinases
Protein
fragment
Residues
Expected
Molecular
Weight
(Da)a
Electrospray
Molecular
Weight
(Da)
Maximum
phosphorylation
sites1 *
Most abundant 
phosphorylation 
state0
Purification
method*1
PknA1290 290 34855.9 36374.8±4 17 12
NTA, Q, 
GF200
PknA1290
K41A
290 34798.2 35038.2 6 4
NTA, Q, 
GF200
PknB1279 279 31680 31992±2.5 5 3
GST, Q, 
GF200
PknB1279
T171A
279 31650 3196014 4 3
GST, Q, 
GF200
PknB1279
T173A
279 31650 3187912.7 3 2
GST, Q, 
GF200
PknB1279
T171A/T173A
279 31620.18 31850.113.2 3 2
GST, Q, 
GF200
PknB1279
K40A
279 31622.3 3177717.0 2 1
GST, Q, 
GF200
PknB1332 332 37377.9 37606.3113.3 5 3
GST, Q, 
GF200
105aAs calculated from constituent amino-acids using ProtParam tool (www.us.expasy.org)
bAs  identified by the number of different mass/charge peaks differing by 80 Da (molecular
weight of a HP03). See Figure 4.1 for a typical electrospray mass spectrum.
'Determined  from  the  peak  with  the  greatest  intensity  signal  corresponding  to  the  protein 
phosphorylation state.
Purification methods include GST (glutatione S-transferase affinity purification), NTA (His-tag 
affinity purification), GF75 (gel filtration on a S75 Superdex column), GF200 (gel filtration on 
a S200 Superdex column), S (SP sepharose ion-exchange), Q (Q Sepharose anion-exchange).
Proteins  were  purified  using  standard  methods  (Section  3.2.2).  The  purification  of 
Rv0019 and PknA proved most difficult and the purification of these proteins will be 
discussed in more detail in this chapter. In addition, the phosphorylation state of PknB 
is of great relevance to the biophysical and biochemical experiments in this study and 
will be discussed at the end of this chapter.
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Figure 4.1. Mass spectra ofPknB1'279K40A mutant. Mono- and Di-phosphorylated species 
of pknB1'279 K40A mutant protein, A and B, were determined to be,  31697Da and 
31777Da, respectively. These mass are equivalent to the calculated mass of pknB1" 279 
K40A (31623Da) plus one phosphate group (A) and two phosphate groups (B).The 
molecular weight of HP03  is 80Da.4.2  Purification and Characterisation of Rv0019
4.2.1  Overview
Rv0019  is  a  small  (156  residues)  putative  transmembrane  protein  containing  an 
intracellular  segment  (128  residues)  encompassing  an  FHA  domain  and  a  short 
extracellular  segment  (6  residues)  (Figure  1.11).  The  transmembrane  portion  of the 
protein was predicted to be between residues 7 and 28 according to the on-line database 
SMART  (Simple  Modular  Architecture  Research  Tool,  www.smart.embl- 
heidelberg.de). The following Section describes the cloning, expression and purification 
of the isolate FHA domain and complete intracellular segment of Rv0019.
Rv0019  gene  fragments  from  the  M.  tuberculosis  genome  were  inserted  into  the 
expression vector pGEX-6P-l  LIC  for expression of recombinant protein with  a N- 
terminal GST tag. Rv0019  contains the putative cytoplasmic segment including the 
FHA domain homology region and the juxtamembrane  sequence.  This protein had a 
propensity  for  aggregation  and  consequently  there  was  considerable  loss  of protein 
during the purification process.  However,  the minimal  tryptic  fragment RvOO 1956-156 
proved to be more stable and allowed concentration to 10 mg/mL, with an overall yield 
of ~25mgs per 6 litres culture, using the procedure outlined in Chapter 3.
4.2.2  Purification of RvOO 19 intracellular segment
The  expression  of  the  full  intracellular  segment  of  RvOO 19,  Rv001928-156,  was 
monitored  following  induction  (Figure  4.2a).  A  comparison  of  lanes  1-3  shows 
detectable  expression  of fusion  protein  GST-Rv0019  had  occurred  two  hours  after 
induction.  Maximum  yield  was  obtained  at  three  hours  post  induction.  An 
approximately  90%  pure  recombinant  protein  solution  was  produced  after  affinity 
purification and by the  removal of the GST tag by means of cleavage of the  fusion 
protein bound glutathione-Sepharose matrix using 3C protease. This resulted in a band 
of approximately 17kDa (Figure 4.2b), which corresponded to the expected size of the 
recombinant protein.
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Figure 4.2. SDS-PAGE analysis of FHA-domain containing protein Rv0019. (A) The egression of 
GST-RvOO 1928'156 was monitored after induction. Lysates of cells taken 0, 30 min, 1   hr, 2 hr, 3 hr after 
induction was analysed by SDS-PAGE. Molecular weight marker sizes are shown on the left. These 
marker are used in all subsequent gels. (B) Tryptic digestion of RvOO 1928* 156 with an enzyme: protein 
ratio of 1250 at time points ofO, 30 secs, 1,5,10,15,30 minutes. Purified RvOO 1928'156 protein produces 
three bands at molecular weights around 17- 14kDa after 30 seconds of digestion with trypsin. The band 
running slowest corresponds to the undigested Rv001928 156, the other two bands represented the digest 
products, (c) Purification of the minimal tryptic fragment of RvOO 19 (Rv001959'156). Lanes contain 
samples taken of the protein containing fractions after gel filtration on a S75 column (lanes 1-5), cell 
lysate before loading on affinity resin (lane 6), and after loading on affinity resin (lane 7), sample taken 
after 3C protease cleavage of GST-RvOOl 959'156 bound to affinity resin (lane 8) and 3C cleaved 
Rv00 1  959-156 prior to gel filtration (lane 9).
109The  eluate  from  the  affinity  column  was  also  analysed  spectrophotometrically  by 
measuring light absorbance between 220nm-340nm. Significant DNA contamination of 
the sample was detected as absorbance at 260nm. The isoelectric point,/?/, of Rv001928~ 
156 is  10.38, as calculated from the sequence, which suggests that the protein will be 
positively charged in buffer at pH 8.0. Applying the RvOO 1928-156 protein sample to a Q 
Sepharose ion-exchange column at pH 8.0 and collecting the flow-through removed the 
bound DNA.  This bound the  DNA whilst allowing the  RvOO 1928-156 protein to pass 
through  and had  a  significantly  improved protein  spectrum between 220nm-340nm. 
However, it retained a propensity to aggregate.
To utilise the RvOO 19  protein for further biochemical experiments the protein was
purified and stored as a GST fusion protein. The addition of the GST domain helped to
*yo  i cfi
stabilise the RvOO 19  fragment and in this form the protein could be concentrated to
over  lOmg/mL.  The  soluble nature of the GST domain makes it ideal for stabilising 
recombinant proteins prone to aggregation and has been used for this purpose in many 
purification protocols (Grunder et al., 2005). In addition, the N-terminal GST domain 
along with the C-terminal FHA domain of GST-Rv001928  156 reduced the propensity for 
the disordered juxtamembrane region to aggregate.
4.2.3  Limited proteolysis and N-terminal sequencing
Regions  of the  protein  that  have  less  structure  are  susceptible  to  protease  cleavage 
whereas  regions  that  form  tightly  structured  domains  are  less  likely to  be  cleaved. 
Therefore, identification of the cleavage sites using limited proteolysis can infer domain 
boundaries. The purified Rv001928 ~ 156 was subjected to limited proteolysis to define 
limits of the FHA domain.
A tryptic digestion with an enzyme: protein ratio of 1:250 (w:w) produced three bands 
at molecular weights between 14-17kDa after 30 minutes (Figure 4.2b). The band with 
the slowest migration corresponded to the undigested Rv001928'156, whilst the other two 
bands  represented  digested  products.  These  bands  were  transferred  to  blotting 
membrane and the smallest of the three bands was excised and subjected to N-terminal
110amino  acid  sequencing.  Interestingly,  the  minimal  tryptic  fragment  of RvOO 1928-156 
transferred to the blotting membrane with greater efficiency than the uncleaved protein 
suggesting that the fragment has a lower isoelectric point. For the six N-terminal residue 
positions the observed amino acids were:
l.Q/S  2. H/P/F/L  3.A/V  4. D/F/H  5. Y  6. L/V
From  this  information,  the  N-terminus  was  determined  to be  in the  region between 
residues 54-57 (See Figure 1.3 for RvOO 19 amino acid sequence). The ambiguity of the 
sequence information is due to the presence of a number of tryptic sites in the region 
between residues 54-57 (three) resulting in a number fragments differing in size by one 
or two residues. Cloning, expression and purification of a RvOO 19 fragment extending 
from  residues  56-156  produced  a  soluble  protein  which  was  mono-dispersed  as 
determined by dynamic light scattering (data not shown). Purified RvOO 1956* 1 56 protein 
could be concentrated to lOmg/mL with an overall yield of ~25mgs produce per 6 litre 
bacterial culture (Figure 4.2c) using the procedure outlined in Chapter 3 (Section 3.2.2).
4.2.4  Circular dichroism analysis of FHA domains
To examine the secondary structure content of FHA domains and to assess secondary 
structure  content,  circular  dichroism  (CD)  analysis  was  performed  as  described  in 
Materials and Methods (Section 3.2.5). The resulting spectra of FHA domains of known 
and  unknown  structure  were  compared  (Figure  4.3)  in order to  understand why the 
RvOO 1956'156 construct,  containing the probable  isolated FHA domain,  was unable  to 
bind phosphor-threonine  motifs,  as  determined by biophysical  analysis  conducted  in 
Chapter 6 .
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Figure 4.3. Circular dichroism  spectra  of the FHA domains of Rvl827, Rv0019, Rvl827 of 
M tuberculosis  and human Chk2 FHA domain. Protein samples were at ~0.15mg/mL in 
50mM Tris-HClpH 8.0, 150mM NaCl buffer. Multiple scans were averaged and the 
appropriate buffer blanks were subtracted.
112Comparison of CD spectra immediately shows a distinct variation in spectrum despite 
being related in structure. The spectra representing Rvl827 and Rv0020 FHA domains 
seem typical of proteins consisting of mainly P-sheets, with a in mean residue molar 
extinction coefficient,  Aem rw ,  with the  lowest point at around  2 2 0nm.  In the  case  of 
RvOO 1956*1 56 the spectrum displays the decrease in Aem rw  from 240nm but no increase 
beyond  the  220nm  point.  This  may  indicate  improper  folding  of the  RvOO 19  FHA 
domain but may also arise from the inherent variability in CD P-sheet measurement, as 
small changes in p-sheet configuration can result in large changes in the CD signal (S. 
Martin, personal communication).
The  Chk2  FHA  (Li  et  al.,  2002)  also  gives  a  distinct  CD  spectrum  with  a  less 
pronounced  p-sheet  signal  characterised  by  a  depression  in  Aem rw   at  210nm.  The 
observed increase in Agmrw signal beyond 240nm is more characteristic of an extended 
3io-helix or poly (Pro) II helix (Figure 2.5). From the X-ray structure of Chk2 FHA the 
domain is known to have an ~11-residue helix (Glul27 to Thrl38) containing two turns 
which may influence its CD spectrum. In addition, the Chk2 FHA sequence is predicted 
to contain a poly (Pro) II helix N-terminal to the FHA domain, although this appeared 
disordered in the crystal structure of this region (Li et al., 2002)
To ascertain the general stability of the Rv0020 FHA domain and Rv001956'156, thermal 
unfolding was monitored using far-UV CD.  Typical curves are shown in Figure 4.4. 
The measured Tm  and AH values are  57.6°C  and 59.4kcal/mol  for the Rv0020 FHA 
domains  and  60.1°C  and  60.9kcal/mol  for Rv001956'156.  These  data  suggest that the 
minimal  tryptic  fragment  of RvOO 19,  Rv001956’156,  is  slightly  more  stable  than  the 
Rv0020 FHA domain.
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Figure 4.4. Thermal denaturation profile of (A) RvOO 19 and (B) Rv0020 FHA domains. 
Experiments were all conducted in 150mM NaCl, 20mM Tris-HClpH 8.0. Thermal denaturation 
was carried out by heating samples at a constant rate of 2°Cper min from 5 to 90°C. The black 
lines represent the recorded CD at 217nm while heating, and red lines are computed derivative 
plots fitted using a non-linear least-squares analysis.
1144.3  Purification and characterisation of PknA
4.3.1  Overview
PknA proved to be the most troublesome to clone and purify of all proteins in this study. 
Firstly,  initial  cloning of the protein suggested the protein was toxic  to E.coli when 
expressed  at  basal  level  that  occurs  through  the  tac  promoter  of  pGEX  vectors. 
Therefore, only certain fragments, which presumably expressed non-functional protein 
(no/low kinase activity), could be cloned into pGEX vectors. All constructs were then 
made using pET vectors to circumvent toxicity problems.  pET vectors require the DE3 
lysogen which encodes T7 polymerase in host cells for expression of the recombinant 
protein as expression  is under the  control of T7 promoter.  The  T7 promoter system 
allows  greater  control  of  toxic  protein  expression  with  reduced  basal  expression 
compared  to  the  tac  promoter.  Finally,  after  several  failed  solubility  trials  with 
constructs of various lengths, PknA1'290 gene fragments produced with a N-terminal six- 
histidine  tag  gave  rise  to  high  levels  of soluble  expression  in  E.  coli  although  the 
purified protein was extremely heterogeneous with respect to its phosphorylation state 
(Table 4.1). The following discussion details the efforts that were made to purify PknA 
and map the phosphorylation sites of this protein.
4.3.2  Phosphorylation State of PknA
PknA1'290 was purified according to the protocol outlined in Section 3  (Materials and 
Methods). SDS-PAGE analysis of purified PknA showed the apparent molecular weight 
of PknA differs from the expected molecular weights by around 3kDa (Figure 4.5). The 
aberrant migration of proteins  in  SDS-PAGE  can be  caused by a number of factors 
including the presence of phosphorylated residues in the protein  sample that prevent 
binding  of  SDS-molecules  to  the  denature  protein  polypeptide  chain  due  to  their 
negative charge. Further support for the presence of phosphorylation was found upon
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Figure 4.5. SDS-PAGE analysis of recombinant PknA protein, (a) NTA affinity resi n with 
bound Histidine tagged PknA1* 290 protein before imidazole elution (lane 1) and after elution 
(lane2), washing flow-through using 30mM Imidazole (lane3) and samples after protein 
elution at lOOmM and 200mM Imidazole (lanes 4 and 5, respectively), (b) lOpL samples of 
fractions collected after elution of PknA1'290 protein from a Q-sepharose ion-exchange column 
using 50-250mM NaCl gradient, (c) lOpL samples ofprotein peak fractions collected after 
elution of PknA1 * 290 protein from an S200 gel filtration column. The volume at which the 
protein eluted is shown above the gel based on a column of300mL.
116ion-exchange  chromatography.  The  predicted pi  of the  unphosphorylated  form  of 
PknA1'290 is 9.42 suggesting it will have a positive in charge at buffer pH 8.0 and bind 
negatively  charged  SP-sepharose  cation-exchange  resin.  However,  extensive 
phosphorylation  of the  protein  caused  reduction  in  the  pi  allowing  it  to  bind  to  Q 
Sepharose anion exchange resin (Figure 4.5b).  It should be noted that predicted pi, is 
an average of the pis from the constituent amino acids and therefore does not account 
for basic/acidic region on the protein surface that can influence the binding of proteins 
to ion-exchange resins. Therefore, PknA1'290 may contain a highly acidic region (low pi) 
that  facilitates  binding  to  Q-sepharose  resin  at  pH  8.0  even  in  the  absence  of 
phosphorylation.
Subsequent electrospray mass spectroscopy of the protein sample confirmed that PknA 
was  extensively  phosphorylated  with  a  minimum  of  9  phospho-residues,  the  most 
abundant  phosphorylation  state  had  12  phospho-residues,  and  maximum  number 
observed was 17 (Figure 4.6). Despite reported loss of kinase activity upon mutation of 
an important catalytic  lysine residue in the PknA K42A mutant protein, electrospray 
data for PknA K42A shows the mutant protein was still phosphorylated on at least three 
residues. Given this high level of activity, the toxicity associated with PknA1'290 may be 
attributed to non-specific phosphorylation of essential endogenous E.  coli proteins or 
cellular ATP shortage.
The  phosphorylation  of  PknA  must  have  occurred  within  E.  coli  cells  prior  to 
purification, due to the absence of ATP post-purification. Many studies have shown that 
over expression of some eukaryotic kinases in E.  coli results  in autophosphorylation 
(Hubbard et al.,  1998).  Hyperphosphorylation is probably due to autophosphorylation 
through a trans-kinase intermolecular reaction as is the case for close homolog PrkC in 
Bacillus subtilis, the only other bacterial kinase where autophosphorylation pattern has 
been studied (Madec et al., 2002) (Madec et al., 2003).
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Figure 4.6. Ionisation electrospray mass-spectrum of purified recombinant PknA1 '290-  The calculated molecular weight was 
34855.9Da and the first measured PknA1'290 peak was 35579.9Da, equating to the mass of PknA1'290 plus 9 phosphate 
groups (80Da each). The number of phosphate groups in each subsequent PknA1'290 protein mass peak is indicated in red 
above the peaks on the right paneL PknA1'290 protein species with a maximum of 17 phosphate groups and an average of 
12 phosphate groups is observed from the spectrum.4.3.3  Phosphorylation mapping in PknA and PknB
4.3.3.1  Overview
As  PknA was  observed be multiply phosphorylated at  17  sites by electrospray mass 
spectroscopy,  matrix-assisted  laser  desorption/ionisation  (MALDI)/Time-of-flight 
(TOF) mass spectrometry was employed to determine the sites of autophosphorylation.
Identification  of  phosphorylated  sites  can  be  achieved  by 
MALDI/TOF  measurements  of proteolytic  digests before  and  after treatment with  a 
phosphatase.  This  can  be  achieved  using  a  generic  phosphatase  such  as  alkaline 
phosphatase, lambda phosphatase or the more specific mycobacterial phosphatase, ppp 
(Boitel  et  al.,  2003).  pThr  and  pSer-containing peptides  can be  identified  from  the 
resulting  spectra,  indicated  by  mass  values  shifting  80Da  or  multiples  thereof 
(molecular weight of a HPO3).  However, complete detection of all phosphopeptides, 
particularly those  of low stoichiometry,  from  this  complex mixture  is difficult for a 
number of reasons:
■   Neutral losses of phosphoric acid and water from phospho-amino acid residues 
during MALDI/TOF analysis
■   Poor desorption/ionisation properties of negatively charged species -  especially 
important in the case of multiply phosphorylated peptides
■   Ion suppression effects induced by the presence of dominant unphosphorylated 
peptides.
■   Bias for peptide containing basic residues such as lysine or arginine.
To  improve  coverage  and  circumvent  these  problems,  the  peptide  mixture  may  be 
separated by HPLC or enriched for phospho-peptides using affinity methods.
Affinity methods for phosphopeptide enrichment on immobilised gallium ions bound to 
a  chelating  gel  have  been  found  particularly  useful  in  the  identification  of 
phosphorylated  peptides  for  large,  multiphosphorlyated  proteins  (F.Ivins,  personal
119communication).  Therefore,  after  purification,  the  phosphorylated  PknA1'290  was 
excised from the gel after SDS-PAGE and digested in situ with trypsin and Asp-N. The 
resulting mixture of peptides was applied to an immobilised gallium affinity column 
and after stringent washing with 1 0% acetic acid, followed by 10% acetic acid plus 2 0% 
acetonitrile, peptides were eluted in a basic buffer (lOOmM ammonium bicarbonate, pH 
9.0) prior to MS analysis.
The  principle  of  this  enrichment  process  is  based  upon  the  affinity  of  the 
phosphopeptide phosphate groups for the gallium in the range pH 2.0-5.5. Elution of 
phosphopeptides  is  performed  at  a  higher  pH  (>6.0).  Acetonitrile  was  used  in 
elution/wash buffers to reduce non-specific hydrophobic interactions.
The enriched peptide samples were analysed by MALDI-TOF and each candidate peak 
was  subjected  to  post  source  decay  (PSD).  This  technique  delivers  a  high burst  of 
energy to the entire peptide sample while a deflector excludes everything outside of a 
narrow  mass  range  centred  on  the  target  peak.  If  the  peptide  in  this  range  is 
phosphorylated,  a  second  peak  at  98Da  will  be  seen.  This  is  characteristic  of  (3- 
elimination of phosphoric acid (H3PO4). When the sequence of the protein is known, the 
mass of the parent peak is usually unique to only one possible tryptic/Asp-N peptide.
If the number of potential  sites (Ser/Thr)  in a given peptide  exceeds the number of 
phosphorylation  sites  determined  by  MALDI-TOF,  then  the  exact  position  of 
phosphorylation is still unknown and nanospray mass spectrometry is useful. The entire 
sample is injected into the nanospray, and the peptides are trapped by a quadrupole ion 
trap  in  a resonance  determined by their mass to charge  (M/Z)  ratio.  The peptide  of 
interest is selected by applying a high energy pulse at all resonances except for that of 
the target peptide from the ion trap. Then inversely, another pulse is applied at a small 
window  around  the  resonance  for the  target peptide.  This  pulse  is  not  sufficient to 
cleave  the  peptide  at  its  weakest bonds.  The predominant breakdown product  is  p- 
elimination of phosphoric acid as in PSD above. However, in most cases, a subset of the 
sample breaks down at the weak amide bonds.  If this breakage  occurs between two 
ambiguous phosphorylation sites, the  fragment containing the phosphorylated residue 
will have a mass shift of +80Da and the exact phosphorylated residue can be assigned 
with confidence.
1204.3.3.2  Determination of phosphorylation sites in wild-type PknA
Of the  17 phosphorylation sites detected by ionisation-electrospray (17 x 80Da above 
expected weight), eight were detected by MALDI/TOF with overall sequence coverage 
of  55%.  Using  only  MALDI/TOF  four  sites  were  identified.  Additional  nanospray 
fragmentation was required to unambiguously assign the exact location of three sites. 
One site was narrowed down to a singly phosphorylated peptide with two possible sites 
(see Figure 4.7 and Table 4.2).
Four phosphorylation sites were found in the N-terminal lobe and four in the C-terminal 
lobe  of  PknA  with  no  phospho-residues  identified  for  the  vector  encoded  tag  or 
juxtamembrane  linker  regions.  In  addition,  the  predicted  peptide  fragment 
encompassing the activation loop of PknA was not detected by MALDI/TOF. One of 
the  reasons  for this maybe  the  fact that the predicted peptide  is relatively large  (50 
residues) after Asp-N/trypsin digestion and consequently would have difficulty ionising 
before  undergoing  fragmentation.  Furthermore,  the  activation  loop  has  a  number of 
potential phosphorylation sites as multiple phosphorylation events are required in this 
loop for full kinase activity (Boitel et al., 2003). Heavily phosphorylated peptides ionise 
poorly and therefore are less likely to be detected by MALDI/TOF.
It is important to note that mass spectrometry analysis only gives limited information 
about the  stoichiometry of phosphorylation  at a particular  site  and mainly  serves  to 
prove the  existence  of the phospho-residue  in the protein sample.  MALDI/TOF also 
cannot provide reliable detection of phosphorylation at certain residues or a sub-set of 
residues  for  reasons  listed  in  Section  4.3.3.1.  Whilst,  9  potential  sites  remained 
undetermined  it  was  decided  further  phospho-mapping  investigations  was  not 
appropriate. Many of the sites currently identified are likely to be non-specific and were 
found  on various  sites  over the  surface  of the  PknA  kinase  domain.  The biological 
significance of the bulk of the mapped (and mapped) sites remains to be determined.
4.3.3.3  Determination of phosphorylation sites in PknB K40A
Removal of a conserved catalytic lysine in the kinase domain of PknA and PknB did not 
completely abrogate autophosphorylation and the reason for this will be discussed in the
121following  chapter.  PknB  K40A was  found to have  two phosphorylation  sites.  In an 
effort to determine the phosphorylated residues, a purified PknB K40A protein sample 
was  subjected to  MALDI/TOF  analysis.  The procedure  was performed as  described 
above.  Unfortunately,  neither  of  the  two  sites  detected  by  electrospray  mass 
spectroscopy could be located despite 46%  sequence coverage, although this did not 
include the activation loop region.
1224.4  The Phosphorylation state of PknB
Sequence analysis of the 626  amino acid protein, PknB, using the SMART database 
predicts  an  N-terminal  cytoplasmic  region  and  a  C-terminal  extracellular  region 
separated by a short transmembrane region (Figure 1.11). In this study, two recombinant 
protein fragments of PknB were expressed and purified from E.  coli by the methods 
described in Chapter 3  (Section 3.2.3), PknB1'332 and PknB1 '279.
The  protein  fragment  PknB1'332  makes  up  the  entire  intracellular  region  of  the 
transmembrane  protein PknB  and includes the  kinase domain of 279  residues  and  a 
juxtamembrane region of 53 residues. If compared to close homolog PrkC in Bacillus 
subtilis, PknB would be expected to form a dimer. In PrkC, autophosphorylation occurs 
through  a  trans-kinase  phosphorylation  from  one  subunit  to  the  opposing monomer 
following ligand-induced dimerisation of the extracellular PASTA domains (Madec et 
al.,  2002).  An  X-ray  structure  of the  PknB  kinase  domain  also  suggests  a  dimeric 
architecture  (Young  et  al.,  2003).  Using  electrospray  mass  spectrometry,  this  study 
found PknB1'332  is phosphorylated  at total  of four sites with a triply phosphorylated 
species being most abundant. The phosphorylation status of PknB was later determined 
(Young  et  al.,  2003)  and  the  protein  was  found  to  be  phosphorylated  within  the 
activation  loop  at  residues  S162,  S166,  T171,  T173  and  within  the juxtamembrane 
linker at T294, S295 and T309 (Figure 4.7). This was confirmed in a more recent study 
that also mapped phosphorylated residues of PknD,  PknE and PknF (Grunder et al., 
2005).
1   279 Expression  and  purification  of the  isolated  catalytic  core  domain,  PknB '  ,  again
resulted in a  soluble but heterogeneously phosphorylated protein sample. Using high 
mass  accuracy  electrospray  mass  spectrometry  we  have  found  that  PknB1'279  is 
phosphorylated at a total of five sites with a species phosphorylated at four sites being 
most  abundant.  This  contradicts  previous  studies  that  only  found  four  sites  of 
phosphorylation,  as  listed  above.  It  is  therefore  possible  that  the  fifth  site  of 
autophosphorylation found here may reside in the LIC vector encoded sequence which 
adds  13 residues and contains of two serines, although this remains to be confirmed. 
Mutants of the PknB 1.279 protein fragment were generated for further analysis and
123Table 4.2. Phosphorylated peptides of PknA1'290 oberseved by MALDI-TOF
Position on 
PknA1’290
Phosphorylated peptide sequence -po4
groups3
Phosphorylated
residue
5-12 VGVTLSGR *  be T8, S10
13-34 YRLQRLLATGGMGQVEVDNR 1 T21
60-89 AEARITAMLNHPGLASVHDYGESQMNGEGR 1,2C T64, T65
117-127 HALDMLEQT  GR 1 T125
141-156 DVKPGNILITPTGQVK 1 T152
215-228 RPFAGDGALTVAMK 1 T224
247-260 ELIEITLVKNPAMR 1 T252
aEach peptide was found with different degrees of phosphorylation 
bPhosphorylated residue in mono-phosphorylated peptide was not found 
cThese residues were identified by PSD sequencing
163-AKAVDAAPVTQTGMVMG-179
141  148^158  160 185 187-^272  290
P-loop Catalytic  DFG 
loop  motif
APE  Juxtamembrane 
motif  linker
PknB1 3 3 2 a  *  2  a 
162-AIADSGNS VTQTAA VIG-178
18  23  K40 137  143  156  158 184 186  279  i   332
Activation  loop
P-loop Catalytic  DFG 
loop  motif
SPE  Juxtamembrane 
motif  linker
Figure 4.7. Schematic representation of the recombinant protein kinase constructs PknA1-290 and 
PknB1279. Known phosphorylation sites for the two constructs determined by MALDI mass- 
spectrometry are highlighted in red. All phosphorylated sites determined for PknA1'290 were found in 
this study. Phosphorylation of PknB1'279 sites S163, S166, T171, T173, T294 and S295 was first 
determined by Young et al., 2003 and S309 by Duran et al., 2005.
124purified mutant proteins were applied to an electrospray mass spectrometer to confirm 
the mutation and characterise their phospho-residue content. PknB T173A is maximally 
phosphorylated  on  four  sites  whereas  PknB  T171A  is  maximally phosphorylated  on 
three  sites.  Loss  of the  T171  therefore has  a  greater impact on autophosphorylation 
activity than loss of the T173. Interestingly, PknB K40A was generated as a supposedly 
‘kinase dead’ mutant after removal of an important catalytic lysine that is conserved in 
all  kinases.  However,  removal  of this  conserved lysine  did not completely  abrogate 
autophosphorylation  with  two  phosphorylation  sites  identified.  All  PknB 1.279  K40A 
molecules were phosphorylated on one site with a small proportion phosphorylated on a 
second site, as determined through electrospray mass-spectrometry. Although this lysine 
residue is widely conserved and critical for normal kinase function, in the case of PknA 
and PknB this residue does not prevent partial phosphorylation in vivo. Residual activity 
presumably arises from weak binding of ATP through remaining conserved residues.
1254.5  Discussion
In order to deconstruct the signalling pathway of the PknA/PknB operon (Figure 1.9) it 
was  important to produce  pure  samples  of these  important proteins  as both  isolated 
domains and full cytoplasmic proteins fragments. This task was aided by the fact that 
the  Mycobacterial  FHA  domain-containing  Rv0020  and  Rvl827  had  already  been 
purified as isolated core FHA domains (S. Westcott, unpublished data) (Durocher et al., 
2000). In addition, an atomic resolution structure of the core catalytic domain of PknB 
has  been  solved  (Young  et  al.,  2003)  (Ortiz-Lombardia  et  al.,  2003).  Challenges 
remained including the purification of full-length protein of Rvl827, Rv0020, the FHA 
and  cytoplasmic  region  of Rv0019  and  PknA.  The  cloning  and  expression  of these 
proteins  involved  a  number  of  purification  problems,  as  detailed  in  this  chapter. 
Fortunately, recombinant protein fragments of PknA,  Rv0019 (FHA and cytoplasmic 
region),  full-length  Rv0020  and  full-length  Rvl827  were  generated  in  sufficient 
quantity for subsequent assays.
Although Alber and co-workers expressed the full-length construct of Rv0020 recently 
(Grunder et al., 2005), little work has been published on PknA or Rv0019 to date. These 
proteins are important for M. tuberculosis viability as they are predicted to play a role in 
the  coordination  of cell  growth  and morphology,  possibly in conjunction with other 
coexpressed proteins including PknB, Rv0020 and Ppp (Figure 1.9) (Section 1.8). Some 
evidence has suggested that PknA and PknB genes are essential and consequently, they 
were unable to be removed from the mycobacterial genome (Sassetti et al., 2003). In 
addition,  partial  depletion  of PknA  and  PknB  in M.  bovis  BCG  and M.  smegmatis 
resulted  in  narrow,  elongated  cell  morphology.  Over-expression  of both proteins  in 
these same strains caused reduction in growth rate and long, broad and in some case 
branched cell morphology (Yang et al.,  2005).  Although  PknB was found to have  a 
more  severe  effect on cell morphology than PknA,  this  illustrates the  importance  of 
studying PknA signalling. Until recently, full-length PknA had only been expressed and 
purified as a fusion with a maltose-binding protein tag (Chaba et al., 2002) and this was 
used for limited analysis. Here, PknA was purified as a kinase domain with a portion of 
its juxtamembrane linker (-11 residues) and found to be active.
126The cloning, expression and purification of these proteins make it possible to conduct 
further extensive biochemical and biophysical investigations. It is clear from previous 
work that FHA domains  are  involved  in the phospho-threonine-dependent signalling 
directed by  STPKs  such as PknA and PknB  and the genetic  linkage  of Rv0019  and 
Rv0020 to these kinases suggests that there is likely to be some interplay between these 
proteins.  The  availability of the  FHA-domain containing protein Rvl827 means it is 
now possible to investigate whether PknA and PknB function in a simple linear pathway 
involving coexpressed proteins  or whether they have regulatory roles in conjunction 
with independently expressed proteins.  In the proceeding chapters I have investigated 
these  ideas  by  using  in  vitro  phosphorylation  assays  and  quantitative  binding 
experiments to screen for interactions between these purified proteins.
1275  Biophysical Characterisation of Kinase-FHA Interactions
5.1  Introduction
The primary focus of this project is a putative operon in the M.  tuberculosis genome 
that contains two FHA domain-containing proteins (Rv0019 and Rv0020) along with 
two  STPKs  (PknA  and  PknB)  (Figure  1.9).  The  co-expression  of  FHA  domain- 
containing proteins  and  STPKs,  coupled with the  fact that STPK domains and FHA 
domains are often found covalently linked in eukaryotic proteins (i.e. Chk2 and Rad53) 
strongly  suggests  that  these  bacterial  FHA  domain-containing  proteins  engage  in 
regulatory phospho-dependent protein-protein interactions. As FHA domains are protein 
interaction domains which are known to recognise specific phospho-threonine motifs 
(Durocher et al., 2000) and both PknA and PknB are shown to autophosphorylate at 
threonine residues (Section 4.3  & 4.4) this indicates FHA domain-containing proteins 
could form complexes with STPKs.
The potential of kinase-FHA interactions in directing signalling in the M.  tuberculosis 
was  investigated  using  a  combination  of isothermal  titration  calorimetry  (ITC)  and 
surface plasmon resonance (SPR).  A detailed explanation of these techniques can be 
found in Chapter 2. The ITC and SPR experiments described here were carried out in 
order to establish whether PknA and PknB function in a simple linear pathway where 
they  interact  with  the  co-expressed  FHA  domain-containing  proteins,  Rv0019  and 
Rv0020. Rvl827 is an FHA domain containing protein found encoded at a locus in the 
M.  tuberculosis  genome  far apart from the pknA  and pknB  genes  and therefore, this 
protein was investigated as a binding partner for PknA/B to see whether they can play a 
role in a more complex signal transduction pathway involving FHA domain-containing 
proteins  from  other operons.  Details on the possible biological role  of Rvl827  have 
been previously discussed (Section 1.8.8).
To characterise kinase-FHA interactions, the kinase domains of PknA and PknB, and 
FHA domains of Rv0019, Rv0020 and Rvl827 were isolated, then subjected to analysis
128by  ITC  and  SPR.  In  addition  phosphopeptides  representing  the  different 
phosphorylation states of the PknB  activation loop were synthesised (Table  5.1), and 
binding to each FHA domain was measured and compared with the measurements of 
FHA binding to the intact kinase domains.
1295.2  Isothermal Titration Calorimetry Measurements of Kinase-
FHA Interactions
5.2.1  Overview
ITC  was  used  in  this  study  to  define  the  equilibrium  binding  properties  and 
thermodynamic parameters of interactions between STPKs and FHA domains.
Table 5.1. Peptides synthesised for this study
Designation3 Sequence
PknB Activation loon
TQT A-Y-K-K-N-S-T-Q-T-A-A-V-I
pTQpT A-Y-K-K-N-S-pT-Q-pT-A-A-V-I
TQpT A-Y-K-K-N-S-T-Q-pT-A-A-V-I
PTQT A-Y-K-K-N-S-pT  -Q-T  -  A-A-V-I
Rvl827 N-terminal
pTTSV D-E-V-T-V-E-pT-T-S-V-F-R-A-Y-K-K
TpTSV D-E-V-T-V-E-T-pT-S-V-F-R-A-K-K
Optimal peptideb
Rvl827 optimal peptide A-L-I-P-pT-Q-L-Y -  A-Y-K-K
Rv0020 optimal peptide D-T  -  A-P-pT-E-K-I-A-Y-K-K
*pT represents phosphorylated threonine residues.
bOptimal peptides were determined in a prior study using peptide library screening analysis (Westcott, S., 
PhD thesis 2003).
130In general, when analysing protein-peptide interactions, the peptide was loaded in the 
syringe at concentrations ranging from 350pM to  1.6mM and the protein in the cell at 
concentrations between 29pM and 159pM. When analysing protein-protein interactions, 
the  FHA  domain  was  generally  loaded  in the  syringe  at concentrations ranging  from 
217pM  to  620pM  and the kinase  in to the cell at concentrations between  25pM  and 
59pM.  In  all  titrations,  the  ratio  of concentrations  of material  in  syringe:cell  were 
between 9 and  12 and all were performed at  18°C. Proteins were exchanged from their 
storage buffer into a buffer containing  150mM NaCl  and  50mM Tris-HCl pH  8.0 by 
overnight dialysis. Phospho-peptides derived from the PknB activation loop amino-acid 
sequence (168-NSTQTAAVI-176) were dissolved into the identical  ITC buffer.  In all 
cases, the resulting data fit to a one-site model for binding.
131Table 5.2. Thermodynamic parameters for FHA interactions
Material in  syringe  Protein in ceil  n  ,^ n \,^ ^ ! b  .\  T^ f b  n,^9/b  n 3  ®   (pM) (kcai/mol)  (kcal/mol)  (kcal/mol)
Protein:Protein
<f PknB Wt 1.3 3.2 -9.2 -1.8 -7.4
X
LL PknB T171A 0.6 2.0 -11.0 -3.3 -7.7
O
CN
O
O PknB T173A 0.9 9.4 -15.1 -8.4 -6.7
tr PknB T171A/T173A NDB - - - -
Rv0020 FHA S473A PknB Wt NDB - - - -
<r PknB Wt 0.9 9.3 -7.7 -0.9 -6.8
X
LL PknB T171A 0.7 30.7 -10.1 -4.1 -6.0
C N J
oo PknB T173A 0.8 22.6 -18.2 -12.0 -6.2
c r PknB T171 A/T 173A NDB - - - -
Rv1827 FHA S95A  PknB Wt 
FHA'.Activation Iood DeDtidea
NDB • • -
TQT <
X
NDB - - - -
pTQpT LL
O
CM
0.7 2.1 -9.8 -2.2 -7.6
TQpT O
O 0.8 3.2 -11.2 -3.8 -7.3
pTQT X 0.9 34.0 -11.1 -5.2 -6.0
pTQpT Rv0020 FHA S473A NDB - - - -
TQT <
X
NDB - - - -
pTQpT LL
r -
C N I
0.8 11.4 -4.9 1.7 -6.6
TQpT 00 0.9 14.3 -3.2 3.2 -6.4
pTQT tr 1.0 23.6 -5.8 0.4 -6.2
pTQpT Rv1827 FHA S95A NDB - - - -
* AGb   = AHb  —  TASb  . All ITC experiments were conducted at 29IK (18°C).
“Full  peptide  sequences  are  provided  in  Table  5.1.  (NDB)  No  detectable  binding.  Stoichiometry  (n), 
equilibrium binding constant (KD ), observed binding enthalpy (AHb), observed binding entropy (ASb), and 
binding free energy (AGb)
1325.2.2  The FHA domains of Rv0020 and Rvl827 interact with the PknB kinase domain
Calorimetric titration of the PknB kinase domain with FHA domains of Rv0020 and 
Rvl827  generated measurable  interactions  in the  absence  of ATP  (Figure  5.1).  The 
thermodynamic parameters  stoichiometry («),  equilibrium dissociation constant (KD ), 
observed binding  enthalpy  (AHb),  observed binding  entropy  (AS),),  and binding  free 
energy (AGb) were determined from calorimetric data and are listed in Table 5.2.
It is known that mutation of a conserved serine within the FHA domain of both Rvl827 
and Rv0020 FHA domains  (S95  and  S473, respectively) results  in complete  loss  of 
phospho-threonine  binding  (Durocher  et  al.,  2000,  Westcott  S.,  PhD  thesis  2003). 
Importantly,  no  binding  was  detected  upon  titration  of  serine  mutants  of Rv0020 
(Rv0020 S473A) and Rvl827 (Rvl827 S95A) with both phosphopeptides and purified 
phosphorylated kinase  domains  (Table  5.2  and Figure  5.2),  underlining the  fact that 
FHA-phosphothreonine  binding  is  essential  for kinase-FHA  complex  formation,  and 
that these conserved serine residues are an absolute requirement for phosphothreonine 
binding.
5.2.3  The  site  of FHA  domains  of Rvl827  and  Rv0020  interaction  is  the  PknB 
activation loop
The autophosphorylation of PknB has been mapped to four residues in the activation 
loop  (S166,  S169,  T171,  T173)(Young  et  al.,  2003)  and  the  presence  of  four 
phosphorylated residues has been confirmed in wild type PknB protein used here by 
electrospray mass spectroscopy (Table 4.1 and Figure 4.7). The fact that FHA domains 
are  protein  interaction  domains  that  recognise  specific  phospho-threonine  motifs 
suggests that T171 and/or T173 of the PknB activation loop are the likely binding site(s) 
for the FHA domains.
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Figure 5.1. Binding isotherms of the FHA domains of Rvl827 and Rv0020 for the 
phosphorylated kinase domain ofPknB, PknB1'279, determined by isothermal titration 
calorimetry. The upper panel shows a representative raw ITC trace for the binding of 
Rv0020 FHA domains binding to PknB1'279. The tower panel shows the overlapping ITC 
data for interactions between PknB1'279 and both Rv0020 and Rvl827 FHA domains fit 
to a one-site binding model. All of the observed binding stoichiometries were consistent 
with a 1:1 complex between the FHA and kinase domain. Resultant thermodynamic 
parameters are shown in Table 11.
134Activation loop residues, T171  and T173 were therefore mutated to alanines with the 
expectation  that  this  might  interfere  with  PknB-FHA  complex  formation.  After 
purification of the PknB T171 A/T 173 A kinase domain protein, use of electrospray mass 
spectrometry confirmed the presence of all remaining phosphorylation sites (SI66 and 
S169)(Table  4.1).  The  calorimetric  titrations  of  Rv0020  and  Rvl827  with  PknB 
T171A/T173A  showed  no  detectable  heat  change  greater  than  the  heat  of dilution 
consistent with complete loss of binding.  This result was reproduced when replacing 
PknB  T171A/T173A with  an unphosphorylated peptide  of the  PknB  activation loop 
(Table  5.2 and Figure  5.2).  These ITC experiments provide convincing evidence that 
FHA domains of Rv0020 and Rvl827 bind to pT171  and/or pT173  in the activation 
loop of PknB.  Furthermore, these data suggest Rv0020 and Rvl827  do no form any 
interactions with the PknB kinase domain other than that with the activation loop.
A fourth PknB  mutant kinase,  PknB  K40A, was constructed in which the conserved 
catalytic  lysine  residue  (K40)  was  substituted  with  an  alanine.  Electrospray  mass 
spectrometry  showed that most PknB K40A protein was phosphorylated on one  site 
with a small proportion phosphorylated on two sites consistent with a severe reduction 
in autophosphorylation activity as observed for other kinases (Table 4.1)(Ozes et al., 
1999,  Iyer et al.,  2005).  Titration  of Rv0020  with  PknB  K40A  generated  a binding 
isotherm  which  showed little evidence  of complex  formation presumably due  to the 
small active (phosphorylated) fraction of the mutant kinase domain.
5.2.4  The Rv0020 FHA domain binds preferentially to specific PknB phosphorylation 
states
After establishing an interaction between the FHA domain of Rv0020 and the kinase 
domain of PknB and establishing this involved binding of Rv0020 to phosphothreonines 
of the  activation  loop  (pT171  and  pT173),  it  was  necessary  to  determine  if either 
phosphorylated  threonine  was  favoured.  After  generating  two  PknB  mutants  (PknB 
T171A and PknB T173A) and synthesis of activation loop peptides (pTQT, TQpT and 
pTQpT) a series of ITC experiments were conducted to clarify these issues.
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Figure 5.2. Binding isotherms of the FHA domains of Rvl827 and Rv0020 for the 
phosphorylated kinase domain of PknB, PknB1'279,  and PknB activation loop peptides 
determined by isothermal titration calorimetry. The upper left panel shows a 
representative raw ITC trace for the binding of Rv0020 FHA domains binding to 
PknB1279, besides which are overlapping ITC data for interactions between Rv0020 
FHA and various activation loop peptides fit to a one-site binding model. The lower two 
panel show the same for the Rvl827 FHA domain. All of  the observed binding 
stoichiometries were consistent with a 1:1  complex between the FHA and kinase 
domain. Resultant thermodynamic parameters are shown in Table 11.
136Rv0020 showed a preference for binding to the PknB activation loop mutants in this 
order: PknBWt « PknBT173 > PknBT171  only. The equilibrium dissociation constant 
(Kd) observed for the binding of Rv0020 to PknB (wild-type and T171A) was ~2-3pM 
(Table 5.2). The interaction of the Rv0020 FHA domain to PknB T173A was weaker, 
with a Kd  of 9.4pM.  Similar results  were  obtained  after analysis  of protein-peptide 
interactions.  The  binding  of  the  Rv0020  FHA  domain  with  peptides  pTQpT 
(representing wild-type PknB) and TQpT (representing PknB T171A) also had a Kd of 
~2pM.  As might have been predicted, the Rv0020 FHA domain interaction with pTQT 
(representing PknB T173A) was significantly weaker, with a Kd of 33.5pM, consistent 
with  a  small but  significant preference  of the Rv0020  FHA domain for pT173  over 
pT171. This observation will be discussed at the end of the Chapter (Section 5.4).
5.2.5  Rvl 827 shows no specificity for particular PknB phosphorylation states
In  a  similar  way,  the  mutant  kinase  domain  and  phosphopeptides  were  used  to 
determine which phosphorylated threonine in the PknB activation loop is favoured by 
the Rvl 827 FHA domain.
In contrast to the  Rv0020  FHA interactions  described above,  Rvl 827  showed  slight 
preference for binding to the wild-type kinase domain (Kd of 9pM) over both mutants 
PknB  T171A  and  T173A  (KD   of  31pM  and  23 pM,  respectively)  indicating  that 
phosphorylation of both residues contributes equally to overall binding. The binding of 
the Rvl 827 FHA domain with peptides pTQT (representing PknB T173A) and TQpT 
(representing PknB T171A) gave a Kd of 24 pM and 14pM, respectively. The Rvl 827 
FHA domain interacted with pTQpT (representing wild-type PknB) with a Kd of 11 pM. 
Thus, the results from the protein-protein titrations were recapitulated by the protein- 
peptide interactions measured although the discrimination was less marked.
1375.2.6  RvOO 19 is unable to bind phospho-peptides
The minimal tryptic fragment of RvOO 19 was determined (Section 4.2.3) encompassing 
the  FHA domain homology region.  An ITC experiment was conducted with the cell 
containing  this  purified  RvOO 19  FHA  domain  (27.8pM)  and  the  syringe  containing 
wild-type PknB kinase domain (175pM). All other conditions were as described above. 
Surprisingly, the ITC data showed no detectable binding even when repeated under a 
number  of  different  conditions  (i.e.  changing  protein  concentrations,  conducting  a 
reciprocal  titration  by  swapping  components  in  the  cell  and  syringe,  conducting 
titrations at different temperatures). In addition, an ITC experiment was conducted with 
the  cell  containing  purified  RvOO 19  FHA  domain  at  five  times  the  concentration 
(132pM)  and the  syringe  an appropriately higher concentration of the  TQpT peptide 
(1.12mM). Again no binding was detected.
Since  it  seems possible  that proteolytic  fragment may have  contained  a  structurally 
compromised  FHA  domain,  ITC  experiment  was  also  conducted  between  the  full 
intracellular  domain  of RvOO 19  as  a  GST  fusion,  GST-Rv001929'156,  and  the  PknB 
activation loop peptide, pTQpT. Here, the cell contained the GST-Rv001929'156 protein 
(27.8pM) and the  syringe contained the pTQpT peptide (175pM). No binding signal 
was observed in either of two separate experiments.
Although the reasons for lack of binding activity of full-intracellular RvOO 19 protein or 
its  isolated  FHA  domain  are  unclear,  there  are  a  number  of possible  explanations. 
Firstly, the RvOO 19 FHA domain may have a completely different specificity to that of 
other FHA domains of Rv0020 and Rvl 827.  Secondly, as mentioned above, RvOO 19 
may fail to fold correctly when produced in E.coli. Nevertheless, the protein construct 
Rv001956'156 was stable after purification (i.e.  no aggregation of protein samples) and 
thermal stability similar to that of the Rv0020 FHA domain (Section 4.2.4)(Figure 4.4). 
Despite displaying good homology to known functional FHA domains (Figure 1.3) the 
RvOO 19  FHA  domain  does  show  variation  in  its  far UV  CD  spectrum,  although  it 
nonetheless is consistent with a high proportion of p-sheet structure (Figure 4.3). The 
sequence of the RvOO 19 FHA domain is close enough to the Rv0020 FHA to create a 
model of the RvOO 19 FHA domain based in the Rv0020 FHA domain (Figure 5.3). This 
served to demonstrate that conserved residues of RvOO 19 would be correctly placed for 
phosphopeptide binding. Sequence analysis using SMART also shows RvOO 19 contains
138a  transmembrane  region  and therefore  it would be  membrane-associated  along with 
PknA and PknB. This suggests it could bind to PknA and/or PknB at weak affinities 
aided by co-localisation with these proteins and the resulting high local concentrations. 
Nonetheless, the association constants for this interaction in free solution may be below 
the  detection  limit  of ITC.  Finally,  it  is  possible  that  RvOO 19  plays  non-phospho- 
dependent role in TB signalling.
In a related case,  the mitotic  checkpoint protein Chff contains  an FHA domain that 
failed  to  show  binding  to  phosphopeptides  in  a phosphopeptide  library  screen  (M. 
Yaffe, unpublished data). The structure of the Chff FHA was solved with a tungstate, a 
phosphate analog, bound in the expected phosphate binding site (Stavridi et al., 2002), 
suggesting  that  it  is  able  to bind phosphoproteins  by  a  similar mechanism  to  other 
known FHA domains.
The phosphorylation of RvOO 19 the FHA domain by PknB may represent a mechanism 
by which STPKs may modulate the FHA domains phospho-peptide binding ability, and 
this was  investigated in the next Chapter.  For example phosphorylation may lead to 
activation of the FHA phosphothreonine binding ability. The important DNA-damage 
response  protein  in  eukaryotes,  Chk2  contains  a  STPK  domain that  is  also  able  to 
phosphorylate its N-terminal FHA domain. In this case, this modification reduces the 
Chk2 FHA domains affinity for a primary phosphorylation site on the protein (Ahn et 
al., 2002).
139Figure 5.3. A model of the Rv0019 FHA domain based on the known structure of the Rv0020 
FHA domain. Both structures are depicted as cartoon representations with conserved residues 
shown in stick representation in red. The model of the RvOO 19 FHA domain was constructed by 
threading the amino-acid sequence of the Rv0019 FHA homology region onto the structure of the 
Rv0020 FHA domain (Westcott, S., PhD thesis 2003) using SwissModel first approach mode 
(Schwede et al,. 2003).5.2.7  The PknA-FHA interaction
Purification  of PknA  resulted  in  a  heterogeneous  and  hyperphosphorylated  protein 
population as determined by electrospray mass spectrometry (Section 4.3). Calorimetric 
titration, carried out with the Rv0020 FHA domain in the syringe at 608pM and PknA 
in the cell at 70pM, produced a significant heat change (-3kcal/mol) for all injections 
without saturation of binding sites (Figure 5.4A). Phosphorylation mapping performed 
earlier (Section 3.2.4) demonstrated that there are a number of potential binding sites for 
FHA domains as the protein is heavily autophosphorylated. It is possible that multiple 
FHA molecules could bind to the phospho-threonines of PknA, as all FHA domains 
have  some  non-specific  affinity  for  phospho-threonine  residues;  this  would  result 
explain  the  slow  saturation  of  binding  sites  upon  titration.  To  test  this  theory  a 
reciprocal titration was conducted with the Rv0020 FHA (38pM) in the cell and PknA 
(300pM) in the syringe. Indeed, this produced a substantial heat change (-70kcal/mol) 
for early injections of IOjiL but the binding was quickly saturated consistent with the 
presence  of multiple  sites  on the  purified  PknA  kinase  domain  (Figure  5.4B).  This 
titration displayed an n value of ~0.09 and yielded a Kd of 2pM, which is close to the 
SPR observed Kd of 1.6pM (Section 5.3.2 and Table 5.3). It should be noted that the 
apparent  thermodynamic  and  affinity  parameters  for  this  interaction  would  be  an 
amalgamation  of many  interactions  and  therefore  the  autophosphorylation  on  PknA 
would have  to  be  reduced to  the  level  of PknB  before  and meaningful data  can be 
obtained.
Steps were taken to improve the thermodynamic and affinity data of the ITC experiment 
described  above,  conducted  with  the  Rv0020  FHA  (38pM)  in  the  cell  and  PknA 
(300pM) in the syringe (Figure 5.4B), in light of data suggesting the PknA contained 
multiple FHA binding sites.  The raw data generated from the ITC was input into the 
Origin ITC  analysis  software,  with a  higher than  actual  concentration of PknA  also 
input and data was fitted as before to a one-site model. The concentration of PknA was 
increased  iteratively  until  the  fit  provided  an  n  value  close  to  1.  This  simulated  a 
decrease  in  the  amount  of  sites  in  a  single  PknA  molecule,  compensating  for  the 
multiple sites present in the PknA molecules and thereby allowing the data to fit better 
to a one-site model.
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Figure 5.4. Binding isotherm of the Rv0020 FHA domain for the h>perphosphorylated kinase 
domain of PknA. (A) a representative raw ITC trace with Rv0020 FHA domain in the syringe at 
608^iM and PknA in the cell at 70|iM. No saturation ofbinding was evident. (B) the raw ITC 
trace and binding isotherm generated by a reciprocal ITC experiment with Rv0020 FHA domain 
in the cell at 13jaM and PknA in the cell at 150(iM. (C) the binding isotherm generated from the 
ITC data shown in panel B after increase the computationally increasing the PknA concentration 
12-fold. All the available Rv0020 FHA binding sites were quickly saturated. Data fit to a one-site 
model and the calculated thermodynamic parameters are given to right of the graph.
142A value of 0.97 for n was achieved when the true syringe concentration of PknA was 
increased 12-fold, implying each PknA molecule could bind to 12 FHA domains. The 
resultant  data  from  this  modelled  fit  (Figure  5.4C)  lie  within  the  range  of values 
expected for FHA-phosphothreonine interactions. The enthalpy change of binding, AHb, 
was -13 kcal/mol, which is similar to that observed for the binding of the Rv0020 FHA 
domain  to  PknB  (-9.2  to  15.1kcal/mol)(Table5.2).  Furthermore,  the  equilibrium 
constant, KD, for the modelled fit was ~30pM, which is within the range expected for 
FHA-phosphothreonine  interactions  despite  being  rather  weaker  than  interaction 
measured previously involving the Rv0020 FHA domain (Table 5.2). It should be noted 
that the apparent thermodynamic and affinity parameters for this interaction would be a 
combination  of  multiple  interactions.  Therefore,  the  relatively  weak  interaction 
observed between Rv0020 FHA domain and PknA would be an average of numerous 
weak non-specific interactions with a small contribution from tight biologically relevant 
interactions. It is likely that the PknA activation loop is the only true target for binding 
by the Rv0020 FHA domain, and this interaction may have similar properties to that 
observed for PknB as activation loop sequences are highly homologous (Figure  1.11). 
Whilst these data cannot be considered a true reflection of the biological interaction 
between  PknA  and  Rv0020  they  do  suggest that  PknA may  indeed be  a bona  fide 
binding partner of Rv0020 in vivo.
1435.3  Surface Plasmon Resonance
5.3.1  Overview
SPR was performed according to the procedure outlined in Section 3.2.5.  In general, 
when analysing protein-protein interactions  it is advisable to immobilise the  smaller 
component of the complex on the surface of the sensor-chip as this provides a greater 
signal  (related  to  mass  change)  upon  complex  formation.  In  this  case,  the  smaller 
components (FHA domains) were more difficult to immobilise due to a lack of surface 
accessible lysine groups that are utilised in the immobilised reaction, and therefore the 
kinase  domains of PknA and PknB  were immobilised instead.  Immobilisation of the 
purified  kinase  domains  onto  a  carboxymethyldextran-modified  gold  surface  was 
achieved  using  standard manufacturers  guidelines,  as  described in Section  3.2.7.  All 
proteins  were  immobilised  to  a  level  of around  1000  response  units  (RU)  using  a 
standard buffer containing  lOmM  sodium acetate, pH 4.5-6, at 40-120pg/mL protein 
concentrations. Equilibrium binding analysis was performed by injecting FHA domain 
over the  immobilised protein  surface and similarly over a control surface at varying 
concentrations and at a flow-rate of 5pL/min. Kinetic experiments were conducted at a 
flow-rate of 50pL/min. The sensor chip did not require a regeneration step as binding 
was relatively weak, meaning all proteins could be removed by running HBS-EP buffer 
over the surface for 5 minutes to return to a baseline response (Figure 5.5). Readings 
were  taken  for  at  least  12  different  FHA  concentrations  and  equilibrium  binding 
constants were calculated by fitting the response versus substrate concentration to the 
single-site saturation curve described in Section 2.1.
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Figure 5.5. Equilibrium and kinetic analysis of Rv0020 binding  with immobilised PknA and PknB 
conducted by Surface Plasmon Resonance. Equilibrium analysis of Rv0020 with immobilised PknA 
and PknB. (A) A series of concentrations of Rv0020 (0.02, 0.039, 0.08, 0.16, 0.3, 0.63, 1.25, 2.5, 5, 
10, 20 fj.M) were injected over immobilised PknA1-290  and (B) PknB1’279 until the maximal response 
was achieved. The flow speed was 5pL/min. The recorded response at equilibrium was corrected for 
background from a control flow cell. Kinetic analysis of Rv0020 with immobilised PknA and PknB. 
(C) A series of concentrations of Rv0020 (16, 31, 63, 125nM) were injected over immobilised 
PknA1'290. (D) A series of concentrations of Rv0020 (31, 63, 125, 250nM) were injected over 
immobilised PknB1'279. The flow speed was 50pL/min. The kon and koff were determined from the 
relevant portions of the sensorgram curve (coloured lines) using BLAevaluation 3.0 software using 
global fitting to a 1:1 Langmuir binding modeL The fitted curves (black lines) are overlaid on the 
sensorgram traces. All samples were in HBS buffer pH 7.4 at 25°C. Resultant equilibrium binding 
parameters are shown in Table 12.________________________________________________________
145Table 5.3. Comparison of equilibrium binding data derived from ITC and SPR
FHA  PknB
domain  Method*  PknA  PknB  PknB T171A PknB T173A T171A/T173A
SPR 1.6 2 2 2 NDB
Rv0020
ITC N/A 3 2 9.4 NDB
SPR 5 11 23 13.4 NDB
Rv1827
ITC N/A 9 30.7 22.6 NDB
SPR NDB NDB NDB NDB NDB
Rv0019
ITC NDB NDB NDB NDB NDB
*All binding data is given as KD in 
(NDB) No detectable binding
5.3.2  Rv0020 binding to PknB
The real-time measurement of the biophysical interaction between PknB and Rv0020 by 
SPR generated a typical sensorgram, shown in Figure 5.6.  These raw data were used to 
determine  the  equilibrium  binding  curves  for  interactions between FHA  domains  of 
Rv0020 and Rvl 827 and kinase domains of PknA and PknB (mutant and wild-type). 
Although the curves display different capacities for the binding surface, the interactions 
between the Rv0020 FHA domain and PknB (Wt, T171A and T173A) resulted in the 
same Kd (2pM) (Table 5.3). Using ITC, Rv0020 had ~4-fold preference for binding to 
the activation loops phosphorylated at solely at T173 or both T171 and T173 over T171 
only. However, the ITC data did show the same Kd of 2pM for the Rv0020 FHA-PknB 
(wild-type,  T171A) interactions.  As with ITC measurements, there was no detectable 
binding  of the  Rv0020  FHA  domain to  PknB  T171A/T173A,  confirming that these 
residues are the sites of interaction.
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Figure 5.6. Equilibrium analysis of Rv0020 FHA domain with immobilised PknA1  290 and 
PknB1'279 conducted using surface plasmon resonance. Data from equilibrium experiments 
were analysed by fitting to a saturation binding curve using a one-site binding model by non­
linear regressional analysis. (A) binding curves for the interaction of Rv0020 FHA domain to 
wild-type forms of PknA1" 290 and PknB1'279. (B) binding curves for the interaction of Rv0020 
FHA domain to wild-type and mutant PknB1-279. All samples were injected over SPR 
surfaces in HBS buffer pH 7.4 at 25°C. Data were fitted to a single-site binding curve using 
non-linear regressional analysis and all fits were generated from the average of three 
independent e>q}eriments. All values were within 1  standard deviation of the average data 
point. The measured interaction parameters are shown in table 12._______________________
1475.3.3  Rv1827 binding to PknB
The  interactions  of Rvl827  were  analysed  in  a  similar manner to  those  of Rv0020 
(Figure 5.7 and Table 5.3). As was observed by ITC, the Rvl827 FHA domain did not 
bind  to  PknB  T171A/T173A.  Rvl827  also  showed little  preference  for  a  particular 
phosphorylation  state,  except  that  its  interaction  with  PknB  T171A  was  modestly 
weaker than interaction with PknB Wt or T173A by  ~2-fold. The equilibrium binding 
data are similar to ITC data that also suggest no clear preference of Rvl827 for binding 
to either activation loop phosphothreonine of PknB.
5.3.4  The Rv0020 and Rvl827 FHA domains form a complex with PknA
PknA kinase domain purified as a fusion with a hexahistidine tag was immobilised onto 
the CM5  sensor chip as described above then subjected to conventional SPR analysis 
(Figure  5.5). The resultant sensorgrams of steady-state analysis were similar to those 
involving  PknB  binding  (Figure  5.6  and Table  5.3)  and revealed that Rv0020  FHA 
could bind PknA with a Kd of 1.6pM and that Rvl 827 was able to bind to PknA with a 
Kd of 5pM. As described earlier, there are a number of potential binding sites for FHA 
domains  as the protein is heavily phosphorylated and that the precise phospho-motif 
that  the  FHA  domains  recognise  is  still  unknown.  It  is  possible  that multiple  FHA 
molecules could bind to the phospho-threonines of PknA with only a subset binding to 
sites  of physiological  relevance.  However,  the  stoichiometry  of binding  cannot  be 
determined as the immobilised species of SPR experiments assumed to be in excess and 
therefore saturation of the binding sites is unobtainable.
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Figure 5.7. Equilibrium analysis of Rvl 827 FHA domain with immobilised PknA1 '290 and 
PknB1 '279 conducted using surface plasmon resonance. Data from equilibrium experiments 
was analysed by fitting to a saturation binding curve using a one-site binding model by non­
linear regress ional analysis. (A) binding curves for the interaction of Rvl 827 FHA domain to 
wild-type forms of  PknA1'290 and PknB1'279. (B) binding curves for the interaction of Rv0020 
FHA domain to wild-type and mutant PknB1 '279. All samples were injected over SPR 
surfaces in HBS buffer pH 7.4 at 25 °C. Data were fitted to a single-site binding curve using 
non-linear regress ional analysis and all fits were generated from the average of three 
independent experiments. All values were within 1  standard deviation of the average data 
point. The measured interaction parameters are shown in table 12.______________________
149Although not investigated in detail,  it seems  likely that the FHA domain containing 
proteins bind to PknA through the activation loop, which is similar in sequence to that 
of PknB  (Figure  1.11).  The binding affinities of the FHA domains from Rv0020 and 
Rvl 827  to  wild  type  PknA  are  of similar  affinity  to  their  interaction  with  PknB. 
Importantly, the reduced phosphorylation of full-length Rv0020 and Rvl 827 proteins by 
PknA  relative  to  PknB,  as  reported  in  the  next  Chapter  (Section  6.2.3),  cannot be 
attributed to lower interaction affinity of the FHA domains.
5.3.5  Kinetics parameters of FHA-Kinase interactions cannot be determined by SPR
The  kinetic  rate  constants  of the binding between PknA and PknB  to  Rv0020 FHA 
domain and Rvl 827 FHA domain were measured by injecting a series of concentrations 
of the FHA domains over the immobilised kinase domains at a flow-rate of 50pL/min, 
significantly  faster  than  for  equilibrium  analysis.  Faster  flow  rates  can  reduce  the 
amount  of  analyte  rebinding  during  dissociation  phase  making  dissociation  rate 
constants easier to evaluate. During dissociation phase, the amount of available binding 
sites  increases  leading  to  rebinding  of  the  analyte.  Consequently,  the  apparent 
dissociation-rate is lower than the actual rate. Raw data on the response change upon 
binding (Figure  5.5) were then analysed using the BIAevaluation software.  Here, the 
data acquired from several FHA concentrations were simultaneously fitted to a one-site 
model by a non-linear least-squares method and analysed according to the integrated 
rate  equations  described  in  Chapter  2.  Using  this  procedure,  only  a  few  low  FHA 
domain concentration experiments fitted to an acceptable chi-squared value; a statistical 
measure  for  the  goodness  of  fit.  From  the  resultant  rate  constants,  the  derived 
equilibrium  constants  were  in  the  nanomolar range  and did not agree with previous 
findings from SPR equilibrium experiments and ITC which both show binding affinities 
in the micromolar range (Table 5.3). By modelling these interactions, it was found that 
there  was  an  error  in  fixing  an  accurate  dissociation  rate  constant  through  the 
BIAevaluation global  fit process.  Therefore,  the dissociation phase of the  interaction 
was analysed separately to yield a more precise value for the dissociation rate constant. 
This was then used to constrain the analysis of the association phase to provide a better
150estimate. Although, the data were much improved in terms of chi-squared value, this 
still failed to fit adequately implying that the rate constants are too fast to be accurately 
determined by SPR (S. Nicols, personal communication).
5.3.6  Competition studies
Although ITC measurements had suggested a binding preference of Rv0020 for pT173, 
equilibrium SPR experiments failed to show this difference.  In order to eliminate the 
possible problems associated with the behaviour of differentially phosphorylated PknB 
proteins on the sensor surface, a series of competition studies were used to determine 
the  binding  specificity  of  Rv0020  and  Rvl 827  FHA  domains  to  activation  loop 
peptides.  This has the important advantage that a single sensor chip surface modified 
with  only  wild-type  PknB  can  be  used  for  all  the  experiments,  permitting  a  more 
reliable  comparison  of  relative  ligand  affinities.  In  brief,  the  SPR  competition 
experiments were conducted using immobilised PknB and passing a fixed concentration 
of FHA domain (lpM for Rv0020 and 5pM for Rvl 827) over them spiked with varying 
concentrations of synthetic peptide. As with equilibrium SPR experiments, the steady- 
state response values (maximum response) were obtained at each peptide concentration 
after subtracting the control value.  This response value would equate to the maximal 
binding of the FHA domain (Rv0020/Rvl827) to the ligand (PknB Wt) at a specific 
concentration of competing peptide. Readings were taken from a flow cell containing 
immobilised wild-type PknB  for at least  12  different peptide concentrations and IC50 
values were calculated by fitting the response versus peptide inhibitor concentration to a 
dose response curve (Section 3.3).
151Table 5.4. Equilibrium binding parameters for the interaction of FHA domains of 
Rv0020 and Rvl827 with PknB activation loop peptides
Activation Loop Peptides*
pTQT  TQT  TQpT  pTQpT
SPR /C50 71 DNB 15 3.6
o
CM
O o SPR Kq 20 ND 4.2 1.0
>
a:
ITC Kd 34 DNB 3.0 2.0
SPR ICso 14 DNB 22 2.6
h -
CN 00 T “ SPR KD a 9.6 ND 18 1.9
>
O'
ITC Kd 24 DNB 22 11
*A11 binding data is given in pM units.
“SPR generated Kq values were determined using the following equation:
Kd
where  K J D  is the peptide equilibrium dissociation constant as determined by SPR competition assay, /C50 
is the concentration  of the peptide that inhibits binding of the FHA  domain to the surface immobilised 
kinase  by  50%,  Kd  is  the  equilibrium  dissociation  constant,  as  measured  by  SPR  (Table  5.3)  for the 
complex between the FHA and surface immobilised kinase and [S] is the concentration of FHA domain.
These experiments demonstrated that the Rv0020 FHA domain binding preference for 
the  various  peptide  ranks  as  follows:  pTQpT  >  TQpT  >  pTQT  (Figure  5.8).  The 
unphosphorylated activation loop peptide was not competitive indicating that it cannot 
bind to either FHA domain. Rvl 827 was generally less able to bind the activation loop 
peptides than Rv0020, and showed no significant specificity for each site, which was 
consistent with the ITC data. Again, the FHA domain bound more tightly to the doubly 
phosphorylated peptide than either singly phosphorylated peptide by a factor of 10.
/c„
i+M
152A.
x   #
— A  \
Solution Competition
B.
pTQT
TQpT
Z 3 cn
pTQpT
Log Peptide Cone. (Log hM)
c.
0 8 —
aS fi
S. 3 a
TQpT
1
a: pTQT
0.4 —
•TQpT
o.i
Log Peptide cone  (Log pM)
Figure 5.8. Competition binding studies of  the interaction of Rv0020 FHA domain with 
PknB activation loop phospho-peptides. (A) illustration of surface competition interactions. 
(B) A fixed concentration of Rv0020 FHA domain (lpM) with various concentrations of 
peptide was injected (5pL/min) over immobilised wild-type PknB. (C) A fixed concentration 
of Rvl 827 FHA domain (5pM) with various concentrations of peptide was injected 
(5pL/min) over immobilised wild-type PknB. All samples were injected over SPR surfaces 
in HBS buffer pH7.4 at 25°C. The ratio of RU with and without competing peptide was 
determined and plotted against the log peptide concentration. Data were fitted to a dose 
response curve using non-linear regress ional analysis and IC50 values were determined 
(Table 13). All fits were generated from the average of three independent experiments and all 
values were within 1  standard deviation of the average data point.
153The IC50 calculated for the titration of each peptide can be related to the equilibrium 
dissociation  constant  of the  complex  between  the  peptide  and  FHA  domain  using 
equation (30) (Section 3.2.7.2). For these experiments, the FHA domain concentration 
was fixed (lpM for Rv0020 and 5pM for Rvl 827) and the value of KD  was taken from 
the equilibrium dissociation constant for the complex between wild-type PknB and FHA 
previously determined using direct SPR (2pM for Rv0020 and 9pM for Rvl 827) (Table
5.3). The calculated equilibrium affinity constants for the binding of FHA domains to 
the various activation loop peptides are shown in Table 5.4. The peptide equilibrium 
binding constants as determined by SPR compare well to the direct ITC measurements 
of FHA-peptide interactions. Rvl 827 displays a ~4-fold tighter affinity for the doubly 
phosphorylated peptide using SPR compared to that derived from ITC. Rv0020 shows a 
~4-fold lower affinity for the TQpT peptide relative to ITC data but again displays a 
significant (~20-fold) preference for TQpT over pTQT.
1545.4  Discussion
5.4.1  The  specificity  of activation  loop  binding by the  Rv0020  and  Rvl 827  FHA 
domains
The  results  presented  here  provided  the  evidence  for  physical  interactions  between 
activation  loop  phospho-threonines  of PknB  and  the  FHA  domains  of Rv0020  and 
Rvl 827. Both ITC and SPR show that mutation of the two threonines in the activation 
loop of PknB abrogates interaction with these FHA domains.
The  FHA  domains  of Rv0020  and  Rvl 827  did  show  differences  in  their  binding 
specificity towards differentially phosphorylated PknB  constructs and activation loop 
peptides.  In  the  ITC  experiments,  Rv0020  showed  a  preference  for binding  to  the 
activation loops phosphorylated at solely at T173  or both T171  and T173  over T171 
(pT173  «  pl71  &  pl73  >  pT171),  and  this  result  was  supported  by  SPR.  SPR 
competition studies showed peptides TQpT and pTQpT competed for the binding to the 
Rv0020 FHA domain with PknB (wild-type) more effectively than the pTQT peptide 
and  therefore  bound  more  tightly  to  the  FHA  domain.  An  earlier  series  of  ITC 
experiments  (Westcott,  S.,  PhD thesis  2003)  investigated the binding of the Rv0020 
FHA domain to various peptide sequences. The results of these experiments suggested 
that the Rv0020 FHA domain prefers a medium sized hydrophobic residue (i.e. Leu, lie 
or Val) in the +3 position relative to a phospho-threonine.  The high-resolution X-ray 
structure  of  the  Rv0020  FHA  domain-optimal  peptide  complex  shows  that  this 
hydrophobic residue is accommodated in a hydrophobic pocket at the peptide-binding 
surface (Westcott, S., PhD thesis 2003, and Section 1.6.5).
These  ITC  experiments  also  find  the  Rvl 827  FHA  domain  demonstrates  little 
preference  for  a  particular  activation  loop  phosphorylation  state.  Previous  peptide- 
library  selection data  for the  Rvl 827  FHA domain that suggests it favoured bulkier 
hydrophobic residues (i.e. Tyr or Met) in the +3 position (Durocher et al., 2000). These 
residues  are  not present in  the  +3  position to either phospho-threonine  in the  PknB 
activation loop and therefore may account for the weaker interaction relative to Rv0020.
1555.4.2  A  comparison  of ‘optimal’  phospho-peptide  interactions  with binding  of the 
PknB activation loop
As discussed previously, the ‘optimal’ or tightest binding peptide sequences for Rv0020 
and Rvl 827 FHA domains are known from peptide library screening and are shown in 
Table 5.1. The interactions between both FHA domains and their optimal peptides are 
significantly stronger than their interaction with their potential in vivo partner PknB (35- 
fold  reduction  for  Rv0020  and  45-fold  reduction  for  Rvl 827).  This  trend  is  also 
observed when comparing binding of these FHA domains to their optimal peptides and 
to the PknB activation loop peptides.
Whether or not Rv0020 or Rvl 827 interact with PknA/B is governed by various factors 
including local concentration conditions brought about by subcellular localisation and 
temporal  expression.  Rvl 827  may  possibly  interact  with  PknB  within  the 
Mycobacterium cell after Rvl 827 was detected as a substrate for PknB phosphorylation 
in whole-cell protein extract (Villarino et al.,  2005). Rv0020 is also likely to interact 
with PknB given its genetic proximity and co-expression (Figure 1.9). For this reason, 
data described in this Chapter demonstrates that optimally selected phospho-motifs are 
not always favoured as binding partners to FHA domains in vivo and that the interacting 
phospho-peptide motif is likely to evolve particular affinities for their targets in order to 
fit the requirements for the dynamics of its signal transduction cascade. The use of in 
vitro peptide-library  screens  to  determine  ‘optimal’  binding peptides  for a phospho- 
recognition domain rarely provide a precise biological motif. They do however facilitate 
studies into the molecular basis for specificity of interaction domains.
5.4.3  Stoichiometry of Kinase-FHA domain interactions
In all cases, ITC data for phospho-peptide interactions could be fitted to a standard one- 
site binding model and gave stoichiometries that were consistent with a 1:1 molar ratio. 
This  suggests  indicating  that  FHA  domains  have  only one  binding  site.  In  contrast, 
Kinase-FHA  domain  interactions  showed  a  variable  binding  stoichiometry  between
1560.6:1  and 0.9:1. This most likely indicates heterogeneity in the kinase domain protein 
samples and a resulting variable active fraction. In the case of PknB K40A, the n value, 
which specifies the number of binding sites, was extremely low (0.03) which indicated 
that only a small proportion of the sample contained phospho-threonine sites.
The fact that the FHA domains of Rv0020 and Rvl 827 are able to bind to the wild-type 
PknB kinase domain with a stiochiometry of one implies that only one FHA domain can 
only  bind  to  a  single  PknB  activation  loop  despite  the  presence  of  two 
phosphothreonines.  This is possibly because these two phosphothreonine residues are 
found  within  the  space  of three  residues  and  that  FHA-phosphopeptide  interactions 
involve  close  contacts between with  the  carbon-backbone  of the peptide  around the 
phosphothreonine residue. Consequently, the FHA binding surface may perhaps engage 
two  phosphothreonine  residues.  The  SH2  domain  of the  APS  adaptor protein  is  an 
example  of interaction  domain that is  able  to bind  two phosphorylated residues per 
domain (Hu et al., 2003).
The  observed  binding  parameters  observed  from  an  ITC  experiments  describe  the 
average of the true binding parameters for all the interactions that occur in the titration. 
As the activation loop of PknB  contains two phosphothreonine binding sites and the 
pT173 site is favoured for binding by Rv0020 ~9-fold over the pT171  site (Table 5.2), 
the wild-type PknB-Rv0020 FHA domain titration should provide a weaker apparent Kd 
than that of the PknB T171 A-Rv0020 FHA domain titration. As the PknB-Rv0020 FHA 
domain interaction and PknB T171A-Rv0020 FHA domain interaction show a similar 
Kd  the  pT173  site  seems  to  be  favoured  for  binding  over  the  pT171  in  the  fully 
phosphorylated PknB activation loop. This may possible be due to the fact that a pT in 
the -2 position (as would be the case upon pT173 binding) is accommodated by the 
Rv0020 FHA domains in favour of a pT in the +2 position (as would be the case upon 
pT171 binding).
5.4.4  The primary/secondary phosphorylation sites of PknB
Figure 5.1  shows the calorimetric titration of Rv0020 and Rvl827 FHA domains with 
wild-type PknB reveals the number of binding sites (n) is close to  1   (0.9), suggesting
157that the wild-type PknB preparation is pure and contains a population of kinase domain 
molecules which are phosphorylated on at least one phospho-threonine. As the data for 
these titrations shows single site binding, the PknB wild-type sample is likely to contain 
protein wholly phosphorylated on one or both of the threonines in the activation loop. 
The values for n generated by the titration of Rv0020 and Rvl 827 with PknB T173A 
are 0.9 and 0.8, respectively, which are similar to the wild-type PknB titrations {n of
1.3). Thus, the PknB T173A mutant appears to be wholly phosphorylated on T171. The 
values for n  generated by the titration of Rv0020 and Rvl 827 with PknB T171A are 
both -0.65 suggesting that PknB T171A appears to be partially phosphorylated at T173 
in the sample.  Electrospray data shows PknB T173A is maximally phosphorylated on 
four sites whereas PknB T171A is maximally phosphorylated on three sites. The T171A 
mutation therefore seems to have a greater impact on autophosphorylation activity than 
the T173A mutation.
Taken  together  these  data  suggest  that  T171  is  the  primary  site  and  T173  is  the 
secondary site for PknB activation loop autophosphorylation. This assumes that PknB 
has a general preference for threonine over serine as the phosphoacceptor as proposed 
by  evidence  from  Cantley  and  colleagues  PLSA  (Yang  et  al.,  2005).  PLSA  is  a 
technique  used to  determine  preferred  substrate  motifs  for kinases  and is  similar to 
peptide library screen used for phospho-recognition domains. This technique involves 
generating peptide libraries with a fixed central phospho-acceptor residue (Ser or Thr) 
and random amino acid sequences flanking this residue. Each degenerate peptide library 
was phosphorylated in the presence of [y-32P]ATP by PknA and PknB. The peptides 
preferred as substrates for the kinase had a highest incorporation of 32P. PLSA provided 
another important piece of information by demonstrating the importance of a glutamine 
residue +1 relative to the phosphoacceptor residue for peptide phosphorylation (Yang et 
al.,  2005).  This  implies the  glutamine  residue  +1  relative  to  T171  makes  T171  the 
favoured  phosphoacceptor  in  the  activation  loop  and  therefore  the  primary 
phosphorylation site.  It is  important to note  that there  are -4000 TQ  sites  in the M. 
tuberculosis  proteome  suggesting  additional  factors  are  involved  in  vivo  substrate 
selectivity.
The conclusion that T171  is the primary phosphorylation site is  further supported by 
electrospray mass spectrometry data and therefore loss of T171  is predicted to have a 
greater  impact  on  autophosphorylation  activity  than  loss  of  T173  (Chapter  6).
158Interestingly, if Rv0020 binds pT173 of PknB after autophosphorylation of both pT171 
and  pT173,  as  indicated  by  specificity  data  presented  here,  this  could  confer  a 
mechanism to ensure that Rv0020 would only bind to the fully activated kinase domain.
In  many  RD  kinases,  the  primary  phosphorylation  site  plays  an  essential  role  in 
maintaining the kinase in an active conformation. Phosphorylation of the primary site 
allows the activation loop to refold optimally for substrate binding. The critical driver in 
this  conformational  change  is  the  electrostatic  interaction  between  the  primary 
phosphorylation site and a basic pocket that pins the loop in an active conformation 
(Nolen et al., 2004). The main conserved residue involved in this process is the arginine 
that immediately precedes the invariant aspartate in RD kinases, as would be expected 
this motif is present in the RD kinase PknB.  However, the X-ray structure of active 
PknB implies a disordered activation loop. Others (Boitel et al., 2003) have investigated 
the surface charge distribution of PknB and highlighted the fact that the area near the 
active site contains an exposed cluster of basic residues that are favourably positioned 
for anchoring the phospho-threonines of the activation loop to a fixed position on the 
domain surface.  Data presented here indicates this cannot be the case,  as this would 
preclude the binding of FHA domains to the activation loop.
5.4.5  Conclusion
The observation that FHA domains bind to activation loop residues of the PknB kinase 
domain may illustrate a mechanism by which the disordered loop becomes more rigid 
leading to stabilisation of the kinase in an active conformation as proposed in a recent 
study (Duran et al., 2005). In addition, the presence of the FHA domain may serve to 
protect the kinase domain for down-regulation by preventing dephosphorylation of the 
activation  by  protein  phosphatase  Ppp.  Another  potential  function  of  a  physical 
interaction  between  activation  loop  phospho-threonines  and  the  FHA  domains  of 
Rv0020 and Rvl 827 could be to facilitate phosphorylation of FHA domain-containing 
proteins by PknA and PknB. A series of in vitro kinase assays were carried out to shed 
light on this matter and are described in the following Chapter.
1596  Kinase Activity of PknA and PknB
6.1  Introduction
The  wild-type  kinase  domain  proteins  PknA1 '290  and  PknB1 '279  were  found  to  be 
autophosphorylated upon purification (Section 4.3 and 4.4, Table 4.1  and Figure 4.7). 
The phosphorylation of PknB has been mapped to four residues in the activation loop 
(SI66,  SI69,  T171,  T173)  (Young  et  al.,  2003)  and the  presence  of four phospho- 
residues  has  been  confirmed  in  wild  type  PknB  by  electrospray  mass  spectroscopy 
(Section 4.4).  In the RD class of protein kinases, which includes PknA and PknB, the 
presence  of phosphorylated  residues  in  the  activation  loop  is  characteristic  of the 
activated  form  thus  providing  an  opportunity  to  identify  and  study  the  substrate 
preferences of these STPKs in vitro.
The results presented in Chapter 5 provided strong evidence for physical interactions 
between the kinase domain of PknB and the FHA domains of Rv0020 and Rvl 827. In 
addition  to  establishing  an  interaction  between  the  PknB kinase  domain  with  FHA 
domains of Rv0020 and Rvl 827, the site of interaction was identified as encompassing 
two phospho-threonines in the activation loop (T171 and T173). This demonstrates that 
autophosphorylation  is not only required  for kinase  activity in PknB  but also that it 
creates  a  binding  site  for  FHA  domain-containing  proteins  Rv0020  and  Rvl 827.  I 
therefore  investigated  whether the  kinase-FHA  interaction might be  associated with 
FHA  domain-containing  protein  phosphorylation  using  two  different  in  vitro 
phosphorylation  assays:  autoradiographic  assays,  for  initial  identification  of
phosphorylation activity, and where applicable, enzyme-coupled phosphorylation assays 
for kinetic measurement of the reactions. The results suggest that PknA and PknB do 
not only function in a simple linear pathway where they phosphorylate the co-expressed 
FHA-domain containing proteins, Rv0019 and Rv0020, but also play a role in a more 
complex  signal  transduction  pathway  involving  FHA-domain  containing  proteins  at 
other genetic loci.
1606.2  PknA  and  PknB  Phosphorylate  FHA-domain  Containing 
Proteins
6.2.1  Overview
To  identify  the  substrates  of the  STPKs,  PknA/B,  full-length  proteins  Rv0020  and 
Rvl 827 (from now on called Rv0020155'527 and Rvl827M62) and the kinase domains of 
PknA, PknB were cloned, expressed and purified (Table 4.1). The actual translational 
start  site  of  Rv0020  differs  from  the  Genbank  sequence  (NP_214535)  and  was 
determined by N-terminal sequencing to be residue  155  (Weldingh et al.,  1998). The 
complete Rv0019 intracellular domain
(Rv00 1  928-156) was also purified but as a fusion protein with GST to circumvent poor 
stability associated with the Rv001928'156 (Section 4.2). The kinase domains of PknA 
and PknB were incubated at 2pM with 20pM Rv00201-527, Rvl8271-162, GST-Rv001928- 
156  or  a  non-cognate  substrate,  MBP  in  the  presence  of  [y32-P]ATP.  The  reaction 
products  were  separated  using  SDS-PAGE  and  identified  by  autoradiography.  This 
procedure  was  also  repeated  by  replacing  GST-Rv001928'156,  Rv0020155-527  and
1  1 6 7 Rvl 827 "  with isolated FHA domains or serine-to-alanine mutants of these proteins
(Rv0020155-527  S473A  and  Rvl8271-162  S85A)  that  result  in  complete  loss  of 
phosphothreonine-dependent  binding  (Durocher  et  al.,  2000).  A  summary  of 
phosphorylation activity for PknA and PknB is provided in Table 6.1.
161Table 6.1. PknA and PknB phosphorvlate specific FHA domain containing
proteins.
Protein PknA PknB
Rvl8271-162 ++ i- i I  i-i
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§  ' &  
H  s Rv00201 5 5  527 + ++
h GST-Rv001928 156 + +
.5 Rvl82725’162 _ _
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Rvl82 7423 527S95A - -
00 Rv0020423 527S473A - -
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n
t
r
o
l
s MBP
GST
++ ++
(-) represents an experiment with no detectable phosphorylation
(+) represents a qualitative measure of the phosphorylation observed in the experiment with the 
number of + symbols representing the relative level of apparent phosphorylation determined by 
band intensity analysis
6.2.2  PknA and PknB phosphorylate FHA domain-containing proteins
PknA and PknB were each able to phosphorylate full-length FHA domain-containing 
proteins  Rvl827M62  and  Rv0020155'527  (Figure  6.1  and  Table  6.1,  top  panel).  An 
interesting and somewhat surprising observation from these in vitro kinase assays is the 
marked preference of PknA and PknB for Rvl827M62 over Rv0020155'527 as a substrate. 
Comparing  band  intensities,  PknA  and  B  show  a  ~20-fold  and  500-fold  higher 
preference for Rvl 827 over Rv0020 respectively. These observations are contrary to the
162expectation that co-expressed proteins such as Rv0020 would be a better substrate for 
PknA and PknB than Rvl 827, which is expressed from a separate operon.
6.2.3  PknB is a more active kinase in vitro than PknA
There was significant difference in relative phosphorylation activity of PknA and PknB 
on both Rv0020 and Rvl827  (Figure 6.1a).  As expected both STPK kinase domains 
were able to phosphorylate myelin basic protein (MBP) as a generic kinase substrate, 
with similar efficiency. Band intensity analysis of the autoradiograph determined using 
ImageQuant  software  (Kodak)  shows  that  PknA  has  a  ~ 10-fold  lower activity  than 
PknB on Rv0020 and ~200-fold lower activity on Rvl 827. The result was surprising 
since  a  much  higher  autophosphorylation  activity  was  evident  for PknA  relative  to 
PknB  and both  are  equally effective  at phosphorylating the  generic  kinase  substrate 
MBP.
6.2.4  FHA domains of Rvl 827 and Rv0020 are not phosphorylated by PknA or PknB
The kinase activity of PknA and PknB towards isolated FHA domains of Rv0020 and 
Rvl 827 was examined (Figure 6.2 and Table 6.1, middle panel). The N- and C-terminal 
limits of the FHA domains of Rv0020155'527 and Rvl827M 62 were isolated by limited 
proteolysis experiments (Section 4.2.3). The assay conditions remained the same as that 
of the previous assay (Figure 6.1) with the exception of the kinase concentration, which 
increased  from 2pM to  5pM.  Both PknA and PknB  auto-phosphorylated but neither 
exhibited significant activity on FHA domains of Rv0020 or Rvl 827. However, PknB 
did  show  catalytic  activity  on  the  minimal  tryptic  fragment  of  Rv0019.  These 
observations  strongly  suggest  that  phosphorylation  sites  in  full-length  Rv0020  and 
Rvl 827 lie in the amino-acid sequences N-terminal to the FHA domains (Residues 155- 
431 in Rv0020 and residues 1-24 in Rvl 827; Figure 1.11).
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Figure 6.1. Specific phosphorylation activity of M. tuberculosis STPKs PknA and PknB on FHA 
domain-containing proteins. PknA1-290 and PknB1-279 were assayed in in vitro kinase reactions where 
each kinase was incubated at 2pM atone or with full length protein constructs of Rvl 827 (Rvl8271 _  
162), Rv0020 (Rv0020,_527) and myelin basic protein (panel A) and the intracellular region of RV00191' 
156 (panel B), all at 20 pM. Reaction were carried out by incubating the proteins at room temperature 
for 1   hour in the presence of [y-32P]ATP. Coomassie staining was performed to verify the amount of 
protein in each reaction of panel A.
1646.2.5  The RvOO 19 FHA is phosphorylated by PknB but not by PknA
The minimal FHA domain of RvOO 19  suggested by limited proteolysis, Rv001956'156, 
can be phosphorylated by the kinase domain of PknB, but not significantly by PknA, as 
observed by the autoradiograph in Figure 6.2, and confirmed by subsequent radioassays. 
Indeed, the FHA domain of Rv0020 and that of Rvl 747 (incidentally co-expressed with 
PknF), were both found to be phosphorylated by PknF (Grunder et al., 2005).
The efficient phosphorylation of the RvOO 19 ‘FHA domain’ by PknB may represent a 
mechanism by which STPKs may modulate the FHA domains phospho-peptide binding 
ability.  In this respect, it is interesting to note that the human DNA-damage response 
kinase, Chk2 contains a STPK domain that is also able to phosphorylate its N-terminal 
FHA domain. In this case, phosphorylation reduces the Chk2 FHA domains affinity for 
a primary phosphorylation  site  on  the  protein  (Ahn et al.,  2002).  The physiological 
effects of RvOO 19 phosphorylation are still to be investigated.
6.2.6  FHA binding affects kinase autophosphorylation
Examination  of the  phosphorylation  of PknA/B  in the  presence  of an FHA  domain 
demonstrates both Rv0020 and Rvl 827 FHA domains can affect autophosphorylation 
of PknA and PknB  (Figure 6.2).  Rv0020 reduced autophosphorylation of PknA ~20- 
fold  and  Rvl 827  completely  abolished  autophosphorylation.  The  FHA  domain  of 
Rv0020 has a more modest effect on the autophosphorylation of PknB, reducing it ~3- 
fold  (based  on  band  intensity  as  determined  using  ImageQuant  software,  Kodak). 
Surprisingly,  when  PknB  is  incubated  with  the  Rvl 827  FHA  domain  its 
autophosphorylation ability is stimulated by ~10-fold.
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Figure 6.2. Specific phosphorylation activity of M. tuberculosis STPKs PknA and PknB on 
isolated FHA domains. PknA1" 290 and PknB1-279 were assayed in in vitro kinase reactions where 
each kinase was incubated at 5pM with the purified FHA domains of Rvl 827 (Rvl82725‘162), 
Rv0020 (RV00201'527) and Rv00191_156 all at 20 pM. Reaction were carried out by incubating the 
proteins at room temperature for 1   hour in the presence of [y-32P]ATP. Coomassie staining was 
performed to verify the amount of protein in each reaction (upper panel).
166The  inhibitory  effect  of  FHA  domains  on  autophosphorylation  suggests  that  the 
domains may bind to the kinase domain in a manner that prevents the intermolecular 
interaction  between  kinase  domains  that  is  required  for  autophosphorylation.  It  can 
therefore be proposed,  the  FHA domains will bind to  close to or on this interaction 
surface.  The  differences  in  autophosphorylation  inhibition  imposed  by  the  FHA 
domains on the kinase may reflect the affinities of the various interactions and this was 
analysed in the previous  Chapter.  For example, Rv0020  FHA would be predicted to 
bind with a tighter affinity to PknA and PknB than Rvl 827, because it has a greater 
inhibitory effect on autophosphorylation and this was shown to be case (Section 5.4.1).
Information presented in Section 5.4.4 shows that pT171 and pT173 are the primary and 
secondary autophosphorylation sites respectively, in the PknB activation loop. PknB is 
fully  activated  after  phosphorylation  of both  T171  and  T173  (Biotel  et  al,  2003). 
Biophysical experiments described in the previous Chapter (Section 5.4.1) indicate that 
the Rv0020 FHA domain binds preferentially to pT173 which confers a mechanism to 
ensure that Rv0020 would only bind to the fully activated kinase domain. This implies 
that  the  Rv0020  FHA  domain  will  predominately bind to  the  fully activated kinase 
domain of PknB  and thereby prevent cross-phosphorylation of sub-stoichiometrically 
phosphorylated (partially activated) species of PknB.
6.2.7  Phosphorylation requires a functional FHA domain
One key finding from the experiment shown in Figure 6.1  was that PknA and PknB 
were  able  to  phosphorylate  Rvl 8271-162  and  Rv0020155-527  but  no  significant 
phosphorylation  of Rvl8271-162  S95A  or  Rv0020155'527  S473A  mutant  proteins  was 
detected  for  either  enzyme  (Figure  6.1  and  Table  6.1,  top  panel).  Therefore,  the 
mutation of the conserved serines, that are essential to phospho-ligand binding, leads to 
abrogation  of  phosphorylation  in  FHA-domain  containing  proteins,  Rv0020  and 
Rvl 827. Therefore, the fact that these mutant proteins are not phosphorylated may show 
the importance of phospho-threonine binding for phosphorylation of Rv0020155-527 and 
Rvl8271-162.
1671686.3  Rvl827 is phosphorylated on a conserved Threonine, Thr22
6.3.1  Overview
Phosphorylation mapping studies carried out by Alzari and colleagues, have indentified 
the site of Rvl 827 phosphorylation by PknB to be T22 (Villarino et al., 2005). Multiple 
sequence alignments of close homologs of Rvl 827 (Figure 6.3) show that there is high 
conservation of not only the phospho-acceptor residue, T22, but all residues in the 20- 
ETTSVFRAD-28  motif.  This  observation  implies  suggests  an  important role  in  the 
physiological function of Rvl 827, potentially by serving as a binding site for another 
FHA-domain containing protein or itself.
6.3.2  The effect of truncation on Rvl 827 interactions
Limited proteolysis experiments were carried out to define the FHA domain boundaries 
in Rvl 827.  Regions of the protein that have less structure are susceptible to protease 
cleavage  whereas  regions  that  form  tightly  structured  domains  are  less  likely to  be 
cleaved.  Therefore,  identification  of the  cleavage  sites  using  limited proteolysis  can 
infer domain boundaries.  Limited proteolysis this resulted in a reduction in size from 
162  residues  to  138  residues  (Westcott,  S.,  unpublished  data).  These  previous 
investigations  also  demonstrated  that  the  effect  of truncation  on  the  Rvl 827  FHA 
domains ability to bind its optimal peptide is negligible; with both protein constructs 
able bind the peptide with a Kb of ~200nM (Westcott, S., unpublished data).
To determine whether truncation of the protein would affect its ability to interact with 
the wild-type PknB kinase domain, an ITC experiment was performed at concentrations 
of  143pM  FHA  domain  and  13.5pM  kinase.  The  resulting  thermodynamic  and 
equilibrium data generated were close to that observed for the Rvl 827 FHA domain (n 
1.28, Kd 11.4 pM, AH -4.7kcal/mol, TAS -1.9kcal/mol AG -6.6 kcal/mol) and show that 
there was no effect of truncation on the ability of Rvl 827 to bind PknB. This confirms 
that the FHA domain is  sufficient for full binding to the kinase domain and isolated 
phosphopeptides.
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Figure 6.3. Multiple sequence alignment of close homo logs ofM tuberculosis Rvl 827 (GarA). Secondary structure elements (all 
p-sheets) were predicted from homology to Rv0020 and are shown above the sequence. Conserved residues in the N-terminus 
outside the FHA domain region containing the putative phosphorylation site, pThr22, of Rvl 827 are indicated by a red bar above 
the sequence. Bars below the alignment show are a measure of the conservation at each residue position. (Mt, M. tuberculosis' . ;  
Ma, M. avium sp. paratubercubsis; Ml, M. leprae’ , Ms, M. smegmatis; Rf, Rhodococcus fascians’ , N f Nocardia farcinica\ Cg, 
Corynebacterium glutamicum; Ce, C. ejficiens; Cd, C. diptheriae, Cj, C. jejuni)6.3.3  Rv0020  and  Rvl 827  can  interact  with  the  phospho-threonine  22  region  of
Rvl827
The  site  of Rvl 827  phosphorylation by  PknB  was mapped to  T22  (Villarino  et al., 
2005) which resides in a highly conserved amino-acid sequence (Figure 6.3). The fact 
that this N-terminal region is conserved suggests this motif plays an important role in 
the physiological function of Rvl 827. Indeed, this sequence seemed a likely candidate 
for a dimeric interaction of the Rvl 827 FHA domain due to a bulky aromatic group, 
Phe,  at  the  +3  position  relative  to  the  phospho-acceptor  residue,  T22.  In  order  to 
investigate this possibility, a phosphorylated peptide representing the phospho-threonine 
22 region  of Rvl 827  with the  sequence  DEVTVETpTSVFRAYKK was  synthesised 
and binding measured by ITC.
171Table 6.2. Thermodynamic parameters for FHA:Rvl827 N-terminal peptide
interactions.
Material in  syringea Protein in cell n
Kq  AHb
(pM) (kcal/mol)
TASb
(kcal/mol)
AGb*
(kcal/mol)
TTSVF
TpTSVF
R
v
0
0
2
0
F
H
A NDB
1.0 1.3 -7.5 0.3 -7.8
TTSVF
TpTSVF
R
v
1
8
2
7
F
H
A NDB
0.9 7.8 -5.6 1.1 -6.7
* AGb  = AHb  —  TASb . All ITC experiments were conducted at 291K (18°C).
“Full  peptide  sequences  are  provided  in  Table  5.1.  (NDB)  No  detectable  binding.  Stoichiometry  (n), 
equilibrium binding constant (KD), observed binding enthalpy (AHb), observed binding entropy (AS1 *,), and 
binding free energy (AG*,)
This phosphopeptide shows detectable binding to the Rvl 827 FHA domain with similar 
binding parameters to Rvl827-pTQpT peptide complex (Table 5.2). This indicates that 
Rvl 827  may  be  able  to  form  a  head-to-tail  dimer  upon  phosphorylation  by  PknB, 
assuming that this head-to-tail dimer conformation is sterically feasible. Furthermore, 
this peptide was found to interact with Rv0020 FHA 6-fold more tightly (Kd of 1.3pM) 
than the interaction with Rvl 827 FHA (Kd of 7.8pM) using ITC.
Therefore, an Rv0020-Rvl827 heterodimer could be expected if T22 of Rvl 827 was to 
be  phosphorylated.  However,  it  is  important  to  note  that  the  Rvl 827-Rv 1827 
dimerisation affinity are likely to much greater than the individual affinities of the FHA 
domain for the TpTSVF site due to cooperativity effects. Similar cooperativity was seen 
for  the  Chk2  FHA  domain-containing  protein  homodimer,  where  the  overall 
dimerisation  affinity  was  substantially  greater  than  the  affinity  of the  Chk2  FHA 
domain for its phospho-peptide target on the Chk2 protein.
1726.4  Kinetic Characterisation of PknA and PknB
6.4.1  Overview
In light of the qualitative information accumulated on phosphorylation of FHA-domain 
containing proteins Rvl827 and Rv0020 by PknA and PknB, the kinetic parameters for 
each  of these  putative  substrates  was  further  investigated  using  an  enzyme-coupled 
spectroscopic assay. The phosphorylation reaction rates were measured by coupling the 
formation of ADP to the oxidation of NADH using the enzymes pyruvate kinase and 
lactate dehydrogenase (Figure  3.2a).  ATP turnover is  stoichiometrically linked to the 
formation of NAD+, which results in a decrease in absorbance at 340nm.
The assay described above is one of the most popular assays for measurement of the 
release of Pi, ADP or H+. The method is particularly suitable for enzymes sensitive to 
the accumulation of ADP, as it is based on ADP recycling coupled to the oxidation of 
NADH.  Furthermore,  the  high  molar  absorption  coefficient  of  NADH  at  340nm 
wavelength  light  and  the  virtual  absence  of  protein  or  DNA  absorbance  at  this 
wavelength  ensures  reliable  ATP  hydrolysis  measurement  down  to  a  micromolar 
concentration  scale  (Kiianitsa et al.,  2003).  The assay is valuable in enzyme kinetic 
studies because it is continuous, therefore,  initial velocities are apparent immediately 
and do not require a laborious series of time points to be sampled as with radioisotopic 
methods (Roskoski,  1983). A limitation of the technique is that accuracy can drop off 
when examining enzymes with low turnover rates (i.e. <1 min'1 ) as the ATPase activity 
may  not be  significantly higher than  the  background rate  of NADH  decomposition. 
Therefore,  errors  can  arise  from  UV-induced  NADH  decomposition  and, 
spectrophotometer-bome errors accounting for a low signal: noise ratio.
Although  Rv0020155‘527  was  not  stable  enough  at high concentrations  to measure  its 
kinetic properties as a substrate in phosphorylation reactions, the assay was sensitive 
enough to measure phosphorylation of full-length Rvl827 (Rvl827M 62) by PknA and 
PknB. The following Section will describe kinetic studies of PknA and PknB with the 
substrate  Rvl827M62.  Next,  the  Km   and  Vm ax  values  were  determined  for  various
173activation loop mutations in PknB. In addition, the effects of activation loop threonine 
autophosphorylation  on  ATP  binding  and  kinase  reactivity  were  investigated.  Two 
serines in the activation loop of PknB (SI62 and SI6 6 are sites of autophosphorylation, 
in addition to the two threonine residues (Figure 4.6b). However, a mutational analysis 
of these residues was not carried out since the Rv0020 and Rvl827 FHA  domains are
only able to bind phospho-threonine residues and SI62/166 are known  to be unable to
activate PknB upon phosphorylation (Boitel et al., 2003).
6.4.2  Kinetics of phosphorylation of Rvl 827 by PknA and PknB
Traditional steady-state analyses of the kinase reactions were conducted with the goal of 
providing values for the Michaelis constant (Km ) and maximal reaction velocity (F max) 
for the phosphorylation of Rvl 827 by PknA and PknB.
Kinase assays for Rvl 827 with PknA and PknB were carried out in a standard coupled 
reaction buffer including 2pM kinase, ImM ATP and an Rvl827 protein concentration 
ranging from 870nM to ImM (Section 3.6.2). Purified kinase domains of PknA (PknA1 ' 
29°) and PknB (PknB1 '279) were used in this experiment as well as purified full-length 
Rvl 827 proteins (Rvl827M62, Rvl827M 62 S95A). Reactions were only initiated after a 
stable A340 reading appeared. The initial velocity values were obtained by varying the 
concentration  of Rvl 827  under  the  fixed  concentrations  of ATP  and  PknA/PknB. 
Reading  were  taken  for  at  least  nine  different  Rvl 827  concentrations  and  kinetic 
parameters were calculated by fitting the initial velocity versus substrate concentration 
to the Michaelis-Menten equation.
174Table 6.3. Kinetic Parameters for the phosphorylation of Rvl827 by PknA and
PknB.
Protein
Km V  * T max kcat kcaJ Km
(HM) (fimolATP.min1) (min'1) ((iM'Vmin'1 )
PknB wild-type 143±11.4 0.0044±0.0001 22 0.15
PknB T171A 393±15 0.0025±9.6E-5 13 0.032
PknB T173A 352±9 0.0033±0.0002 17 0.047
PknB
T171A/T173A 1900±0.07 0.0007±0.0004 3.5 0.0018
PknA 2070±0.9 0.000410.0001 2.0 0.00097
*Vrmx is defined in pmol ATP tumover.min'1  from 2pM kinase in a lOOpL reaction.
These  kinetic  data  support  previous  radiolabelling  experiments  which  show 
significantly higher activity exhibited by PknB over PknA (Figure 6.4). The apparent 
Km  for the reaction catalysed by PknB  was  143pM, ~ 14-fold better than the reaction 
catalysed by PknA (2mM). However, the activity of PknA was at the close to the limit 
of detectable phosphorylation using this technique, therefore the kinetic parameters for 
reaction  involving  PknA  phosphorylation  of Rvl 827  should  be  taken  with  caution. 
There was also a concurrently high Vm ax displayed by PknB (0.0044pmol .min'1 ) relative 
to the  Fm ax of PknA (0.0004pmol.min‘1 ).  Since the protein was used at subsaturating 
concentration, particularly in the case for PknA, these apparent kinetic constants should 
be  taken with  caution.  Higher concentrations  of Rvl827  could not be used in these 
reactions owing to aggregation of the protein at concentrations above ImM. In the case 
of PknB the Michaelis-Menten catalysis curve was well defined, particularly in the area 
around the Km  of the enzyme which indicates the apparent kinetic parameters can be 
considered close to the true kinetic parameters. Finally, there was no detectable signal 
above background NADH decomposition for the reaction containing Rvl8271162 S95A.
The possible reasons for the low activity of PknA have been discussed in the previous 
Section.  The  steady-state  kinetic  parameters  for  the  phosphorylation  of Rvl 827  by 
PknB  was  also determined  in a more recently study (Villarino et al,  2005), the  Vm ax 
found to be 0.00024pmol.min'1 , 18-fold lower than the value
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Figure 6.4. Apparent Km  and Vm ax determination for the phosphorylation of Rvl827M62 by 
PknA1 '290 and PknB1 '279 using an in vitro enzyme coupled kinase activity assay. The kinetic 
profiles of PknA1* 290 (open circles) and PknB1'279 (solid circles) at increasing Rvl8271_162 
concentrations were fit to the Michealis-Menten equation using non-linear regressional analysis. 
Fits were generated from the average of three separate experiments.
Resultant reaction kinetic parameters are shown in Table 8.
176determined in this study. However, these results were determined using a less rigorous 
study based on radiolabelling and using only three different concentrations of Rvl 827. 
Additional disparity between the two results may arise from differences in active site 
purity of the PknB protein preparations.  Catalytic activity may not correlate perfectly 
with enzyme activity as a consequence of misfolded protein or modified forms of the 
enzyme. Without conducting an active site titration, good active site homogeneity can 
be  achieved  by  fractionation  of the  enzyme  preparation  on ion-exchange  and/or gel 
filtration assuming misfolded and/or modified forms of the enzyme migrate differently 
to the active enzyme species (Lew, 2003). The following Section will show that PknB is 
only  fully  active  upon phosphorylation  of two threonines  of the activation loop  and 
electrospray mass  spectrometry of PknB preparation show that the proportion of this 
phosphorylation state in the sample is variable. Thus, the PknB protein sample utilised 
by Villarino et al may be substoichiometrically T-loop phosphorylated. Unfortunately, 
no mass spec data were supplied in the publication to verify this.
6.4.3  Activation loop autophosphorylation and kinase activity
The  effect  of  activation  loop  autophosphorylation  on  the  activity  of  PknB 
phosphorylation  of Rvl827  was  explored.  Previous  work  has  shown  that  PknB  is 
regulated by phosphorylation and dephosphorylation by the co-expressed phosphatase, 
ppp. This appears to be a general feature of regulatory circuits involving protein kinases 
genetically  linked  to  protein  phosphatases  in  bacteria  such  as  Bacillus  subtilis 
(Obuchowski  et  al.,  2000),  Streptococcus  agalactiae  (Rajagopal  et  al.,  2003)  and 
Streptococcus pneumoniae  (Novakova  et  al.,  2005).  Steady-state kinetic  analyses  of 
different activation loop mutants of PknB would provide a clearer picture of the effect 
of alteration in the presumed binding sites for the FHA domains on the FHA domains 
containing  protein  phosphorylation.  Additionally,  due  to  the  potential  effects  of 
activation  loop  mutation  on  the  overall  kinase  activity  and  activation,  the  effects  of 
these mutations on ATP binding was also investigated (Section 6.4.5). Unfortunately, as 
the wild-type form of PknA displayed low kinase activity, close to the lowest detectable 
limit  (lmin'1 ),  activation  loop  mutants  were  unlikely  to  exhibit  measurable  activity 
using the enzyme-coupled assay and consequently were not studied.
177The phosphorylation of PknB has been mapped to four residues in the activation loop 
(S166, S169, T171, T173; Figure 4.7b.) and the presence of four phospho-residues has 
been  confirmed  in  wild  type  PknB  protein  preparation  by  electrospray  mass 
spectroscopy in this study (Table 4.1  and Figure 4.7). Purified activation loop mutants 
of PknB,  T171A,  T173A,  T171A/T173A  and  the  ‘kinase  dead’  mutant K40A  were 
generated  by  site-directed  mutagenesis.  The  mutants  were  expressed  and  purified 
according the protocol for wild-type PknB and once the mutations were confirmed by 
DNA sequence analysis and electrospray mass spectrometry (Section 3.2.2,).
Kinetic  analysis revealed that mutation of threonines to alanine in activation loop of 
PknB had a substantial effect on phosphorylation of Rvl 827 (Figure 6.5 and Table 6.3). 
As  expected  fully phosphorylated wild-type PknB  displayed the best Km   for Rvl 827 
(143juM),  while  both  triply  phosphorylated  PknB  mutants,  PknB  T171A  and  PknB 
T173A, showed a ~3-fold weaker Km. The maximal velocity of wild type and mutants 
forms  of  PknB  was  determined  and  ranks  as:  wild-
type>T173A>T171A>T171A/T173A>K40A. Wild type kinase had an apparent Vm ax of 
0.0044pmol.min'1,  whereas  no  significant  kinase  activity  was  observed  above 
background  for the  reaction  using  PknB  T171A/T173A.  This  suggests  a  cumulative 
inhibitory effect of dephosphorylation of the activation loop. Note that the  Vm ax values 
generated  in this experiment cannot be considered true  Fm ax values until the  K*rp is 
determined,  to  be  sure  ATP  was  used  in  saturating  concentrations  in the  reactions. 
Reactions  carried  using  a  synthetic  peptide  encompassing  the  N-terminal  region  of 
Rvl827 produced no detectable phosphorylation.
As  predicted,  these  data  confirm  requirement  for phosphorylation  on  key  threonine 
residues within the activation loop for full activity of PknB. Thr-to-Ala point mutations 
in this region significantly decrease the kinase activity towards
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Figure 6.5. Apparent Km  and Vmax determination for the phosphorylation of Rvl8271162 by 
(wild-type and activation loop mutant proteins) using an in vitro enzyme coupled kinase 
activity assay. The kinetic profiles of all PknB1 279 proteins at increasing Rvl8271162 
concentrations were fit to the Michaelis-Menten equation using non-linear regressional 
analysis. Fits were generated from the average of three separate experiments.
Resultant reaction kinetic parameters are shown in Table 8.
179the endogenous substrate Rvl 827 and may help to link the atomic resolution structure 
of PknB with its biochemical function. The two independent crystal structures of PknB 
in complex with nucleotide  reveals  disorder in die  activation loop even though they 
depict  an  enzyme  poised  for  phospho-transfer.  Conformational  disorder  of flexible 
regions, such as loops or extended coils, which are mobile with respect to the rest of the 
protein, result in reduced and sometimes lost electron density, as is the case with PknB. 
Although many  of the  inactive  structures  exhibit disorder in these  loops  (Wybenga- 
Groot et al., 2001)(Lie et al., 2000)(Sicheri et al.,  1997), disorder only correlates with 
inactivity if it extends to the anchor points of the activation segment. In the case of the 
PknB  structures,  disorder  seems  only  confined  to  the  activation loop  and  P+l  loop 
allowing the kinase to maintain activity in a similar manner to that seen in the structures 
of kinases  PDK1  (Biondi  et  al.,  2002)  and  Src  kinase  (Ogawa  et  al.,  2002).  The 
observation  that  FHA  domains  bind  to  activation  loop  residues  may  illustrate  a 
mechanism by which the disordered loop become more rigid leading to stabilisation of 
the kinase in an active conformation.
The  interaction  of the  FHA  domains  of Rv0020/Rvl827  with the kinase  domain of 
PknA/B  and the requirement of kinase-FHA interactions for efficient phosphorylation 
of full-length Rv0020 and Rvl 827 has been demonstrated. The only possible interacting 
residues are the phospho-threonines on the activation loop, mutations of these residues 
will  not  only  disrupt  the  essential  phospho-binding  interactions,  it  will  also  reduce 
activity of the kinase itself. Scheme 1   shows a basic kinetic scheme for the steady-state 
phosphorylation  of  substrates  catalysed  by  a  protein  kinase  under  saturating 
concentrations of a substrate (Lew, 2003). Taken together the information gathered so 
far  from  this  study  suggests  a more  complex  scheme  for the  for phosphorylation of 
Rvl 827 by PknB (Sheme 2).
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The reactions described in scheme 1  and 2 include the association {ki) and dissociation 
(k.2) of both ATP, enzyme (E), product (P) and substrate (S), phosphoryl transfer (hi), 
and product release (£4). The reactions specific to scheme 2 are the association (ki) and 
dissociation (&_i) of FHA domain from the kinase:  FHA complex and the association 
(£1) and dissociation (k.\) of FHA domain from the fully catalytic complex.
6.4.4  A substrate peptide of Rvl 827 is not phosphorylated
The site of phosphorylation of Rvl 827 by PknB was mapped to T22 residing in the N- 
terminal non-structured region of the protein (Figure 1.10) by (Villarino et al., 2005). A 
peptide of the N-terminal sequence containing this phosphorylation site was synthesised 
with the sequence:  20-ETTSVFRAD-28.  To separate the effect of FHA binding from 
the  phosphorylation  of  Rvl 827  by  PknB  an  in  vitro  coupled-enzyme  assay  was 
conducted using this N-terminal Rvl 827 peptide as the substrate for the reaction. There 
was  no  detectable  phosphorylation  of the  peptide  at the  highest  concentration  used 
(7.5mM). This result is in line with previous finding that prove FHA domain of Rvl 827 
is required for efficient phosphorylation of the N-terminal region.
1816.4.5  The effect of ATP concentration on the phosphoryl transfer reaction
To complete the kinetic characterisation of the PknB-Rvl827 phosphorylation reaction
the K*tp for wild-type and activation loop mutants of PknA and PknB was determined.
This  would  provide  more  information  about  the  role  of autophosphorylation on the
activation process  of these  enzymes.  The  K*T P  values are also required to determine
whether  optimal  an  ATP  concentration  were  used  in  previous  experiments  on  the
kinetics  of Rvl827M62  phosphorylation.  Furthermore,  the  K *TPvalues  for wild-type
PknA and PknB will be useful to find the optimal ATP concentration in a screen for 
ATP-competitive inhibitors.
Table 6.4. The effect of ATP concentration on the phosphorylation of PknB by
Rvl827.
vA r p   v   * Protein  m   .  ; “a p x
_______________________(HM)  (nmol ATP.min ‘)
PknB 
wild-type 
PknB 
T171A 
PknB
T173A  386pM±9  0.0007±5.5e-5
13.6pM ±1.7  0.001 l±4.68e-5
651.4pM±138  0.0005±3.6e-5
PknB
T171A/T173A 1.12mM±0.35  0.0006±7.18e-6
*Fniaxis defined in pmol ATP tumover.min'1  from 2pM kinase in a lOOpL reaction.
The in vitro coupled-enzyme kinase assay was performed using a protocol based on the 
previous series of assay with the following differences: phosphorylation of Rvl 827 was 
carried  out in the  standard  coupled reaction buffer (Section 3.6.2) plus 2pM kinase, 
40pM Rv1827M62 and an ATP concentration ranging from 390nM to 5mM. The initial 
velocity  values  were  obtained by  varying  the  concentration of ATP  under the  fixed 
concentrations of the  substrate protein Rvl 827.  Reading were taken for at least nine 
different  ATP  concentrations  and  kinetic  parameters  were  calculated  following  the 
previous protocol.
182Kinetic analysis revealed that mutation of activation loop threonines had a substantial 
effect on catalysis, as expected (Figure 6.6 and Table 6.3). The fully phosphorylated 
wild-type  PknB  displayed  the  best  KA m T P   (13.6pM),  while  PknB  T171A  and  PknB
T173A mutant proteins showed 48- and 28-fold weaker KA T P ,  respectively. The double 
mutant,  PknB  T171A/T173A,  showed weakest  KA T P  {\.\2mM).  The  literature values 
for  the  KA T P   of several  important  eukaryotic  protein  kinases  are  as  follows:  PKA 
(12pM),  PKC  isoforms  from  tissue  (15pM),  recombinant  PKC(3II  (70 pM)  and  Src 
kinase (24 pM) (Sun et al., 2005). These are all in a similar range to the  K A J P   of PknB. 
The maximal velocity of wild type PknB 0.001 lpmol.min'1 , whereas all activation loop 
mutants  display Vm ax values  in the  range  of 0.0007-0.OOOSpmol.min"1.  However,  the 
Fm ax values generated in this experiment cannot be considered true  Vmsx as the values 
were  not  determined  under  saturating  concentrations  of  a  fixed  substrate.  As  the 
AT™ 82 7  of PknB  proteins  (native  and  mutant  forms)  is  known  one  can  see  that  an 
Rvl 827  concentration  of  40pM  is  subsaturating.  This  assumes  a  saturating 
concentration of substrate would be defined as a 20-fold in excess of the  A'*1 '1827but m
millimolar concentrations of Rvl 827 are not possible due to limited protein solubility.
As expected these data confirm that phosphorylation of the activation loop has an effect 
on PknB kinase activity. As discussed previously (Section 1.7) one of the principle roles 
of phosphorylation of the activation loop is to correctly configure conserved residues in 
the active  site for catalysis and neutralise a region of high positive charge within the 
active site (Johnson et al.,  1996). Data presented here suggest that the remodelling of 
the PknB active site upon autophosphorylation is required for ATP association. In the 
absence of any FHA binding requirement for catalysis Km is a function of all the steps in 
the phosphoryl transfer reaction pathway (scheme 2) where
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Figure 6.6. Apparent  T P   and Vmax determination for the phosphorylation of Rvl 8271 *162 by 
PknB (wildtype and activation loop mutant proteins) using an in vitro enzyme coupled kinase 
activity assay. The kinetic profiles of all wild type (panel A) and mutant (panel B)
PknB1'279 proteins at increasing ATP concentrations were fit to the Michealis-Menten 
equation using non-linear regressional analysis. Fits were generated from the average of 
three separate experiments, all values were within 2 S.D. of the average data point.
Resultant reaction kinetic parameters are shown in Table 9.
184K ATP  =  K±ATP) + k i  ( 3 4 )
k\(ATP)
From  scheme  2,  the  K*TP\s  a  composite  of multiple  catalytic  reaction  steps  this
parameter does not give direct information on any individual steps. However, if the rate 
of  phosphoryl  transfer  is  slow  in  relation  to  that  of  substrate  release  (k.2),  Km  
approximates the ATP binding affinity (Lew et al., 2003). This assumption cannot be 
made without information on the microscopic constants, particularly IC 3. Therefore, the 
affinity of ATP for the PknB binding site must be directly measured, for example by 
using fluorescence spectroscopy to determine the binding of a fluorescent ATP analog 
to the PknB active site.
The  A^rpwas used to determine if the optimal fixed ATP concentration required for 
subsequent reactions where Rvl 827 would be varied. Ideally this concentration would 
be 20-fold higher than the  K*T P  to ensure that over 90% of enzyme molecules in the
reaction are bound to ATP at any one time, this would ensure the ATP association step 
is not rate-limiting. A concentration of ImM was chosen as the preferred for assay.  As 
a consequence the only true  Fm ax determined from this study would be for the reaction 
of wild-type PknB with Rvl 827, as wild-type PknB K*T P  was 13.5pM and thus reaction
conditions of ImM ATP would be saturating. Although the majority of the Vm ax values 
determined  in  this  Chapter cannot be  considered the  true  Vm ax  values,  they  serve  to 
measure relative activity of kinases tested under the same conditions.
1856.5  Discussion
6.5.1  Molecular  docking  is  required  for  FHA-domain  containing  protein 
phosphorylation
Purification of full-length protein and isolated FHA domains of Rv0019, Rv0020 and 
Rvl 827 as well as the core catalytic domains of PknA and PknB enabled the design of a 
series  of  in  vitro  kinase  assays  to  investigate  the  interrelationship  between  these 
proteins.  These experiments were conducted after establishing an interaction between 
the PknA/B kinase domain and FHA domains of Rv0020 and Rvl 827 and identifying 
the site of interaction on PknB as two phospho-threonines in the activation loop (T171 
and  T173)  (Chapter  5).  In  vitro  kinase  assays  demonstrate  PknA  and  PknB  STPK 
domains  are  able  to  phosphorylate  the  FHA  domain-containing  proteins.  Critically, 
there  was  no  phosphorylation  of the  isolated FHA  domains  of Rv0020,  Rvl 827  by 
either PknA or PknB,  whereas Rv0019 was phosphorylated within the FHA domain. 
Hence, the phosphorylation site of Rvl 827 and Rv0020 must reside outside the FHA 
domain. Taken together these data suggest a sequential mechanism for phosphorylation 
of these FHA domain-containing proteins which consists of initial binding of the FHA 
domain to the activation loop of the kinase domain via phospho-threonine interactions. 
This  in turn  allows the  substrate  motif to  fit into  its binding  site  on the  STPK and 
become phosphorylated (Figure 6.7).
To test this  theory,  conserved  serines  of the FHA domains  of Rv0020  and Rvl 827, 
which enable the FHA-phospho-threonine interaction, were mutated to alanine residues. 
PknA/B could not phosphorylate these mutant proteins lending support for a molecular 
docking  mechanism  for  phosphorylation  as  explained  above.  Alber  and  colleagues 
reproduced  the  findings  for the  interaction between  PknB  and  Rv0020  in  a recently 
published report (Grunder et al., 2005).  Indeed, a synthetic peptide of the N-terminal 
region purported to contain the site of phosphorylation of Rvl 827 (Duran et al., 2005) 
was synthesised but is not phosphorylated by PknB in enzyme-coupled assays, further 
illustrating the need for an active FHA domain.
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Figure 6.7. A possible mechanism for the interaction of FHA domain-containing proteins 
with the kinase domains of PknA and PknB. (A) After autophosphorylation of PknA/B at 
the activation loop, the FHA domain binds to the activation loop of the kinase domain via 
phosp ho-threonine interactions. This is followed by movement of the substrate motif (N- 
terminal portion of the protein) into the activate site of the kinase domain. This leads to 
phosphorylation of this region. (B) Possible consequences of FHA do main-containing 
protein phosphorylation. (1) The phosphorylated FHA domain-containing protein may form 
a homodimer (2) The phosphorylated FHA-domain containing protein may recruit further 
FHA do main-containing proteins whilst bound to the kinase domain (3) The phosphorylated 
FHA-domain containing protein may form a heterodimer with other phosphorylated FHA- 
domain containing proteins. (4) After phosphorylation of many molecules a ‘daisy chain’ 
effect may occur.
1876.5.2  The effects of hyperphosphorylation of PknA on kinase activity
PknA  displayed  similar  activity  to  PknB  when  using  generic  substrate  MBP  which 
shows  that  the  general  catalytic  activity  of  PknA  is  not  affected  by 
hyperphosphorylation of its surface residues. While PknB displayed activity typical of 
many other STPKs (Vm ax of 0.0044pmol.min"1 ), PknA showed ~20-fold and ~300-fold 
lower activity on Rvl 827 by enzyme-coupled assay and radioassay, respectively.
Hyperphosphorylation  may  prevent  correct  docking  of  Rv0020  and  Rvl 827  FHA 
domains resulting in lower phosphorylation of these proteins. As PknA is known to be 
phosphorylated at a number of threonines not in the activation loop region, the FHA 
domains of Rv0020 and Rvl827 could well bind to site on the kinase domain, away 
from the active  site of PknA.  Although Rv0020 and Rvl 827 can interact with PknA 
through  a  number  of  non-specifically  phosphorylated  sites  these  do  not  support 
phosphorylation of the FHA domain-containing protein N-terminal region. Therefore, 
any differences in activity of PknA and PknB towards Rv0020 and Rvl 827 are likely 
due  non-productively bound  FHA  domains  rather than any difference  in  specificity. 
The fact that PknA and PknB were found to have similar peptide substrate specificity by 
PLSA  analysis  lends  further  support  to  the  above  argument  (Kang  et  al.,  2005). 
However, it is important to note that specificity could differ between docking-dependent 
phosphorylation and docking-independent interactions, which is the basis of the PLSA 
analysis.
The  reduced  kinase  activity  of  PknA  relative  to  PknB  is  consistent  with  in  vivo 
experiments  where  over-expression  of both  kinases  in M.  bovis  and M.  smegmatis 
caused reduced growth  and bulbous morphology but the  effect was noticeably more 
severe in the case of PknB (Kang et al., 2005). The function of PknA may be redundant 
due to the more efficient activity of PknB and could explain why a PknA homolog is 
not present in putative operons containing PknB, Ppp, RodA and PbpA homologs in 
bacteria such as C. diptheria, C. efficiens and S. coelicolor.
1886.5.3  The effects of activation loop dephosphorylation on STPK signalling in TB
Detectable  PknB  kinase  activity on Rvl 827 by the  enzyme-coupled phosphorylation 
assay  provided  the  opportunity  to  investigate  the  effect  of autophosphorylation  on 
kinase activity.  Removing threonines from the activation loop by mutation to alanine 
has  a cumulative  effect on the reduction of kinase activity when using Rvl 827 as a 
substrate.  Previous  studies  by  (Boitel  et al.,  2003)  and more recently  (Duran  et al., 
2005) have demonstrated that this same trend is apparent when using the generic STPK 
substrate MBP. However, using Rvl 827N 162 substrate in this study, the conditions inside 
the mycobacterial cell can be reproduced more accurately. For example the removal of 
phosphate groups from threonines of the activated PknB activation loop would not only 
result in generally lower kinase activity by means of a common regulatory strategy used 
by  kinase  of  the  RD  class,  but  also  remove  the  binding  site  for  FHA  domains. 
Consequently, the effect of coexpressed protein phosphatase; Ppp (dephosphorylation of 
activation  loop  residues)  would  be  amplified.  This  could  well  be  a  conserved 
mechanism  for  regulation  of  all  STPKs  in  M.  tuberculosis  as  indicated  by  the 
conservation of these phospho-acceptor threonines in their activation loops (Figure 6.8).
The  cross-phosphorylation  ability  of PknA  and  PknB  was  not  tested  in  this  set  of 
experiments but has been published recently (Kang et al., 2005). Native forms of PknA 
and PknB were shown to phosphorylated inactive mutants of PknA and PknB in a set of 
in vitro kinase reactions similar to that described in this Chapter. The existence of this 
intermolecular  interaction  implies  there  may be  cross-talk between  PknA  and  PknB 
during signal transduction involving these proteins.
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Figure 6.8. Amino-acid sequence alignment of activation loop residues in kinases 
domains of M. tuberculosis. The conserved residues located in the N- and C-terminal 
anchor regions of the activation loop are highlighted in green. The conservation of 
residues specific phospho-acceptor residues in the above sequences are indicated by 
arrows.
Adapted from Duran et al., 2005.
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190Finally,  ITC  experiments  used  to  investigate  the  binding  of FHA  domains  to  the 
phosphorylated motif created by phosphorylation of Rvl 827 by PknB  provide  some 
tantalising insights into the nature of STPK signalling networks in mycobacteria. The 
N-terminus of Rvl 827 contains a highly conserved stretch of six residues that contains 
one  confirmed  phosphorylated  residue,  Threonine  22,  as  a  result  of PknB  activity 
(Villarino  et  al.,  2005).  A  peptide  representing  the  phosphorylated  N-terminal  of 
Rvl 827 was found to bind to both Rvl 827 and Rv0020 FHA domains, with 7.8pM and 
1.3pM affinities  (K d).  In the absence of any steric hindrance, this is evidence that the 
phosphorylated  Rvl 827  would  form  either  homodimers  or  hetero-oligomers  with 
Rv0020.  The  phosphorylation-  dependent  oligomerisation  of  these  FHA-domain 
containing  proteins  could  represent  a mechanism  by which receptor kinase  detected 
signals are propagated through the cell. Moreover, the fact that Rvl 827 is found in M. 
tuberculosis cells in a truncated form, Rvl82731'162 (Weldingh et al.,  1999) where the 
phosphorylation site has presumably been cleaved off suggests that these FHA domain 
propagated signals are regulated by separation of these dimers.
1917  Inhibitor Studies
7.1  Introduction
Protein kinases have emerged as the second largest potential group of therapeutic targets 
after G-protein-coupled receptors (Cohen., 2002). Not only are kinases abundant in the 
human genome (Manning et al., 2002), with 518 currently identified, but are also found 
in a  subset of bacterial  genomes,  including those that cause  disease in humans.  The 
kinase  active  site  can  be  divided  into  an  Mg2+-ATP  complex  binding  site  and  a 
peptide/protein substrate binding site.  Compounds that are able to bind either of these 
two sites with high affinity can be effective inhibitor of this enzyme (Al-obeidi et al., 
1998). Despite the large number of proteins in this enzyme class, a sizeable number of 
small-molecule  inhibitors  of  protein  kinases  are  undergoing  human  clinical  trials, 
indicating that adequate specificity of inhibitors to targets can be achieved. This is in 
contrast  to  detractors  of anti-kinase  drugs  in the  early  1990s  that  argued  that there 
would  be  difficulties  in  developing  compounds  to  effectively  compete  with  ATP 
binding due to overall sequence and structure similarity (Cohen., 2002).
The first inhibitor to be approved for clinical use that seemed to target a single protein 
kinase, was Rapamycin which inhibited mTOR, a kinase responsible for Gl-to-S phase 
progression (Davies et al., 2000).  Rapamycin was important for stimulating interest in 
the  development  of  other  protein-kinase  inhibitors.  Since  then,  small  molecule 
inhibitors Iressa (Astrazeneca compound ZD 1839) and Tarceva (OSI Pharmaceuticals 
compound OSI-774) have been shown to specifically inhibit Epidermal Growth Factor 
Receptor (EGFR) tyrosine kinase, which is over-expressed in many cancers of epithelial 
origin such as lung and breast cancers, and displayed marked efficacy for a number of 
other  cancers  in  human  trials  (Moyer.,  2000).  However,  the  most  successful  kinase 
inhibitor so far to be developed was Gleevec (Novartis compound STI-571), approved 
for clinical use in May 2001.  It is an ATP competitive inhibitor of Abelson tyrosine 
kinase (ABL), which has enhanced activity in chronic myelogeneous leukaemia (CML). 
The structure of the ABL-Gleevec complex showed the drug to be bound in the catalytic
192site  whilst  interacting  with  the  N-terminus  of the  activation  loop.  This  causes  the 
complexed kinase to revert to an inactive conformation (Schindler., 2000).
In this Chapter, small molecule inhibitor studies on the serine/threonines kinase PknB, 
are described. It is hoped that a basic knowledge of the catalytic mechanisms of PknB 
combined with structural and biological information can be translated into a therapeutic 
strategy to treat tuberculosis.  The vaccine for tuberculosis, BCG, is unable to confer 
significant protection in many parts of the world including India and parts of the USA 
(www.who.inf).  The  current  most  effective  strategy  to  treat  tuberculosis  sufferers 
involves a cocktail of four drugs taken for six months requiring direct observation by 
health  care  workers.  Standard  therapy  for  pulmonary  TB  includes  isoniazid  and 
rifampicin  for  6  months,  along  with pyrazinamide  and  ethambutol  for the  first two 
months (isoniazid and rifampicin without pyrazinamide and ethambutol may be used for 
9 months, if necessary).  Occasionally used are streptomycin, thiacetazone, rifabutin and 
rifapentin.  New drugs are required to shorten this regimen and to combat the spread of 
new multidrug resistant strains of Mycobacterium tuberculosis. The importance of new 
drugs in treating tuberculosis has been discussed in detail (Section 1.9)
PknB  and PknA would appear to be excellent drug targets for the following reasons. 
Global  transposon screens  demonstrated PknA and PknB  were required for bacterial 
growth (Sassetti et al., 2003) and attempts to isolate knockout mutants of these kinases 
have  been  unsuccessful  (K.P.  Papavinasasundaram,  personal  communication). 
Furthermore, in M. smegmatis depletion of both kinases by 50-80% using RNAi results 
in  significant reduction  in  growth rates  in  vivo  as well  as producing morphological 
changes (Yang et al., 2005). Interfering with these targets is likely to attenuate growth 
of M. tuberculosis in vitro and hopefully in in vivo infection.
Although  the  precise  role  of  PknB  in  mycobacterial  signalling  is  not  yet  fully 
understood it is clearly involved in response to its host environment. As shown in this 
thesis  and  other  studies,  PknB  interacts  with  proteins  encoded  within  its  operon 
(Rv0020) and proteins encoded at distant genetic loci (Rvl 827).  Thus it is likely that 
there may be more than one final target of PknB, and interfering with its function may 
have multiple deleterious effects on the bacterium. Sequence analysis shows that PDK- 
and MARK-family kinases are its closest human homologues (-31% identity within the 
kinase domain). This contrasts with a significantly greater homology with, for example
193M.  tuberculosis paralogues  (PknL  (-46%),  PknA and PknJ (44%),  PknD  (40%)  and 
suggests that inhibitors of pknB may also show cross-specificity for other mycobacterial 
kinases,  many  of  which  have  been  implicated  in  growth  and/or  pathogenicity. 
Therefore,  inhibitors  able  to  simultaneously  target  a  combination  of these  enzymes 
would have clear benefits in terms of overcoming problems of drug resistance. PknB 
inhibitors  may  also  display  cross-species  specificity  as  the  PknB  kinase  domains 
possesses significant homology to other important bacterial kinase domains including 
those of Corynebacterium diphtheriae (60% identity), Listeria monocytogenes (45%), 
Bacillus  anthracis  str.  A2012  (42%),  Streptococcus  pyogenes  MAS8232  (40%), 
Staphylococcus aureus (37%), Streptococcus pneumoniae (39%) and Clostridium tetani 
(43%) potentially making any inhibitor of PknB potentially a broad spectrum agent.
The  following  Chapter describes  efforts  to  identify  small-molecules that  specifically 
inhibit PknB activity. Here, the justification for the preferred screening strategy will be 
outlined and in particular the nature of the assay and compound libraries used. Initial 
experiments for optimisation of a high-throughput screen will be discussed, followed by 
the standard operating procedure for the screen. The subsequent ‘hit’ compounds will be 
validated to confirm they are genuine inhibitors.
1947.2  High-Throughput Inhibitor Screening
7.2.1  Overview
Protein-protein  interactions between PknA and B  with Rv0020c and Rvl 827  (GarA) 
were found to be phospho-dependent and Rvl 827 was found to be a particularly good 
substrate for PknB in vitro (Section 5.2.2). The interaction with Rvl 827 has also been 
found in a global proteomics screen involving separation of PknB phosphorylated cell- 
free extract by 2D-gel electrophoresis. I have shown that this FHA domain-containing 
protein  interacts  with PknB  and  is highly phosphorylated by this kinase.  In contrast 
generic substrates such as MBP are poorly phosphorylated. Therefore, we have chosen 
to use Rvl 827 as a substrate for high-throughput screening.
In  collaboration  with  the  Drug  Discovery  Group  (DDG),  part  of Medical Research 
Council Technology (MRCT), a strategy was devised for high-throughput screening of 
inhibitors  to  the  phosphorylation  of Rvl 827  by  PknB.  The  protein  utilised  for  all 
experiments described in this Chapter were purified by me, whilst all experiments were 
carried  out  by  Dr.  Barbara  Saxty  and  David  Whalley.  The  basis  of this  screening 
strategy was the Kinase-Glo  Luminescent Kinase assay developed by Promega.  This 
method indirectly measures the turnover of ATP  and is particularly suitable to high- 
throughput screening (HTS)  for kinase inhibitors.  The Kinase-Glo reagent contains a 
recombinant  ‘UltraGlow’  luciferase  enzyme  that  catalyses  the  mono-oxygenation  of 
luciferin in the presence of Mg2+, ATP and molecular oxygen to produce one photon of 
light  per  ATP  turnover  (Figure  7.1).  The  luminescent  signal  is  correlated with  the 
amount of ATP present and is therefore inversely correlated to the kinase activity which 
is, in turn an indirect measure of ATP consumption.
195A.
-OH  ^  OPO,
Kinase
+  A TP ---------------------► + ADP
OH  _  Q  N  CO O -  ,  OH  o  N  O"
Beetle Luciferin  Oxyluciferin  1   +  Light  "
B.
12000-1
10000-
8000-
6000-
4000-
2000  -
T
10 100
Figure  7.1. The Kinase-Glo kinase activity assay, (a) The mono-oxygenation of luciferin 
catalysed by UltraGlow luciferase (Promega) in the presence ofMg2 *, ATP and molecular 
oxygen produces one photon of light per turnover, (b) ATP titration curves for PknA1 '290 and 
PknB1'279. 50p.L reactions were made up with ATP concentrations between 0.4pM and 15pM 
were made with 1  pM PknB and 10pM Rvl827, ImM MnC^, 150mMNaCl, 50mM Tris- 
HClpH 8.0. As a control, a repeat titration was performed in the absence of  kinase. The 
incubation was performed at room temperature for a total of 10 minutes. The reactions were 
then stopped by the addition of an equal volume of Kinase-Gfo reagent. The change in 
luminescence signal relative the no enzyme control (RLU) was plotted against Log ATP 
concentration. Fits were generated from the average of three separate experiments and EC50 
values were determined.
196Early kinase high-throughput assays measured the incorporation of radiolabelled ATP 
into  a  kinase  substrate  using  a  scintillation proximity  assay  (Amersham).  However, 
more convenient, safe and cost-effective non-radioactive assays are generally preferred. 
There are a number of other non-radioactive kinase assays that can be utilised for high- 
throughput screening relying on generation of fluorescent or luminescent signals. These 
assays  are  designed  to  use  phospho-peptide  binding  reagents,  to  detect  the 
phosphorylated substrate in a quantitative manner, such as antibodies, metal-ion coated 
particles  or  fluorescent polymers.  The  particular  drawback of such  assays based  on 
chelation  of  phosphates  is  that  anionic  compounds  (i.e.  ATP,  phospholipids  and 
carboxylate compounds) compete for binding to the chelator (Sun et al., 2005). Despite 
this,  antibody-based  fluorescent kinase  assays have been used to  study a number of 
tyrosine kinases (Braunwalder et al.,  1996). Unfortunately, there are no antibodies with 
sufficient affinity to phospho-serine and phospho-threonine residues.
The  Kinase-Glo  luminescent  kinase  assay  was  chosen  as  it  allows  for batch-mode 
processing of multiple-plates due to the  slow degradation of luminescent signal over 
time,  and it has proven validity for HTS  (Kupcho et al.,  2003).  There are, however, 
problems  associated  with  this  assay.  It has  a  narrow  ATP  dynamic  range  (<15pM) 
which is lower that that required for many kinases. In addition, various compounds are 
found  to  inhibit  the  activity  of the  luciferase  enzyme  (Sun  et  al.,  2005).  Another 
important drawback is that the Kinase-Glo assay is an end-point assay as it can only 
measure  ATP  after the reaction has been  stopped rather the  continuously measuring 
ATP consumption.  The expertise and necessary automated laboratory facilities of the 
DDG were important in initiating and performing the screening procedure. Apart from 
Kinase-Glo reagent kit and multiwell plates used, consumables required for this assay 
were minimal and the quantity of protein required for each reaction was relatively small 
owing to the high activity displayed by PknB on Rvl 827.
1977.2.2  Determination of optimal ATP concentration
The  first  step  towards  designing  a  high-throughput  inhibitor  screen  the  ATP 
concentration was optimisation of initial ATP concentration. To do this, the EC50 of the 
ATP was determined by performing a dose response titration of ATP (Section 3.2.9). In 
brief, various concentrations of ATP between 0.4 and 15pM were added to lpM PknB, 
ImM MnCb,  150mM NaCl, 50mM Tris.HCl pH 8.0. The incubation was performed at 
room temperature  for a total  of 10 minutes.  The reactions were then stopped by the 
addition of an equal volume of Kinase-Glo reagent. As a control, a repeat titration was 
performed in the absence of kinase. Luminescence was read after a further  lOminute 
incubation  using  a  BMG  Polarstar reader (luminescence  mode,  1   second integration 
time) and the change in relative luminescence signal (RLU) compared to the no enzyme 
control. RLU was plotted against Log ATP concentration (Figure 7.1) and the preferred 
kinase substrate concentration was around the EC50.
The EC50 for ATP in this assay was 1.5pM, which is significantly lower than the  K*r p
determined  from  previous  assays  (13.5pM)  (Section  5.3.5).  However,  this  assay 
measures  PknB  autophosphorylation rather than Rvl827  phosphorylation, but it was 
decided all further optimisation work would be carried out at an ATP concentration of 
1.5pM corresponding to 30pmol of ATP per reaction. A concentration of ATP below 
the  K*fP   would be useful in a screen of ATP-competitive inhibitors. This decision was 
also  governed by the fact that this concentration of ATP would give over 50% ATP 
turnover in a time period between 10-20 minutes, which has been shown previously to 
provide a good signal:noise ratio and a acceptable Z’-factor value. The Z’-factor value is 
describes the quality of the assay and is defined in Chapter 3 (Section 3.2.9).
7.2.3  Determination of optimal kinase and substrate concentration
The  optimal  concentrations  of  both  kinase  and  substrate  were  determined 
simultaneously  using  a  series  of time  course  experiments  (Section  3.2.9).  The  most 
convenient  time  for  kinase  reactions  was  around  20  minutes  (B.  Saxty,  personal
198communication),  and it was important to find a concentration of substrate and kinase 
that would provide a linear ATP turnover over this time period and an acceptable Z' 
value for the assay. Reactions were performed containing Rvl827 (3, 5 and 7pM) with 
0.05pM,  0.1 pM  and 0.2pM  of kinase  concentration plus  1.5pM ATP,  ImM MnCh, 
150mM  NaCl,  50mM  Tris.HCl  pH  8.0  in  a  total  reaction  volume  of  100pL.  The 
incubation was performed at room temperature for 20 minutes, and at the time points 
indicated 20 pL aliquots were removed and mixed with an equal volume of Kinase-Glo 
reagent.  As  a  control,  a  repeat  titration  was  performed  in  the  absence  of kinase. 
Luminescence  was read  after a  10  minute  incubation using a BMG Polarstar reader 
(luminescence mode,  1   second integration time) and the change in luminescence signal 
relative to the no enzyme control was recorded. The amount of ATP used as determined 
from the RLU was plotted against time for each concentration of Rvl827 (Figure 7.2).
The preferred substrate concentration should give a linear ATP turnover over the time 
period of 0-20 minutes. This optimum Rvl827 concentration was determined to be 5pM 
at a kinase concentration of 0.2pM, as the ATP turnover appeared most linear whilst 
providing an acceptable Z’ value (0.67). This indicates the substrate and ATP was not 
saturating at these concentrations and, therefore, this concentration of protein gave a 
good indication of reaction velocity after 20 minutes with a high signal:noise ratio. In 
addition,  this  condition resulted  in  66%  turnover of ATP  at the  end  of 20  minutes, 
which is required for improved T  values (B. Saxty, personal communication).
If the kinase substrate, Rvl827, were to be used at 5pM per 20pL reaction then ~300pL 
of a stock solution of 500pM would be required for four 384-well plates (discounting 
void volumes of pipetting apparatus). This is an acceptable protein usage considering 5- 
8mL of 500pM protein stock solution can be purified from a 6 litre culture volume of 
protein-expression E.  coli.  With  respect  to  PknB,  a  final  concentration  of 2pM per 
reaction translates as a ~15pL volume of 350pM stock kinase solution which is again 
acceptable  considering  lmL  of 350pM  stock  can  be  purified  from  a  40g  pellet  of 
protein-expression E. coli.
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Figure 7.2. Determination of optimal kinase (PknB1* 279) and substrate (Rvl8271-162) 
concentrations for high- thro ughput screening. Kinetic profiles of reactions containing a fixed 
concentration of ATP (1.5pM), three different concentrations of R.V18271’162 (3, 5, 7pM) and 
three different concentrations of PknB1-279 (0.05, 0.1  and 0.2pM, Panels A, B and C, 
respectively). Reactions shown in panel C demonstrated a linear phase of the reaction over
20 minutes and the Z' values for these conditions were determined and are indicated in red.
2007.2.4  Determination of optimal reaction time
A more detailed investigation was carried out into duration for which to carry out the 
kinase reaction.  A 20pL reaction mix containing Rvl827 (5pM), PknB  (0.2p),  ImM 
MnCh, 150mM NaCl, 50mM Tris.HCl pH 8.0 was pipetted into all wells of a 384-well 
using the Biomek automated laboratory workstation. The 384-well plate is divided into 
four quadrants of 96-wells.  1.5pM ATP was added to all wells and the reactions in the 
first quadrant were immediately stopped by the addition of Kinase-Glo. These halted 
reactions would serve as the 0 minute time points on a time course. Quadrants 2,3 and 4 
were halted at 10, 20 and 30 minutes, respectively. The luminescent readings were taken 
and the mean and standard deviation was determined from the readings of all wells for 
each time point (Figure 7.3).
These data demonstrate that the robustness of the assay clearly improves with longer 
incubation times. The Z-factor value improves from 0.35 to 0.7 between the 10 and 30 
minute time points, indicative of improving assay signal dynamic range and lower data 
variation compared to the zero time point. Again, after 20 minutes 60% of ATP was 
used and 73% used after 30 minutes.  This confirms that the preferred time for assay 
completion would be 20 minutes.
7.2.5  DMSO tolerance
Stock solutions of compounds used for screening are solubilised in dimethyl sulfoxide 
(DMSO), thus, the effect of DMSO on the phosphorylation of Rvl827 by PknB should 
be tested.  Several of reaction were set up containing various concentrations of DMSO 
(0.14M-1.4M, 0.1-10% v:v) with 0.2pM of kinase concentration, 5pM Rvl827, 1.5pM 
ATP, ImM MnCh, 150mM NaCl, 50mM Tris.HCl pH 8.0 in a total reaction volume of 
lOOpL. The reaction was incubated for 30 minutes prior to reaction initiation with ATP. 
ATP turnover was plotted as a percentage of the positive control value for each DMSO 
concentration (Figure 7.4).
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Time points
(mins) 0 10 20 30
M ean LU 9146.51 5575.75 3723.927 2488.729
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Figure 7.3. Representative IC50 data for Staurosporine inhibition of the reaction between 
kinase (PknB1'279) and substrate (RV18271'162). 4 sets of96 reactions were carried in a 384- 
well plate containing Rvl827 (5pM), PknB (0.2p), ATP (1.5pM), lmMMnC^, 150mM 
NaCl, 50mM Tris-HClpH 8.0 and various concentrations of Staurosporine in a reaction 
volume of20pL. Reactions were stopped by the addition of Kinase-Glo reagent. 
Luminescence (LU) was recorded for each well and LU as a percentage of control activity 
(no inhibitor) was plotted against log inhibitor concentration.
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Figure 7.4. DMSO tolerance test for PknB activity with Rvl827. Reactions were carried out 
in parallel containing Rvl827 (5pM), PknB (0.2p), ATP (1.5pM), ImM MnC^, 150mM 
NaCl, 50mM Tris-HClpH 8.0 and various concentrations of DMSO in a reaction volume of 
lOOpL. Reactions were stopped by the addition of  Kinase-Glo reagent. Luminescence (LU) 
was recorded for each reaction and LU as a percentage of control activity (no DMSO) was 
plotted. Reactions were conducted in triplicate and all values were within 2 S.D. of the 
average.
203Results suggest there is no significant inhibition of PknB activity on Rvl827 by DMSO 
below  ~1M.  As  high-throughput  screening  reactions  will  contain  no  more  than  1% 
DMSO results will not be affected.
7.2.6  Validation of assay conditions
To  establish  whether  the  assay  conditions  selected  above  could  detect  enzyme 
inhibition, a known inhibitor of STPKs, staurosporine, was titrated across each quadrant 
of a plate  containing the previously determined optimal reaction constituents. This is 
facilitated  on  the  Biomek  automated  laboratory  workstation  due  to  the  fact that all 
pipetting  into  384-well  plates  is  conducted  separately  for all  four quadrants by this 
machine.  This  allowed  the  simultaneous  evaluation  of  data  generated  from  each 
quadrant to ensure consistency. Therefore, all the following procedural details are given 
for a 96-well plate format: 20pL of a reaction mixture containing Rvl827 (5pM), PknB 
(0.2pM), ImM MnCl2,  150mM NaCl, 50mM Tris.HCl pH 8.0 were added to each well 
except those  in the  first column which  each  contained 40 pL of the  reaction mix to 
which 10pM staurosporine had been added. A two-fold serial dilution was made across 
the plate by transfer pipetting.  After preincubation, the reactions were initiated using 
1.5pM ATP and stopped after 20 minutes. Readings were taken and the results of this 
inhibitor concentration titration are plotted (Figure 7.5).
Representative  IC50  data  were  obtained  and  showed  good  consistency  between 
quadrants with values obtained in each quadrant within  1   standard deviation (S.D) of 
each other.  The average staurosporine IC50,  as determined from the four curves, was 
126± 25nM.  This  illustrates that the  assay conditions had been correctly adjusted to 
allow for a wide time window for the linear phase of the reaction. This window of ~20 
minutes  for the  inhibited  reaction  allowed reproducible  determinations  of the  initial 
velocity of substrate phosphorylation.
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Figure 7.5. Representative IC50 data for Staurosporine inhibition of  the reaction between 
kinase (PknB1'279) and substrate (Rvl827,_162). 4 sets of96 reactions were carried in a 384- 
well plate containing Rvl827 (5pM), PknB (0.2p), ATP (1.5pM),  ImM MnClj, 150mM 
NaCl, 50mM Tris-HClpH 8.0 and various concentrations of Staurosporine in a reaction 
volume of20pL. Reactions were stopped by the addition of Kinase-Gto reagent. 
Luminescence (LU) was recorded for each well and LU as a percentage of control activity 
(no inhibitor) was plotted against tog inhibitor concentration. The staurosporine average IC50, 
as determined from the four curves, was 126nM.
205High-throughput screening of PknB inhibitors
It was decided that the first compound library to be screened would be the commercially 
available Library of Pharmacologically Active Compounds (LOPAC) from Sigma. This 
is  a  collection  of  1280  compounds  containing  sets  of  approved  drugs,  failed 
development candidates, and pharmaceutically relevant compounds directed at a broad 
range  of targets:  G  protein-coupled  receptors  (GPCRs),  kinases,  nuclear  receptors, 
metabolic enzymes and ion channels. This library was used for initial screening because 
it had good structural diversity and contained known kinase inhibitors, thus it would 
stand a good chance of providing hits.
The assay conditions are detailed in Chapter 2 (Section 3.2.9). In brief, the assay was 
carried out batch wise in 384-well plates with each well containing 0.15pM PknB, 5pM 
Rvl827,  lOpM  compound,  150mM NaCl,  50mM Tris.HCl pH  8.0,  ImM DTT.  The 
master mix was incubated for 30 minutes prior to initiating the reaction by addition of 
ATP to a final concentration of 1.5pM. The reactions were allowed to proceed for 20 
minutes,  after  which  time  they  were  halted  by  the  addition  of an  equal  volume  of 
Kinase-Glo reagent solution. Multiwell plates were incubated for 10 minutes before a 
luminescence reading was taken. Negative controls were carried out in the absence of 
PknB  and compound, while positive controls were carried out in the absence of any 
compounds.
Data  were  normalised  by  subtracting  the  negative  control  luminescence  unit  (LU) 
reading from the data well LU and the percentage activity decrease for each compound 
was derived from the following formula:
1  —  [LU(data well) —  LU(negative control)] 
RLU =  ---------------------------------------------------------
[LU(positive control) —  LU(negative control)]
206The LOP  AC Library was screened in duplicate at a lOpM compound concentration to 
assess assay performance and hit reproducibility. Compounds detected as ‘hits’ by the 
inhibitor screening are those found to inhibit PknB activity by 20% or greater. After the 
primary screen,  11  hits were obtained.  A second assay was conducted with a longer 
preincubation time  (one hour)  and  a further four hits were  identified  (Appendix  2). 
Inter-assay  reproducibility  could  be  illustrated  using  a  ‘scatter  plot’  depicting  the 
percentage  inhibition by compounds  detected over the two  assays (Figure  7.6).  This 
showed a general trend for hits to locate near to the diagonal of the plot suggesting good 
reproducibility, with the exception of the four hits only observed in the second assay. 
Comparison of statistics for each screen also indicated improved performance for the 
second assay (Table 7.3). The Z-value greatly improved between the two assays upon 
longer preincubation (from 0.51  to 0.77), bearing in mind Z' factor values above 0.5 
indicate good assay quality and a value of 1  is a perfect assay (Zhang et al., 1999).
207Table 7.2. Summary of two high-througput screens of the LOPAC chemical library
Assay 1 Assay >
Average s.d. c.v. Average s.d. c.v.
Enzyme control (LU) 2583 105 0.04 2567 104 0.04
No Enzyme control (LU) 9485 1057 0.11 9966 447 0.04
Z-factor 0.51 0.77
Hit Rate (<80% Activity) 11/1024 15/1024
(s.d.) standard deviation, (c.v.) coefficient of variance, (LU) luminescent units. The 
screening window coefficient, Z-factor, is defined in Chapter 3 -  Materials and Methods, 
Section 3.2.9. Z factor values above 0.5 indicate good assay quality and a value of 1   is a 
perfect assay.
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Figure 7.6. Scatter plot indicating interassay reproducibility for the screening of 1024 
compounds from the LOPAC  library (Sigma). 384-well plate containing Rvl827 (5pM), 
PknB (0.15p.), ATP (1.5pM), MnClj (ImM), NaCl(150mM), Tris-HClpH 8.0 (50mM) and 
lOpM compound. Reactions were stopped by the addition of Kinase-Glo reagent. 
Luminescence (LU) was recorded for each well and LU as a percentage of control activity 
(no inhibitor) for the two assays was plotted across each axis of the scatter plot Summary 
statistics for the both assays are provided in table 15.
2087.2.7  Validation of‘hit’ compounds
Compounds detected as ‘hits’ by the inhibitor screening (those found to decrease PknB 
kinase activity by 20% or greater) were further investigated. A dose-response titration 
was performed  for all  hits  and  the  IC50  values  determined  (Materials  and  Methods, 
Section  3.2.9).  The  validation  data  for  three  of  the  hit  compounds  myricetin, 
nordihydroguaiaretic acid and NSC 95397 are shown in Figure 7.7.
All three compounds exhibited low micromolar range IC50 values (4.2-7.3pM). These 
data show that myricetin inhibits PknB slightly more than nordihydroguaiaretic acid and 
NSC 95397.  Myricetin (3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-l-benzopyran- 
4-one) is a naturally occurring flavonoid that can inhibit a broad range of protein 
kinases and is ATP competitive (Srivastava et al., 1985). Myricetin was shown to have 
an IC50 of 4.2pM (Figure 7.7). Nordihydroguaiaretic acid (1,4-Bis(3,4- 
dihydroxyphenyl)-2,3-dimethylbutane, NDGA) is a found in Larrea divaricata 
(Creosote bush) and is an inhibitor of many enzyme systems but most notably anti­
oxidants such as lipoxygenase (Tapple and Marr, 1955). It has an IC50 of 5.9jiM for 
PknB. The IC50 for the compound NSC 95397 was determined (Figure 7.7) and found to 
be 7.3pM. NSC 95397 is a 1,4-naphthoquinone-based compound with a protein tyrosine 
phosphatase antagonist. It has recently been proposed as a specific inhibitor of cdc25, 
the human cell cycle control protein.
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Figure 7.7. Dose response curves of inhibitors of PknB. Inhibition of PknB by myricetin, 
nordihydroguaiaretic acid and NSC 95397 was assayed at 0.15pM PknB, 5pM Rvl827 and 
1.5pM ATP. Inhibitors were initially identified by high-throughput screening of the 
LOPAC library, Sigma.  The IC50 values are the average of three individually measured 
dose response curves.
2107.3  Discussion
The market for drugs against tuberculosis is historically one of low value and limited 
growth,  which has remained static  over the  last 45  years, with no new drug classes 
becoming available since 1966.  This is due to the fact that anti-tuberculosis drugs are 
traditionally associated with poor return on investment, as the disease is predominantly 
limited to the developing world. Consequently, the commercial incentive to develop or 
market drugs has been limited.  However, resurgence of tuberculosis in the developed 
world and the continued health problems that the disease poses in poorer geographical 
regions has  sparked renewed interest.  In particular,  TB has recently re-emerged as a 
threat  to  global  populations  due  to  two  key  factors:  the  HIV  pandemic  and  the 
emergence  of drug-resistant  strains  of TB.  This  has  meant  that  over recent  years, 
funding for TB drug research has become more readily available.
To address the lack of new therapies against TB, the M.  tuberculosis STPK PknB has 
been  proposed  as  a  drug  target.  A  screening  strategy  was  devised  based  on  the 
phosphorylation  of full-length  Rvl827,  R.V18271 '162,  by  PknB.  It  was  decided  that 
phosphorylation of the substrate would be measured indirectly, by measuring the ATP 
depletion using Luciferase  and a luminescent substrate  (Promega Kinase-Glo  assay). 
This assay has the advantage of not being radioactive and being amenable to a high- 
throughput format. The luminescent output produces a long-lived signal, which can be 
read in common plate readers such as those made by BMG and Tecan. The cost of using 
the Promega Kinase-Glo assay is under  10 pence per reaction well based on a 20pL 
reaction. The assay conditions were optimised through a series of experiments with the 
aim of detecting a linear phase of the reaction in a reasonable time window. This was 
achieved by adjusting the  enzyme,  substrate  and ATP  concentrations and measuring 
ATP  turnover  for 20  minutes.  This resulted  in  conditions  that allowed reproducible 
determination of initial velocity of the substrate phosphorylation. These conditions were 
used to  accurately determine  the  IC50  value  for inhibition of PknB  by  staurosporine 
(Section 7.2.5).
211The LOPAC library contains 167 known inhibitors of phospho-dependent signalling 
including those active against protein phosphatases as well as protein kinases. Six of the 
15 confirmed hits identified are known protein kinase inhibitors. One compound, 
identified as a hit compound in both screens, was found to have intrinsic luminescence 
and interfered with the assay and therefore was discounted. Interestingly, compounds 
H7 and H8 which have isoquinol-based structures and are STPK broad spectrum 
inhibitors were represented in the LOPAC library but not identified as hits. H7 was 
shown to be active against PknB by Av-Gay and co-workers (Av-Gay et al., 1999) and 
the inhibition of PknB by H7 and H8 were tested by the MRCT and IC50 values were 
determined to be 44 and 140pM, respectively. Therefore, using a compound 
concentration of lOpM in the previously described high-throughput screen is not 
expected to identify H7 and H8 as hits.
Staurosporine was not present in the LOPAC library but it is expected to be identified as 
a hit compound under the high-throughput assay conditions used in this Chapter. Under 
these conditions the IC50 was determined as 26nM. Staurosporine is clearly an effective 
inhibitor of PknB, although this has been disputed by previous authors (Ortiz- 
Lombardia et al., 2003). They cite the loss of a hydrogen bond between a staurosporine 
nitrogen atom and the Asp 156, the residue equivalent to conserved Asp 102 in PKA. The 
analysis below shows that staurosporine could in fact interact with enough conserved 
and non-conserved residues to bind with nanomolar affinity.
A Basic Local Alignment Search Tool (BLAST) search of the human genome with the 
amino-acid  sequence  of PknB  kinase  domain  reveals  3-phosphoinositide-dependent 
protein kinase-1   (PDK1) to be its closest match with -31% identity.  The divergence 
between the two kinases has been demonstrated previously (Figure  1.10).  PDK1  is a 
member of the AGC (cAMP-dependent, cGMP-dependent, protein kinase C) family of 
human protein kinases (Figure  1.10),  and has a key role in insulin and growth-factor 
signalling  through  phosphorylation  and  subsequent  activation  of a  number  of other 
AGC  kinase  family members  including protein kinase  B.  The  structure  of PDK1  in 
complex  with  staurosporine  has  been  determined  by  X-ray  crystallography.  It  is 
therefore possible to model a potential staurosporine interaction with the kinase domain 
of PknB  (Figure  7.8)  by  overlapping  the  structure  of PknB  with that of the  PDK1- 
staurosporine complex (Komander et al., 2005). These overlapping structures serve to 
demonstrate that although staurosporine binds via residues common to both PDK1  and
212PknB  there  is  sufficient  divergence  between  the  two  active  sites  to  suggest  that 
inhibitors specific for PknB should be obtainable.
Of  the  14  hit  compounds  identified  after  screening  the  LOPAC  library, 
nordihydroguaiaretic  acid  (l,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane,  NDGA) 
generated  most  interest.  NDGA  is  found  in Larrea  divaricata  (Creosote  bush)  and 
extracts  of this plant have  been  used traditionally to  treat  a number of illnesses  in 
Mexico  including  tuberculosis  (Rivero-Cruz  et  al.,  2005).  NDGA  is  an  inhibitor  of 
many enzyme systems but most notably anti-oxidants such as lipoxygenase (Tapple and 
Marr,  1955).  Very recent studies have confirmed NDGA is as also an effective anti- 
mycobacterial agent with a minimal inhibitory concentration (MIC) value of 50pg/mL 
(Rivero-Cruz  et  al.,  2005).  The  MIC  of  a  compound  is  defined  as  the  lowest 
concentration of antimicrobial agent that inhibits the growth of the microorganism. This 
coupled with the fact that NDGA has an IC50 of 5.9pM for PknB suggests PknB may be 
the  target  for  NDGA  in  mycobacteria,  however,  there  is  no  information  about  its 
mechanism of action or selectivity. Prior work has shown that kinase inhibitor H7 was 
able  to  inhibit  the  growth  of M.  smegmatis,  however,  currently  no  work has  been 
published into the effect of kinase  inhibitors on the  growth of M.  tuberculosis.  This 
information presented here may provide evidence that inhibition of PknB and/or other 
kinases in M. tuberculosis can prove effective in preventing growth of this bacterium.
In order to identify as many hits as possible which can then act as a starting point for 
medicinal chemistry, a number of chemical libraries will be screened using the assay 
developed  from  this  study.  These  will  include  libraries  that  specifically  target 
serine/threonine  protein  kinases.  Initially  screening  of the  1280  compounds  of the 
LOPAC library served as validation of assay conditions in a high-throughput format as 
it identified 14 hit compounds after two separate runs, six of which are known inhibitors 
of kinases.  Analysis of results generated by the two runs showed that they were both 
sufficiently robust (run 1, Z' of 0.51  and run 2, Z’ of 0.77). Thus, this assay represents 
an important discovery route for novel anti-TB chemotherapeutics.
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Figure 7.8. Structural basis for the binding of staurosporine into the ATP-binding site of PknB. The structure ofPDKl  in 
complex with staurosporine has been determined by X-ray crystallography (Komander et al., 2005). After overlapping 
the structure of PknB with that of the PDK1-staurosporine complex, it is possible to model a potential staurosporine 
interaction with the kinase domain of PknB. The surface representation of the kinase domain of PknB is shown with the 
bound staurosporine molecule shown inball-and-stick representation. Active site residue surlaces conserved between 
PDK1  and PknB are shown in green. Molecules were overlapped by structural similarity using the Magic Fit program of 
Deepview (www.expasy. org/spdbv)8  Conclusions
8.1  Introduction
This thesis describes a series of biophysical and biochemical analyses of the interactions 
between  two  M.  tuberculosis  STPKs,  PknA  and  PknB,  and  three  FHA  domain 
containing proteins, Rv0019, Rv0020 and Rvl827. After purification of these proteins 
either as isolated domains or longer fragments, in vitro kinase assays were employed to 
evaluate  the  interrelationship  between  each protein.  PknA  and  PknB  were  found  to 
phosphorylate FHA domain-containing proteins following autophosphorylation. These 
observed phosphorylation reactions were then dissected through the use of ITC and SPR 
techniques and biophysical parameters for Kinase-FHA interactions were determined.
These data have added to the growing body of information about the role of STPKs in 
M.  tuberculosis, specifically in conjunction with FHA domains. In particular, the first 
detailed biophysical analysis of interactions between FHA and STPK is presented. A 
model  of the  possible  mechanism  which  FHA  domain-containing  proteins  become 
phosphorylated by STPKs in M. tuberculosis has evolved through data generated by this 
and previous studies (Figure 6.7).
STPKs  PknA/B  appear  to  be  involved  in  a  signalling  pathway  concerned  with  the 
correct regulation of cell wall synthesis and cell division (Av-Gay, Y., and Everett, M. 
2000) (Kang et al., 2005). Perturbation of this pathway, by over- or under-expression, 
results in gross morphological changes and reduced cell viability (Kang et al., 2005). 
Consequently  PknB  represents  a  potentially  important  target  for  anti-TB 
chemotherapeutics. Therefore, the final part of this study was spent developing a high- 
throughput kinase assay to screen for inhibitors of PknB. A systematic approach was 
used  to  optimise  a  screening  method  based  on  the  phosphorylation  of  full-length 
Rvl827 by PknB and utilising a luminescent signal for assessing activity.
2158.2  Kinase Activity Studies and FHA Interactions
In vitro kinase assays were used to elucidate the molecular reactions between various 
STPKs  and FHA domain-containing proteins  of M.  tuberculosis.  Other groups have 
recently substantiated the work presented here (Grunder et al., 2005, Kang et al., 2005, 
Villarino et al., 2005).  These efforts have now been extended to include preliminary 
studies of the activities of PknA and the FHA-domain containing protein, Rv0019. The 
demonstration of Rv1827 phosphorylation by PknB parallels results obtained by (Duran 
et al., 2005). These authors also show phosphorylation of full-length Rvl827 and map 
phosphorylation  to  a  single  threonine,  T22.  Furthermore,  a  portion  of Rv0020  N- 
terminal to the FHA domain was found to be phosphorylated but the site or sites for this 
remain unknown. Phosphorylation of Rv0020 and Rvl827 was abrogated through the 
mutation of a key serine residue in the domain which rendered the FHA domains non­
functional. The absence of FHA domain phospho-threonine binding ability, as there was 
no  detectable  phosphorylation,  might  suggest  a  molecular  docking  model  for  the 
interaction between these FHA domain containing proteins and STPKs, as depicted in 
Figure 6.7.
Two specific phospho-threonine residues on the activation loop of the kinase domain 
were found to be the binding site for FHA domains Rv0020 and Rvl827. This leads to 
the conclusion that the absence of these threonines completely eliminates binding. The 
FHA domain of Rv0020 displayed preferential binding to pT173, the likely secondary 
phosphorylation site of PknB using ITC and SPR. The FHA domain of Rv1827 showed 
no such preference. The FHA domain of Rv0020 showed tighter affinity for PknA and 
PknB than the FHA of Rv1827.
2168.3  An  Emerging  Model  for  FHA  domain-containing  protein 
Phosphorylation
The mechanism by which two FHA-domain containing proteins, Rvl827 and Rv0020 
become  phosphorylated  by  STPKs  PknB  relies  on  the  autophosphorylation  of two 
threonines residing in the activation loop. Functional FHA domains from Rv0020 and 
Rvl827 efficiently bind to the PknB activation loop consisting of one or two phospho- 
threonine residues. This molecular docking interaction that allows the N-terminal tails 
of these proteins to bind in the  substrate-binding site of PknB.  Thus, the N-terminal 
portion  of  Rv0020  and  Rvl827  become  phosphorylated.  This  molecular  docking 
mechanism is also likely to occur in reactions involving PknA but further experiments 
will be required to confirm this or otherwise.
The  activation  loop  of  the  PknB  kinase  domain  is  found  to  be  disordered  after 
autophosphorylation.  However,  upon  FHA  binding,  the  activation  loop  may  be 
sandwiched between the  kinase  and  FHA  domains,  consequently becoming ordered. 
Once the FHA domain binds the activation loop, inactivation of the kinase by a protein 
phosphatase  may  be  prohibited.  This  was  also  suggested  for  a  related  interaction 
discovered by Hubbard and coworkers where the SH2 domain of adaptor protein APS 
complexes  with  two  phosphotyrosine  residues  of the  insulin  receptor  kinase  (IRK) 
activation loop (Hu et al., 2003).
The significance of phosphorylation in the region N-terminal to the FHA domain still 
remains unclear. No domains are predicted in the N-terminal portions of both Rvl827 
and Rv0020  from  homology  searches and they appear not to have any recognisable 
structure. Results presented in this thesis suggest that the known phosphorylation site of 
Rvl827 is able to serve as a binding site for both its own FHA domain and for Rv0020. 
This supports dimer (Rvl827-Rvl827) or hetero-oligomer (Rv0020-Rvl827) formation. 
An explanation as to the precise purpose of these complexes remains elusive. It is hard 
to  envisage  a  possible  function  for  these  complexes  if  both  components  are 
phosphorylated and one FHA binds to the adjacent FHA domain-containing protein’s 
phosphorylated tail and vice versa. However, if Rvl827 were to be phosphorylated and 
its FHA domain were to remain bound to a kinase activation loop, then binding of any
217FHA-domain  containing  protein  onto  this  phosphorylated  tail  would  result  in  a 
multimeric  complex  which  immediately  localises  the  newly  bound  protein  for 
phosphorylation.
8.4  The Control of M. tuberculosis Growth and Morphology with 
STPKs
Genetic  and inhibitor studies  carried out mainly in E.  coli cells have  identified that 
bacteria  use  two  types  of peptidoglycan  synthesis  for  cell  growth;  either  cell  wall 
elongation or septal  synthesis.  The pknA  and pknB  genes are part of an operon that 
includes genes known to be involved in the elongation mode of synthesis; rod  A and 
pbpA (Begg et al., 1990) (Figure 1.9). While rodA andpbpA work in unison to produce 
a rod morphology,^ genes (ftsA, ftsZ, ftsQ, ftsN, ftsL, ftsK, ftsW and zip  A) are required 
for  the  septal  mode  for  cell  division  (Hale  et  al.,  1997).  To  switch  between  an 
elongation  mode  of synthesis,  which  involves  insertion  of peptidoglycan  along  the 
cylinder of the  cell,  to  septal  synthesis requires insertion of peptidoglycan along the 
leading edge of the invagination septum (Wang et al., 1998). Septation starts after FtsZ, 
the bacterial homolog of tubulin, polymerises to form a contractile ring at the future 
division site. Around 12 additional proteins, many of them fts genes, are also recruited 
to the division site to form the ‘divisome’ (Goehring et al., 2005).
The evolution of a rod shape in bacteria, such as M.  tuberculosis and Bacillus subtilis, 
necessitates  a mechanism  to  temporally regulate  the  switch between  elongation  and 
septation.  How  the  cell  switches  from  one  process  to  the  other  remains  unclear 
(Margolin et al.,  2005). pknA  and pknB have been postulated to be  involved in this 
process because  of their genetic proximity to rodA  and pbpA.  Recently, Kang et al., 
(2005), showed that over-expression of PknA and PknB separately in M.  tuberculosis 
cells results in a broad, bulgy cell morphology, while partial  depletion of PknA and 
PknB,  using  an  antisense  strategy,  caused  a  narrow  elongated  morphology.  These 
observations are extremely similar to morphology changes associated with mutants of 
rodA and pbpA in E. coli. This suggests a functional linkage between PknA, PknB, rodA 
and pbpA. The nature of the interaction between PknA and PknB with these proteins is
218yet to  be  established.  However,  PknB  does  contain extracellular PASTA  (penicillin 
binding protein and STPK associated) domains also present in the extracellular portion 
of PbpA homolog in S. pneumoniae, Pbp2x. Although the PASTA domain is not present 
in PbpA itself, this does predict an important relationship between the PbpA and PknB: 
that PbpA and PknB work in concert to exert an effect on cell morphology. The PASTA 
domain binds to peptidoglycan and their /Mactam antibiotics analogues, and are thought 
to direct proteins to the site of cell growth (Yeats et al., 2002). Therefore, this enzyme 
may be localised to areas of cell growth by means of extracellular PASTA domains, 
leading to oligomerisation and auto-activation.  This could produce a signal in response 
to an extracellular signal that informs the cell that division is required, although, cell 
division would also be governed by intracellular factors such as the replication status of 
the genome.
Further  intracellular  regulation  mechanisms  of  PknA  and  PknB  have  also  been 
proposed. Ppp is the only mycobacterial protein phosphatase and was found to be able 
to dephosphorylate PknB (Boitel et al., 2003) and PknA (Chopra et al., 2003). It can be 
hypothesised  that  a  third  mechanism  of regulation  of these  PknA/B  is  via  the  co­
expressed  FHA  domain-containing  proteins  Rv0020  and  Rv0019  and  other  FHA 
domain-containing proteins encoded throughout the M.  tuberculosis genome. Contrary 
to  expectation PknA/B  are  shown to  interact with a protein from  disparate  operons, 
namely Rvl827; this suggests possible temporal control of this signalling system. The 
results  presented  here  suggest  PknB  is  activated  upon  autophosphorylation,  and 
autophosphorylation of a threonine  in the  activation loop is  essential for docking of 
FHA domains to the kinase and the subsequent phosphorylation of Rv0020 and Rvl827. 
This report has uncovered a small part of a larger network of interactions involving the 
STPKs and FHA domains of M.  tuberculosis.  In many cases, the STPK function has 
been linked to cell growth including PknF (Deol et al, 2005), PknG (Walburger et al., 
2004) and PknH (Sharma et al.,2004). Combining this work with existing knowledge of 
STPK-FHA interactions,  a complex picture  of STPK/FHA  signalling emerges where 
specific  interactions  are  controlled  through  the  phospho-protein  binding  ability  of 
various FHA domains.
2198.5  Towards Novel Anti-tuberculosis Chemotherapeutics
In addition to the biophysical and biochemical characterisation of STPK signalling in 
M.  tuberculosis,  the  latter  part  of  this  study  focused  on  the  search  for  a  novel 
intervention strategy to disrupt STPK signalling. Of particular importance, was the goal 
to  discover  compounds  able  to  inhibit the phosphorylation  of Rvl827  by  PknB,  an 
interaction  demonstrated  during  the  course  of  this  study.  Although,  the  precise 
physiological  function of PknB  remains uncertain,  earlier discussion has detailed the 
importance  of PknB  and  PknA  in  the M.  tuberculosis  cell  and  shows  them to be  a 
potentially significant drug targets.
Through the development of a robust, high-throughput enzymatic assay, the screening 
of inhibitors  against  PknB  has  been  conducted  and  is  detailed  in  this  report.  The 
screening of the LOPAC chemical library has been conducted, which validates the assay 
protocol, and several larger screens are planned. However, this represents the first step 
in the longer drug development process.
Once  hit  compounds  are  identified,  it  is  important  to  demonstrate  reproducible 
concentration-dependent  activity  of the  inhibitor  and  determine  the  IC50  value,  as 
conducted for LOPAC library hits (Section 7.2.7). This is followed by confirmation of 
hit  compounds  in  alternative  in  vitro  kinase  assays,  such  as  the  enzyme-coupled 
spectrophotometric assay and radiolabelling assay (Chapter 6). The next phase would be 
to  conduct  additional  assessment  of the  physicochemical  properties  of compounds, 
including confirmation of structure and purity and tests for chemical reactivity. Finally, 
it is necessary to confirm the compound in question is not classed as a ‘frequent hitter’ 
(i.e. a compound that is a common inhibitor in drug screens).
In addition, selectivity assays will need to be conducted where the compounds are tested 
for inhibitory properties against a panel of human kinases. At this stage, it would also be 
important  to  test  any  inhibitors  of PknB  for  activity  against  other M.  tuberculosis 
STPKs (i.e. PknA -  PknL). Despite the unavailability of such a panel, the purification 
of many of these kinases in their active forms has been reported. Here PknA has been 
purified in an active form (Section 4.3).  Although in theory it would not be considered
220a problem if any potential inhibitor also showed inhibitory activity against any of the 
other  M.  tuberculosis  STPKs,  it  is  important  to  note  that  PknH  knockout  M. 
tuberculosis cells are in fact hypervirulent (Sharma et al., 2004) and therefore it may be 
important to determine kinase specificity. PknH knockout M. tuberculosis cells replicate 
to a higher bacillary load than wild-type upon infection of mice, suggesting PknH may 
be important in maintaining the latency stage of infection. It may, thus, be advantageous 
to inhibit PknH and thereby move bacteria out of latency.
Initial evaluation of compounds for inhibition of the in vitro replication of Mycobacteria 
would need to be carried out by following the growth of M. smegmatis in culture media. 
Fortunately, this type of experimentation is relatively straightforward as M. smegmatis 
grows rapidly (approx.  3 days) and growth can be measured by taking optical density 
(O.D.)  readings.  Such  growth  experiments  should  also  be  carried  out  with  M. 
tuberculosis,  but  this  experimental  system  is  more  complex  as  growth  takes 
approximately three weeks and such experiments need to be conducted in containment 
level  3  facilities.  In addition to  evaluation of activity against wildtype strains of M. 
tuberculosis,  it  will  also  be  beneficial  to  investigate  activity  against  variants  with 
resistance to the current antibiotics.  If compounds appear to have inhibitory activity in 
such growth experiments in culture media, then it is necessary to evaluate their effects 
on the growth of M.  tuberculosis in macrophages, as described previously (Tascon et 
al.,  2000).  When  conducting  experiments  in  murine  macrophages  it  will  also  be 
important to check in parallel for any cytotoxicity.
Structure-based drug design and/or screening strategies may be utilised in conjunction 
with traditional  screening strategies.  Computational methodologies could conceivably 
be utilised for hit identification as the structure of the target, PknB, and its active site 
are  known.  Many  drug  discovery programmes  have  involved  structure-based virtual 
screening with successful identification of inhibitors for protein kinases such as CK2 
and BCL-ABL tyrosine kinase (Kitchen et al., 2005). In addition to hit identification, 
other in silico techniques can be similarly effective in structure-based lead optimisation. 
Once  a  lead  compound  has  been  co-crystallised  with  its  target,  modem  software 
applications are available which can model compound modifications onto pre-defined 
core  fragments  of hits  (Ewing  et  al.,  2001).  Minor  modifications  in  the  chemical 
structure  of a  hit  can  lead  to  significant  changes  in  the  binding  affinity.  This  can 
facilitate a hit-to-lead transition where the compound potency should be increased by
221two to three  orders of magnitude  (Kitchen et a l 2005).  The  structure of the PknB 
kinase domain with a modelled structure of Staurosporine is presented here to illustrate 
how structural information can help improve the drug discovery process.
2229  Future work
A number of important experiments are required to extend this area of research.
It may be possible to reduce the extent of non-specific phosphorylation observed upon 
purification of PknA (Section 4.3.2).  This could be achieved by either co-expressing 
recombinant PknA with the protein phosphatase, Ppp, using a pET Duet vector or by 
treatment of PknA with this phosphatase following purification. Ppp has proven to be 
active on PknA (Boitel et al., 2005) and may aid purification of PknA in a form more 
akin to its native phosphorylation state. Functional studies with this form of PknA may 
prove more  fruitful than studies conducted using the hyperphosphorylated form.  The 
effects of protein phosphatase co-expression on the expression of Abl and Src protein 
kinase domains have been studied and it was found that this led to increased bacterial 
expression and reduction in associated toxic effects (Seeliger et al., 2005).
After observation of phosphorylation of the Rv0019 FHA domain it is important to find 
the site of phosphorylation and determine the effect of phosphorylation on the phospho- 
threonine binding ability of the domain. This study reports on the inability of the non- 
phosphorylated  form  to  bind  phospho-threonine  targets.  If  Rv0019  were  to  bind 
phospho-threonine  targets  after  phosphorylation,  this  would  represent  a  novel  and 
interesting mechanism for modulation of FHA activity. In addition, the site(s) at which 
Rv0020  is  phosphorylated  by  PknA  and  PknB  is  yet  to  be  determined.  Although, 
phosphorylation is  found to be in the region N-terminal region of the Rv0020 FHA 
domain,  identification  of the  phospho-acceptor  residue(s)  may  aid  understanding  of 
Rv0020s physiological role. Although, no function can be assigned to this 373  amino 
acid N-terminal  stretch by homology prediction, phosphorylation may could regulate 
the function of this region. The fact that Rvl827 is found in M.  tuberculosis cells in a 
truncated form, Rvl82731'162, where the phosphorylation site may have been cleaved off 
indicates that FHA domain propagated signals that may be regulated by truncation of 
the protein. Information about the levels of this truncated form of Rvl827 present in M. 
tuberculosis  cells  at  different  growth  conditions  may  help  to  elucidate  the  role  of 
Rvl827 and how it is regulated.
223The possibility for FHA oligomerisation of Rv0020 and Rvl827 upon phosphorylation 
of the N-terminal portion of these proteins has been raised. This was postulated after 
demonstrating  the  FHA  domains  of  Rv0020  and  Rvl827  could  bind  a  peptide 
representing  the  N-terminal  phosphorylation  site  of  Rvl827  (Section  6.2.9).  To 
investigate this possibility it would be necessary to obtain a purified and phosphorylated 
form for Rvl827 or Rv0020. Following this, biophysical techniques such as ITC and 
SPR  could  again  be  applied  to  identify  protein  interactions  and  methods  such  as 
analytical ultracentrifugation could be helpful in identifying the oligomerisation state.
There  remains  a  lack  of  information  on  the  physiological  role  of  FHA-domain 
containing proteins in bacteria, despite their presence in important prokaryotic genomes 
and  their  links  to  many important  cellular processes.  The  requirement for knockout 
mutant strains lacking FHA-domain containing proteins is therefore crucial. If genes for 
FHA-domain  containing  proteins  turn  out to  be  essential,  disruption  of FHA-STPK 
interaction  may prove  an  effective  therapeutic  strategy.  In the  case  of Rv0019  and 
Rv0020, if knockout cells of these proteins display similar morphology to cell where the 
levels of are reduced, this would imply a direct functional relationship between Rv0019 
and Rv0020 and PknA/B.
The  opportunity  exists  to  examine  the  full  extent  of STPK-FHA  interactions  in M. 
tuberculosis, as the majority of FHA domains and STPKs have been purified as soluble 
recombinant proteins. Once soluble forms of these proteins are available one can do a 
biochemical and biophysical studies similar to those described in chapters 5 and 6, to 
decipher the complex series of interactions between FHA domains and STPKs present 
in M.  tuberculosis. Although a number of FHA-STPK interactions have been described 
in  this  study,  all  of these  were  observed  in  the  absence  of ATP.  There  may be  a 
difference in binding affinities for these interactions after an ATP is bound within the 
kinase domain, as this is known to induce a conformational change in the kinase domain 
and  this  requires  further  study.  In  this  regard,  co-crystallisation  studies  of  M. 
tuberculosis STPKs with FHA domains will be essential. As yet, the structures of the 
Rv0020 FHA domain and PknB kinase domain have only been solved individually. A 
structure of the PknB-Rv0020 FHA complex may clarify the interactions which occur 
upon  complex  formation,  how  the  Rv0020  FHA  domain  can  coordinate  to  a  motif 
containing  two  phospho-threonines,  if  the  FHA  domain  interacts  with  any  kinase 
domain elements other than the activation loop and what conformation the activation
224loop of PknB adopts upon FHA domain binding. The question of how the Rv0020 FHA 
domain can bind to a motif containing two phospho-threonines can also be answered 
with a structure of the FHA domain in complex with a peptide representing the fully 
phosphorylated  activation  loop  of PknB.  This would  also be  the  first structure  of a 
bacterial FHA domain in complex with a physiological substrate. Additional structures 
of M.  tuberculosis FHA domain containing proteins including Rvl827 may add further 
molecular information to the bacterial branch of known FHA domains.
With respect to the search for inhibitors against PknB, a vast amount of follow up work 
would be required after initial screening is conducted and hits are identified. Much of 
this  is  outlined  in  the  previous  Chapter  (Sections  8.5).  In  addition,  it may  also  be 
advantageous  to  produce  soluble  kinase  domain  protein  fragments  representing  the 
complete complement of M.  tuberculosis STPKs for inhibitor screening. Regardless of 
the  potential  of  such  novel  inhibitor  compounds  for  therapeutic  intervention,  the 
availability of kinase-specific  inhibitors will certainly be  important tools  for further, 
systematic investigation of these fascinating bacterial signalling pathways.
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Appendix 1
A Angstrom (0.1 nm)
CAPS 3 - [cyclohexylamino] -propanesulphonic acid
DTT 1,4-Dithioerythritol
E. coli Escherichia coli
EDTA Ehtylendiamintetraacetate
FHA Forkhead-associated (domain)
GPCR G-protein coupled receptors
GSH Reduced glutathione
GST Glutathione-S-transferase
GTPase GTP-hydrolysing Enzyme
HEPES 4-2-hydroxyethyl-l -piperazineethanesulfonic acid
HPLC High performance liquid chromatography
IPTG Isopropyl-(3-D-1  -thiogalactopyranoside
ODx Optical density at X nm wavelength of light
Q-sepharose Quaternary ammonium sepharose
SDS-PAGE  Sodiumdodecylsulfate-Polyacrylamide gelelectrophoresis 
SH2  Src homology 2 (domain)
SP-sepharose  sulphur propyl sepharose 
STPK  Serine/Threonine protein kinase
ITC  Isothermal Titration Calorimetry
SPR  Surface Plasmon Resonance
MALDI/TOF  Matrix-assisted laser desorption/ionisation/time-of-flight 
Tris  Tris-(hydroxymethyl)-aminomethan
X  Wavelength
234Appendix 2
Sigma Cat 
No. MW Name Description %activity 
assay 2
%activity 
assay 1
D 2064 766.6 Dequalinium analog, 
C-14 linker
Protein kinase C-alpha (PKC- 
alpha) inhibitor 19.19 90.91
D 8065 168.15 Dephostatin CD45 protein tyrosine kinase 
inhibitor 54.68 80.72
G 6416 520.95 GW5074 cRafl kinase inhibitor 40.67 67.93
N 1786 310.39 NSC 95397 'Selective, irreversible Cdc25 dual 
specificity phosphatase inhibitor. -0.65 79.25
M 6760 318.24 Myricetin Casein Kinase II inhibitor 31.26 34.91
M 9440 168.15 Me-3,4-dephostatin
Selective inhibitor of protein 
tyrosine phosphatase 1B and 
SHPTP-1
14.31 82.79
N 5023 302.37
Nordihydroguaiaretic acid 
from Larrea divaricata 
(creosote bush)
Lipoxygenase inhibitor -7.78 21.15
C 3930 687.71 Calmidazolium chloride
Potent inhibitor of calmodulin 
activation of phosphodiesterase; 
strongly inhibits calmodulin- 
dependent Ca2+-ATPase
59.58 89.93
S 5567 220.23 'SP600125 'Selective c-Jun N-terminal kinase 
(c-JNK) inhibitor. 60.93 60.23
M 6545 517.41 Mitoxantrone DNA synthesis inhibitor 60.51 70.93
D 5439 218.21 2,3-Dimethoxy-1,4- 
naphthoquinone
Redox cycling agent used to 
study role of ROS (reactive 
oxygen species)
19.38 97.14
A 1895 422.35 Aurintricarboxylic acid DNA topoisomerase II inhibitor 15.38 5.10
L 2037 242.28 beta-Lapachone Induces apoptosis in HL-60 cells; 
anticancer agent 6.23 74.37
H 2380 213.19 6-Hydroxy-DL-DOPA
Precursor of the 
catecholaminergic neurotoxin, 6- 
hydroxydopamine; converted to 6- 
hydroxydopamine by L-aromatic 
amino acid decarboxylase
5.35 32.86
235Appendix 3
Name Sequence  Vector Direction Protein
PknA T172Ab
caccatgccggtctgggCcacgggcgctgc
ate  Topo 151 Reverse PknA
PknA T172Af
gatgcagcgcccgtgGcccagaccggcatg
gtg  Topo 151 Forward PknA
PknA T174Ab
gcccatcaccatgccggCctgggtcacggg
ege  jTopol51 Reverse PknA
PknA T174Af
gcgcccgtgacccagGccggcatggtgatg
ggc  Topo 151 Forward PknA
PknA T174Sb
gcccatcaccatgccgCtctgggtcacgggc 
gc  Topo 151 Reverse PknA
PknA T174Sf
gcgcccgtgacccagaGcggcatggtgatg
ggc  [Topo 151 Forward PknA
PknA290 T268Ab
gee agg ggg ggg tgC ctg get ggg 
ccgcgg  Topo 151 Reverse PknA
PknA290 T286Af
............  '  '  ........  " "
ccg egg ccc age cag Gca ccc ccc 
cctggc  |Topo 151 Forward PknA
PknA290b gccaggggggggtgtctg  pET 22 Reverse PknA
PknA290b
cgccgaattctca ctcgac
gccaggggggggtgtctggct  pGEX 6p2 Reverse PknA
PknA290b
cgccaagctttca
gccaggggggggtgtctggct  pET 42 Reverse PknA
PknA290b
cgcctca tgcggccgc
gccaggggggggtgtctggct  pET 22 Reverse PknA
PknA290f tcacccggtgtcctgggcgac  pET 22 Reverse PknA
PknA290f
ccgggatcc catatg
agcccccgagttggcgtgacg  pGEX 6p2 Forward PknA
PknA290f
cgccaagctttca
gccaggggggggtgtctggct  pET 42 Forward PknA
PknA290f
cgccactagt
ctgggagttctgttccaggggccc  pET 42 Forward PknA
PknA290f
caccgaattc
ctgggagttctgttccaggggccc  pET 42 Forward PknA
PknB T171A173Ab
gccgatcactgctgcgQctggCtcacgctg 
tt  pLIC Reverse PknB
PknB T171A173Af
aacagcgtgaGccagaGcgcagcagtgatc 
ggc  pLIC Forward PknB
PknB T171Ab
cactgctgcggtctgggCcacgctgttgccg 
et  pLIC Reverse PknB
PknB T171Ab
cactgctgcggCctgggCcacgctgttgcc 
get  pLIC Reverse PknB
PknB T171Af
agcggcaacagcgtgGcccagaccgcagc 
agtg  pLIC Forward PknB
PknB T171Af
agcggcaacagcgtgGcccagGccgcagc 
agtg  pLIC Forward PknB
PknB T173Ab
gccgatcactgctgcggCctgggtcacgctg 
tt  pLIC Reverse PknB
PknB T173Af
aacagcgtgacccagGccgcagcagtgatc 
ggc  pLIC Forward PknB
PknB T173Sb
gccgatcactgctgc gCtctgggtcac gctgt 
t  pLIC Reverse PknB
PknB T173Sf
aacagcgtgacccagaGcgcagcagtgatc 
ggc  pLIC Forward PknB
236Name Sequence Vector Direction 1Protein
Rv0019b tcacgggcgcaactcgat Topo 151 Reverse Rv0019
Rv0019b cgccgaattctcacgggcgcaactcgat  ] pGEX 6p2 Reverse Rv0019
Rv0019f
caccCTGGAAGTTCTGTTCCA
GGGGCCCcagcgccggcacgctgca ropo 151 Forward Rv0019
Rv0019f caccggatcccagcgccggcacgctgca  ] pGEX 6p2 Forward Rv0019
Rv0020 S473Ab
caa gtg acg gcg TGC cac acc ggt 
gtc  1 pGEX 6pl Reverse Rv0020
Rv0020 S473Af
gac acc ggt gtg GCA cgc cgt cac 
ttg pGEX 6pl Forward Rv0020
Rv0020Lf cacc gaattc atgagtgacaattcgagc pGEX 6pl 
pGEX 6pl
Forward
Forward
Rv0020
Rv0020 Rv0020Lr cgcc ctcgag tcagtgcatgcggacgat
Rvl827Nl 17Af
gat gtc ggg agt etc GCc ggc acc 
tac gtc aac pGEX 6pl Forward Rvl827
Rvl 827N117Ar
gtt gac gta ggt gcc gGC gag act 
ccc gac ate pGEX 6pl Reverse Rvl827
Rvl827R81 Af
ate acg teg get ggt GCg cat ccc 
gac age gac pGEX 6pl Forward Rvl827
Rvl 827R8 lA f
gtc get gtc ggg atg cGC acc age 
cga cgt gat pGEX 6pl Reverse____ Rvl827
Rvl827S95Af
gac gac gtg acc gtg GCc cgt cgc 
cat get gaa  _______!pGEX 6pl Forward Rvl827
Rvl 827S95Ar_______________
ttc age atg gcg acg gGC cac ggt 
cac gtc gtc pGEX 6pl Reverse Rvl827
237